



Tuesday – Saturday, November 19-23, 2024

VEITH

VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS



Symposium Chairman

Frank J. Veith, MD

Executive Co-Chairman

Enrico Ascher, MD

Symposium Co-Chairmen

Kenneth Ouriel, MD, MBA

Sean P. Lyden, MD

Sponsored by



www.VEITHsymposium.org

PROGRAM OUTLINE AT A GLANCE

TUESDAY PROGRAMS

Program A (SESSIONS 1-8)

7:02 A.M. - 6:02 P.M.

Progress In The Treatment Of Diseases Of The Heart Valves And The Thoracic And Abdominal Aorta

Location: Grand Ballroom East, 3rd Floor

Program B (SESSIONS 9-16)

6:47 A.M. - 5:59 P.M.

Progress In Wearable Remote Measurement Devices, Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open Vascular Surgery And Treatment Of Aortic Coarctation

Location: Grand Ballroom West, 3rd Floor

Program C-1 (SESSIONS 17-18)

7:00 A.M. - 12:00 P.M.

Management Of Pulmonary Embolism: The Ultimate Approach

Location: Trianon Ballroom, 3rd Floor

Program C-2 (SESSIONS 19-22)

1:00 P.M. - 6:06 P.M.

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments

Location: Trianon Ballroom, 3rd Floor

WEDNESDAY PROGRAMS

Program D (SESSIONS 23-30)

6:40 A.M. - 6:05 P.M.

Progress In Lower Extremity Occlusive Disease And Its Treatment

Location: Grand Ballroom East, 3rd Floor

Program E (SESSIONS 31-38)

6:40 A.M. - 6:05 P.M.

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest; Outpatient And Office Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence Based Medicine

Location: Grand Ballroom West, 3rd Floor

Program F (SESSIONS 39-46)

6:50 A.M. - 6:10 P.M.

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/ EVAR), Multilayer Bare Stents, Infraarenal AAAs And Standard EVAR, And Hot New Aortic Topics

Location: Trianon Ballroom, 3rd Floor

THURSDAY PROGRAMS

Program G (SESSIONS 47-54)

6:56 A.M. - 6:00 P.M.

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

Location: Grand Ballroom East, 3rd Floor

Program H (SESSIONS 55-63)

7:00 A.M. - 5:59 P.M.

New Or Improved Devices For: Standard EVAR And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

Location: Grand Ballroom West, 3rd Floor

Program I (SESSIONS 64-73)

7:00 A.M. - 7:00 P.M.

Superficial Venous Disease

Location: Trianon Ballroom, 3rd Floor

Program J (SESSIONS 74-78)

7:30 A.M. - 12:15 P.M.

Multidisciplinary Stroke Prevention And Treatment

Location: Murray Hill Suites, 2nd Floor

FRIDAY PROGRAMS

Program K (SESSIONS 79-86)

6:40 A.M. - 5:32 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

Location: Grand Ballroom East, 3rd Floor

Program L (SESSIONS 87-94)

6:52 A.M. - 4:56 P.M.

New Developments In The Treatment Of Popliteal Disease; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

Location: Grand Ballroom West, 3rd Floor

Program M (SESSIONS 95-105)

7:30 A.M. - 6:45 P.M.

Deep Venous Disease

Location: Trianon Ballroom, 3rd Floor

SATURDAY PROGRAMS

Program N (SESSIONS 106-109)

7:00 A.M. - 12:06 P.M.

Topics Too Important To Miss In General And In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

Location: Grand Ballroom East, 3rd Floor

Program O (SESSIONS 110-115)

8:00 A.M. - 4:00 P.M.

Improving Outcomes In Hemodialysis Access

Location: Grand Ballroom West, 3rd Floor

Program P (SESSIONS 116-125)

6:50 A.M. - 5:35 P.M.

Advances In Vascular Imaging And Diagnosis

Location: Murray Hill Suites, 2nd Floor



SYMPOSIUM CHAIRMAN

Frank J. Veith, MD

EXECUTIVE CO-CHAIRMAN

Enrico Ascher, MD

SYMPOSIUM CO-CHAIRMEN

Kenneth Ouriel, MD, MBA

Sean P. Lyden, MD

SYMPOSIUM MANAGING DIRECTOR

Jacqueline M. Simpson, BBA

**SYMPOSIUM ASSOCIATE
MANAGING DIRECTOR**

Steven J. Feld, MSW

ASSOCIATE PROGRAM DIRECTORS

Enrico Ascher, MD

Mark A. Adelman, MD

Jacob Cynamon, MD

Sean P. Lyden, MD

Kenneth Ouriel, MD, MBA

EXPERT PROGRAM ADVISORS

Gustavo S. Oderich, MD – Aorta

Brian G. DeRubertis, MD – Lower Extermity

Marc L. Schermerhorn, MD – Carotid

Caron B. Rockman, MD – Medical

ADVISORY COMMITTEE

Ali F. AbuRahma, MD

Mark A. Adelman, MD

Keith D. Calligaro, MD

Timur P. Sarac, MD

Jacqueline M. Simpson, BBA

Carol La Mantia Veith, RN, BA, MA

COMPONENT MEETING LEADERS

Jose I. Almeida, MD

George L. Berdejo, BA, RVT

Allan L. Brook, MD

Jacob Cynamon, MD

Steve Elias, MD

Peter Gloviczki, MD

Michael R. Jaff, DO

Lowell S. Kabnick, MD

Natalie A. Marks, MD, RPVI, RVT

Larry A. Scher, MD

Anton N. Sidawy, MD, MPH

Thomas W. Wakefield, MD

Haimanot (Monnie) Wasse, MD, MPH

LIAISON COMMITTEE

Evan C. Lipsitz, MD, MBA – Virtual Library

Mark A. Adelman, MD – Virtual Library

Chang Shu, MD – China

Wayne W. Zhang, MD – China

Zhong Chen, MD – China

Wei Guo, MD - China

Weiguo Fu, MD - China

CONTENTS

Program Outline At A Glance.....	Inside Front Cover
Acknowledgments.....	4
Fellows & Residents Career Development Program	6-7
Special Non-CME & Other Industry Events	8-10
General Information	11-13
Accreditation	12
Faculty Disclosure	13
Hotel and Travel	13
Agenda	15-118
Faculty Listing	119-128
Registration	129

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants* in support of this activity from:

Abbott Laboratories
Artivion, Inc.
Bentley InnoMed GmbH
Boston Scientific
Canon Medical Systems USA Inc.*
Contego Medical, Inc.
Cook Medical, LLC
Cordis US Corporation
Endospan
Gore & Associates
InspireMD
Medtronic, Inc.
Micro Medical Solutions
Mindray*
Parks Medical Electronics*
Penumbra
Philips
Philips*
Reflow Medical
Shape Memory Medical
Shockwave Medical, Inc.
Silk Road Medical
Terumo Aortic
VentureMed Group Inc
Xeltis



**ASSOCIATE FACULTY PODIUM
PRESENTATIONS COMMITTEE**

Enrico Ascher, MD
Zach AbuRahma, DO
Sateesh C. Babu, MD
Venita Chandra, MD
Zhong Chen, MD
Anahita Dua, MD, MS, MBA
Alex Fairman, MD
Daniel K. Han, MD
Jan M.M. Heyligers, MD, PhD
Anil P. Hingorani, MD
Paulo Eduardo Ocke Reis, MD, PhD
Caron B. Rockman, MD
Rossi M. Silva, MD
Jessica P. Simons, MD, MPH
Sherif A.H. Sultan, MD, PhD
Wayne W. Zhang, MD

LATAM COMMITTEE

Tulio Navarro, MD
Rebeca Reachi Lugo, MD
Jorge H. Ulloa, MD

**CENTER FOR CONTINUING
MEDICAL EDUCATION**

Steven M. Kawczak, PhD

THE VASCULAR WORLD
IS COMING TOGETHER IN NEW YORK
IN NOVEMBER 2024 . . .
AND YOU'RE INVITED!



VASCULAR FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

An Interactive Symposium for Vascular Surgery Fellows and
Residents Preparing to Enter the Job Market!

Friday, November 22, 2024 • 8:00 a.m. - 5:00 p.m. • New York Hilton-Midtown, New York City
Americas Hall 1, 3rd Floor | This is a Non-CME activity.

VEITHsymposium provides vascular surgeons and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.

We are pleased to offer the 9th VEITHsymposium Fellows & Residents Career Development Program this year. This Program is dedicated to bringing together the June 2025 graduating vascular trainee and their potential employers right at the time that the trainees are looking for their first post-training position. The Career Development Program will also provide an environment for career counseling and easy interaction between vascular trainees, senior vascular specialists, and potential employers.

WHO SHOULD ATTEND:

- Graduating Fellows and Residents in Vascular Surgery
- Attending Vascular Specialists seeking new opportunity
- Potential Employers and Vascular Career Recruiters of Vascular Specialists

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants* in support of this activity from:
Gore & Associates, Medtronic, Inc, Shockwave Medical, and Terumo Aortic.

Join us in New York City this November.
Register online for VEITH at: www.VEITHsymposium.org

Program Director:
James F. McKinsey, MD
Program Co-Director:
Anahita Dua, MD, MS, MBA

Vascular Fellows & Residents Career Development Curriculum

8:00 – 8:05	WELCOME <i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	11:20 -11:25	Discussion
SESSION 1	SELECTING YOUR FIRST JOB	11:25 -11:33	Balancing Your Practice With Industry Relationships: From A Physician's Viewpoint <i>Darren B. Schneider, MD</i>
<i>Moderators:</i>	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	11:33 -11:38	Discussion
8:05 – 8:13	What Does A Vascular Practice Look Like In The 21st Century; Academic, Hybrid Or Community Practice? <i>Brian G. DeRubertis, MD</i>	11:38 -11:44	What Industry Is Looking For In Collaboration With Vascular Interventionalists <i>Mr. Samuel Arbefeuille</i>
8:13 – 8:18	Discussion	11:44 -11:49	Discussion
8:18 – 8:26	What To Prioritize In Your First Practice? <i>Karan Garg, MD</i>	11:49 -12:05	Buffet Lunch Available
8:26 – 8:31	Discussion	Luncheon Program	INNOVATIONS IN VASCULAR INTERVENTIONS
8:31 – 8:39	Things I Wish I Had Known When I Was Selecting My First Job <i>Nicole Ilanzo, MD</i>	12:05 -12:20	AI-powered Digital Twin For EVAR Predictive Planning <i>Ross Milner, MD</i>
8:39 – 8:44	Discussion	12:20 -12:35	Insights To Developing Your Advanced Endovascular Skillset For Branched Technologies During Your Fellowship <i>Alyssa J. Pyun, MD</i>
8:44 – 8:52	How Much Should I Get Paid? How Do I Know If I Am Getting Paid Fairly? <i>Sherene Shalhub, MD, MPH</i>	12:35 -12:50	Advanced VTE Management With Lightning Flash 2.0 Computer Assisted Vacuum Thrombectomy (CAVT) <i>Daniel K. Han, MD</i>
8:52 – 8:57	Discussion	SESSION 4	LONG-TERM PRACTICE MANAGEMENT
SESSION 2	UNDERSTANDING OPTIONS AND INTERVIEWING FOR YOUR FIRST JOB	<i>Moderators:</i>	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>
<i>Moderators:</i>	<i>James F. McKinsey, MD</i> <i>Anahita Dua, MD, MS, MBA</i>	1:05 – 1:13	Incorporating Diversity, Inclusiveness And Equality Into Your Practice <i>Dawn M. Coleman, MD</i>
8:57 – 9:05	Interviewing 101: The Right Questions To Ask When Interviewing <i>Jeffery J. Syracuse, MD, MBA</i>	1:13 – 1:18	Discussion
9:05 – 9:10	Discussion	1:18 – 1:26	Opportunities And Resources For Your Career Available To You From The Society For Vascular Surgery <i>Keith D. Calligaro, MD</i>
9:10 – 9:18	How To Find Out What The Practice Is Really Like And Understand The Options Within The Practice <i>Anahita Dua, MD, MS, MBA</i>	1:26 – 1:31	Discussion
9:18 – 9:23	Discussion	1:31 – 1:39	Tips And Tricks To Manage Malignant Settings, Toxic Leadership, Difficult Partners And Turf Wars <i>Shang Loh, MD</i>
9:23 – 9:31	Do I Need To Do An Added Fellowship In Advanced Aortic Interventions Before Starting My First Job <i>Adam Beck, MD</i>	1:39 – 1:44	Discussion
9:31 – 9:36	Discussion	1:44 – 1:52	Tips And Tricks To Managing Family, Wellness And Career Development <i>Vincent I. Rowe, MD</i>
9:36 – 9:51	How To Negotiate Your First Contract <i>James F. McKinsey, MD</i>	1:52 – 1:57	Discussion
9:51 – 9:56	Panel Discussion With Q&A	1:57 – 2:05	Medical Malpractice – How To Avoid A Lawsuit <i>O. William Brown, MD, JD</i>
9:56 -10:10	Break - Visit Your Sponsors' Exhibits And Pavilions (2nd and 3rd Floors)	2:05 – 2:10	Discussion
SESSION 3	FIRST YEAR IN PRACTICE	2:10 – 2:18	Incorporating Social-Media Into Your Vascular Practice <i>Daniel K. Han, MD</i>
<i>Moderators:</i>	<i>James F. McKinsey, MD</i> <i>Venita R. Chandra, MD</i>	2:18 – 2:23	Discussion
10:10 -10:18	Keys To Building A Successful Practice <i>Venita R. Chandra, MD</i>	2:23 – 2:31	Financial Planning Consideration, Tips And Tricks For The Young Surgeon <i>Alan B. Lumsden, MD</i>
10:18 -10:23	Discussion	2:31 – 2:36	Discussion
10:23 -10:47	Setting Up Dedicated Vascular Programs Within A Vascular Practice	2:36 – 2:44	Opportunities And Resources For Your Career Available To You From Your Regional Vascular Societies <i>Brajesh K. Lal, MD</i>
10:23-10:31	PERT Programs <i>Frank R. Arko, MD</i>	2:44 – 2:49	Discussion
10:31-10:39	Wound Care <i>John C. Lantis, MD</i>	2:49 – 2:57	Career Options Throughout Your Career <i>Peter Glociczki, MD</i>
10:39-10:47	Aortic Center <i>Ross Milner, MD</i>	2:57 – 3:02	Discussion
10:47 -10:52	Discussion	3:02 – 4:15	Global IVUS Case Competition at VEITHsymposium
10:52 -11:00	Building Your Practice: Research Considerations <i>Michael C. Stoner, MD</i>	4:15 – 5:15	Interactive Cocktail Reception With Faculty, Fellows/Residents, Potential Employers, And Industry
11:00 -11:05	Discussion		
11:05 -11:20	Vascular Procedure Billing And Coding: What Do You Absolutely Need To Know Going Into Your First Job? <i>Sean P. Roddy, MD</i>		

SPECIAL CME, NON-CME, AND OTHER INDUSTRY SPONSORED EVENTS

(PLEASE VISIT WWW.VEITHSYMPOSIUM.ORG FOR AN UPDATED LISTING OF THESE ACTIVITIES.)

TUESDAY, NOVEMBER 19, 2024

ABBOTT

Lunch Symposium: Esprit™ BTK: A Paradigm Shift in BTK Treatment

Time: 12:00 P.M. – 1:00 P.M.

Location: Americas Hall 1, 3rd Floor

GORE & ASSOCIATES

Lunch Symposium: Clinical Commercial Experience Using the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE)

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

PENUMBRA, INC.

Lunch Symposium: Innovations in Venous & Arterial Thrombectomy: Penumbra Computer Assisted Vacuum Thrombectomy (CAVT)

Time: 12:00 P.M.

Location: Murray Hill Suite, 2nd Floor

WEDNESDAY, NOVEMBER 20, 2024

BD

Lunch Symposium: Real World PAD Strategies for Complex Lesions

Time: 12:00 P.M. – 1:00 P.M.

Location: Nassau Suites, 2nd Floor

CONTROVERSIES IN VENOUS DISEASE MANAGEMENT

Time: 10:00 A.M. – 12:00 P.M.

Location: Americas Hall 1, 3rd Floor

enVveno Medical Corporation

Lunch Symposium: VenoValve Surgical Replacement Venous Valve 1 Year Pivotal Trial Results

Time: 12:00 P.M. – 1:30 P.M.

Location: Madison Suite, 2nd Floor

GORE & ASSOCIATES

Lunch Symposium: Make Your Case: A Bare Metal vs. Covered Stent Debate

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

INTERNATIONAL SOCIETY FOR WOMEN VASCULAR SURGEONS

Time: 7:30 A.M. – 9:30 A.M.

Location: Americas Hall 1, 3rd Floor

MEDTRONIC

Lunch Symposium: New Evidence on Atherectomy for Vessel Preparation Prior to Drug-Coated Balloon Therapy: Conversation with the Experts

Time: 12:00 P.M. – 1:00 P.M.

Location: Medtronic Pavilion, 2nd Floor

PENUMBRA, INC.

Lunch Symposium: Ruby Embolization Coils: Innovation & Precision of Mechanical Occlusion Technology

Time: 12:00 P.M.

Location: Murray Hill Suite, 2nd Floor

SENTANTE

Join us for a hands-on demonstration of Sentante, a fully robotic system for endovascular interventions, with clinical trials recently completed in Europe.

When: Tuesday – Friday

Location: Americas Hall 2 (South Side), 3rd Floor

SPECIAL CME, NON-CME, AND OTHER INDUSTRY SPONSORED EVENTS

SHOCKWAVE MEDICAL

Lunch Symposium: This Vessel is a Rock: Debating the Best Way to Treat Vascular Calcium

Time: 12:00 P.M. – 1:00 P.M.

Location: Sutton Parlor Center, 2nd Floor

VVV@Vs - Venous Venous and More Venous® WORKSHOP at VEITHsymposium®

Workshop will include Video Case Presentations, Lectures and Demonstration on vein management by experts, plus hands-on opportunities where participants can rotate through multiple training stations staffed by professionals to assist with your experience.

Time: 1:30 P.M. – 6:00 P.M.

Location: Americas Hall 1, 3rd Floor

THURSDAY, NOVEMBER 21, 2024

BD

Lunch Symposium: Advancing Venous Care: My Past vs. Present Algorithm

Time: 12:00 P.M. – 1:00 P.M.

Location: Nassau Suites, 2nd Floor

GORE & ASSOCIATES

Lunch Symposium: Navigating Difficult Landing Zones in the Abdominal and Thoracic Aorta

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

MEDTRONIC

Lunch Symposium: The Importance of Continuous Seal in the Dynamic Aortic Environment

Time: 12:00 PM – 1:00 P.M.

Location: Medtronic Pavilion, 2nd Floor

WORLD FEDERATION OF VASCULAR SURGERY at VEITHsymposium



Moderators: Palma M. Shaw, MD, MBA, RVPI, Wei Zhou, MD and Enrico Ascher, MD

The World Federation of Vascular Societies (WFVS) exists to improve the quality of care of vascular patients worldwide, by providing a forum for the international exchange of scientific and educational knowledge related to the diagnosis, treatment and prevention of vascular diseases. The WFVS is composed of 8 member societies consisting of federated, national and affiliate vascular societies.

Time: 1:00 P.M. – 2:45 P.M.

Location: Murray Hill Suites, 2nd Floor

BEST-CLI- NEW DATA AND EVOLVING PERSPECTIVES



Moderators: Alik Farber, MD, MBA, Matthew T. Menard, MD and Kenneth Rosenfield, MD

A Showcase sampling of the most impactful Secondary Analyses from BEST-CLI, including a discussion of novel statistical methodology; updates on BASIL-3 and SWEDE-PAD, and a highlight panel discussion, intentionally moving beyond the open-endo debate and led by leading endovascular specialists, “Who Should Not Get Endo”.

Time: 3:15 P.M. – 5:15 P.M.

Location: Murray Hill Suites, 2nd Floor

SPECIAL CME, NON-CME, AND OTHER INDUSTRY SPONSORED EVENTS

FRIDAY, NOVEMBER 22, 2024

BD

Lunch Symposium: AV Access: Techniques, Challenges, and Maintenance Strategies

Time: 12:00 P.M. – 1:00 P.M.

Location: Nassau Suites, 2nd Floor

FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

Time: 8:00 A.M – 5:15 P.M.

Location: Americas Hall 1, 3rd Floor

GLOBAL IVUS CASE COMPETITION at VEITHsymposium

Join us for the first Global IVUS Case Competition at VEITH and the grand finale of the 2024 Societal IVUS case competition. Six finalists will be presenting their winning IVUS case for a chance to be named the Global IVUS champion and win \$1,000.

Time: 3:00 P.M. – 4:15 P.M.

Location: Americas Hall 1, 3rd Floor

J. LEONEL VILLAVICENCIO LATIN-AMERICAN PROGRAM at VEITHsymposium



Course Leaders: Enrico Ascher, MD (USA), Jorge H. Ulloa, MD (COL), Rebeca Reachi, MD (MEX), Tulio P. Navarro, MD, PhD (BRA) and Frank J. Veith, MD (USA)

Five-minute presentations in English, Spanish, or Portuguese. Best Presentation Award will be given.

Time: 7:00 A.M. – 6:00 P.M.

Location: Murray Hill Suites, 2nd Floor

OPEN VASCULAR TECHNIQUES

Time: 3:00 P.M. – 5:00 P.M.

Location: Americas Hall 1, 3rd Floor

OUTPATIENT FACILITIES FOR VASCULAR PROCEDURES AND CLINICAL RESEARCH

Time: 1:00 P.M. – 2:40 P.M.

Location: Americas Hall 1, 3rd Floor

THE SVS/ESVS/NICE/ACC/AHA DEBATES ON GUIDELINES FOR THE MANAGEMENT OF ABDOMINAL AORTIC ANEURYSMS

Time: 10:30 A.M. – 12:00 P.M.

Location: Americas Hall 1, 3rd Floor

SATURDAY, NOVEMBER 23, 2024

GORE & ASSOCIATES

Lunch Symposium: Clinical Evidence and Considerations in Dialysis Access Creation and Revision to Enhance Clinical Outcomes

Time: 12:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web-based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 1,300 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors
- Incorporate the Vascular Laboratory into the management of patients with vascular disease
- Identify and compare noninvasive tests that are available to aid in the diagnosis of vascular disease

GENERAL INFORMATION

TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists, Cardiac Surgeons, Vascular Technologists, Sonographers and all others interested in the management of vascular disease.

ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS

Wednesday – Friday, November 20-22, 2024

Location: Gramercy Suite East, 2nd Floor

In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our website. The best three abstracts will receive cash prizes of \$1,000 (1st place), \$500 (2nd place) and \$250 (3rd place). Please visit www.veithsymposium.org for additional information about the Associate Faculty Global Podium Presentations component of VEITHsymposium.

ONE-DAY COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:

Multidisciplinary Stroke Prevention and Treatment

Thursday, November 21, 2024

Location: Murray Hill Suites, 2nd Floor

Improving Outcomes in Hemodialysis Access

Saturday, November 23, 2024

Location: Grand Ballroom West, 3rd Floor

ACCREDITATION STATEMENT

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 50.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 50.75 ANCC contact hours.

Certificate of Participation

A certificate of participation will be provided to other healthcare professionals for requesting credits in accordance with their professional boards and/or associations.

ABS CONTINUOUS CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of

GENERAL INFORMATION

the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

ETHICAL MEDTECH COMPLIANCE

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.

CME CERTIFICATES AND COURSE EVALUATION FORMS

Your CME certificate will be available online within two weeks after the meeting. An e-mail with instructions on how to obtain the certificate and complete a brief course evaluation will be sent to all registered attendees. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by **February 28, 2025**.

FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request to VEITHsymposium by e-mail to admin@veithsymposium.org at least one month prior to the activity.

ONLINE ACCESS TO ABSTRACTS

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium website at www.veithsymposium.org after the meeting. Abstracts will be available on the website for one full year.

ONLINE CONFERENCE LIBRARY

The entire program with almost all the talks, slides, audio and videos - fully synchronized - and the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit www.veithondemand.com or call (800) 987-9314, select option 3.

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$369 plus taxes per night. This rate is available until the block is filled or until October 10, 2024. *Please request the VEITH rate when reserving your accommodations.*

New York Hilton-Midtown (Symposium Venue)

1335 Avenue of the Americas

New York, NY 10019

(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)

American Express Global Business Travel at The Cleveland Clinic

Phone: (216) 444-2564, Extension 62134971

E-mail: VEITHtravel@amexgbt.com



TO GET THE MOST OUT OF YOUR VEITHsymposium EXPERIENCE, WE INVITE YOU TO DOWNLOAD THE VEITH 2024 MOBILE APP



With the App, you can:

- Access the Full VEITHsymposium 2024 Agenda
- Explore Event Programs, Faculty, Exhibitors & More
- View the Interactive Floorplan for Guidance
- Create a Personal Daily Schedule (with Reminders!)
- Download & Print Topical Course Materials
- Make Plans to Attend Non-CME Activities
- Receive the Latest News and Updates

To download the app, please visit the Google Play Store or the Apple App Store and search for VEITH 2024. Or scan the QR Code to download the app to your Android, iPhone, iPad or Tablet.



This QR Code works for both Android and iOS devices.

TUESDAY, NOVEMBER 19, 2024

- 6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
 6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor
 6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT TUESDAY PROGRAMS

PROGRAM A (SESSIONS 1-8)

Progress In The Treatment Of Diseases Of The Heart Valves And The Thoracic And Abdominal Aorta

7:02 A.M. - 6:02 P.M.

Location: Grand Ballroom East, 3rd Floor

PROGRAM B (SESSIONS 9-16)

Progress In Wearable Remote Measurement Devices, Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open Vascular Surgery And Treatment Of Aortic Coarctation

6:47 A.M. - 5:59 P.M.

Location: Grand Ballroom West, 3rd Floor

PROGRAM C-1 (SESSIONS 17-18)

Management Of Pulmonary Embolism: The Ultimate Approach

7:00 A.M. - 12:00 P.M.

Location: Trianon Ballroom, 3rd Floor

Course Leader: Michael R. Jaff, DO

PROGRAM C-2 (SESSIONS 19-22)

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments

1:00 P.M. - 6:06 P.M.

Location: Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 1-8)

PROGRESS IN THE TREATMENT OF DISEASES OF THE HEART VALVES AND THE THORACIC AND ABDOMINAL AORTA

Grand Ballroom East, 3rd Floor

SESSION 1 (Grand Ballroom East, 3rd Floor)

PROGRESS IN TRANSCATHETER VALVE REPLACEMENT AND TREATMENT OF ASCENDING DISEASE

Moderators: Roxana Mehran, MD

Hazim J. Safi, MD

Rodney A. White, MD

7:04 – 7:07 Opening Remarks

Frank J. Veith, MD

TRANSCATHETER HEART VALVES

7:08 – 7:13 Update On The Status Of Transcatheter Mitral And Tricuspid Valve Replacement/Repair

Roxana Mehran, MD

7:14 – 7:19 Update On The Current Status Of Transcatheter Aortic Valve Replacement (TAVR)

Ali B. Khojnejhad, MD, PhD

THE ASCENDING AORTA AND ARCH

7:20 – 7:25 Novel Tri-Branch Endograft For Repair Of Ascending Aorta And Arch Aneurysms And Dissections: What Makes It Different And Initial Clinical Results

Qingsheng Lu, MD (PowerPoint Presentation With Synched Audio)

7:26 – 7:31 Progress In Endovascular Treatment Of Type A Aortic Dissections (TAADs) In 2024: What Is Here And What Is Coming: Experience With Ascending Aortic Endografting Including The Gore Device In The ARISE II Trial

Eric E. Roselli, MD

Ali Azizzadeh, MD

7:32 – 7:37 Current Status Of Endo-Bentall Procedures In Patients: Review Of Early Clinical Experiences: How Can It Be Done Without Left Ventricular Access

Stephan Haulon, MD

7:38 – 7:43 Endovascular Graft Repair Of Ascending Aortic Dissections Including Endo-Bentall Procedures And Physician Modified Double Fenestrated Endografts (PMEGs) With Captiva From Medtronic: When Is It Possible And Results

Ludovic Canaud, MD, PhD

7:44 – 7:50 **Panel Discussion**

SESSION 2 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS

Moderators: *Alan B. Lumsden, MD*

Ali B. Khoynezhad, MD, PhD

Mark A. Farber, MD

7:50 – 7:55 Primary And Redo Open Aortic Arch Repair: When Will They And Will They Not Be Replaced By Endo And Hybrid Techniques

Anthony L. Estrera, MD

7:56 – 8:01 Current Status Of Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results

Joseph S. Coselli, MD

8:02 – 8:07 Endovascular Arch Repair With Cook 2 Or 3 Branched Devices For Lesions Involving The Whole Aortic Arch: When Are They Indicated; When Contradicted And Tips For Making Them Work

Mark A. Farber, MD

8:08 – 8:13 Comparative Late Results With 2-Branched Endograft (Relay – Terumo) And A Single Branched Device (Nexus – Endospan) Versus Debranching For Treatment Of Zone 0 Arch Lesions

Toru Kuratani, MD, PhD

8:14 – 8:19 Current Status And Results Of The Terumo Relay Branched Endograft Device For Aortic Arch Lesion Repairs: Unique Features And When Will It Be Available In The US

Vicente Rimbau, MD, PhD

Ciro Ferrer, MD, PhD

Martin Czerny, MD

8:20 – 8:25 Update On Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations

Michael D. Dake, MD

Himanshu Patel, MD

Joseph E. Bavaria, MD

8:26 – 8:31 Physician Modified Endografts (PMEGs) For Treating Aortic Arch Lesions: When Are They Superior Options And Technical Tips

Sukgu Han, MD

- 8:32 – 8:37** How Best To Treat Aortic Dissections (Type A Or Type B) Extending Into The Arch, Its Branches Or Ascending Aorta; When Open, When Endo, When Hybrid: More Updated Meta-Analysis Comparison Between Medical, Surgical And Endovascular Treatment In 2024
I-Hui Wu, MD, PhD
- 8:38 – 8:43** How Best To Treat Aortic Arch Lesions: Is There Still Ever An Indication For Chimney Endografting With OTS Devices For Aortic Arch Lesions, And How To Make Them Work Without Gutter Endoleaks: What Are Other Options For Emergent Patients
Nicola Mangialardi, MD
- 8:44 – 8:49** Comparison Of Indication And Results For Treatment Of Aortic Arch Lesions With Branched Endografts, Fenestrated Endografts, Parallel Stent-Grafts, Hybrid Repairs, Or Open Repairs
Chang Shu, MD
- 8:50 – 8:55** Techniques For Cerebral Protection During Ascending Aortic Arch Repairs – Endo And Open: The Value Of CO₂ Device Flushing
Tilo Kölbel, MD, PhD
- 8:56 – 9:02** **Panel Discussion**

SESSION 3 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE ENDOVASCULAR TREATMENT OF THE ASCENDING AORTA, AORTIC ARCH, AORTIC DISSECTIONS, REPORTING STANDARDS AND CLASSIFICATION SYSTEMS, STABILISE, GUIDELINES AND MORE

Moderators: *Joseph V. Lombardi, MD, MBA*

Michael D. Dake, MD

Christoph A. Nienaber, MD, PhD

- 9:02 – 9:07** Current Status Of The Relay Ascending Aortic Endograft From Terumo: What Makes It Different
Adam Beck, MD
- 9:08 – 9:13** How And Why The Aortic Arch Is An Unhospitable Location For Endovascular Graft Treatments
Piotr M. Kasprzak, MD
- 9:14 – 9:19** The SVS-STS Aortic Dissection Reporting Standards And Classification System: What Is It; What Are Its Advantages; How Widely Is It Being Adopted
Joseph V. Lombardi, MD, MBA
- 9:20 – 9:25** What Is The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: Current Results, And When Should It Be The Treatment Of Choice
Jean-Marc Alsac, MD, PhD
- 9:26 – 9:31** New Developments With The STABILISE Technique For Acute And Subacute TBADs: How Is The STABILISE Registry Helping: Technical Tips, And Precautions
Germano C.G. Melissano, MD
Andrea Kahlberg, MD
Roberto L.V. Chiesa, MD
- 9:32 – 9:37** Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: What Is It; When Is It Useful; How To Do It
Christoph A. Nienaber, MD, PhD
- 9:38 – 9:43** When Is Open Repair For Post-Dissection TAAAs The Best Treatment Option Especially For Preventing SCI: Will There Be Surgeons Trained To Do It
Hazim J. Safi, MD

- 9:44 – 9:49** Advances In Endograft Repair Of The Ascending Aorta Without And With Involvement Of The Aortic Valve (Endo-Bentall): What Lesions Are Or Will Be Suitable: World Clinical Experience With Endo-Bentall To Date
Ali B. Khoynezhad, MD, PhD
Shahab Toursavadkahi, MD
- 9:50 – 9:55** Distal Stent-Graft Induced New Entry Tears (SINeS): Do They Prevent Aortic Remodeling After TBAD Treatment: How To Prevent And Treat Them
Chun Che Shih, MD, PhD
- 9:56–10:01** High Risk Features Of TEVAR For TBAD: Did The AHA Guidelines Get Them Right: TEVAR Outcomes For TBAD Are Worse Than For Degenerative Aneurysms
James H. Black, III, MD
- 10:02–10:07** Multicenter International Study Shows That There Is A Role For Endovascular Treatment Of Complex Aortic Diseases From Marfans, Loeys-Dietz And Ehlers-Danlos Syndromes: What Is This Role
Anders Wanhainen, MD, PhD
- 10:08–10:14** **Panel Discussion**
- 10:14–10:24** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 4 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)

Moderators: *Jean M. Panneton, MD*

Michael J. Jacobs, MD

Eric L.G. Verhoeven, MD, PhD

- 10:24–10:29** When Should Hybrid Treatment (Endograft Proximal + Open Distal) Be The Preferred Treatment For TAAA Repair: Advantages And Technical Tips
Gilbert R. Upchurch, MD
- 10:30–10:35** New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results
Andrea Kahlberg, MD
Germano C.G. Melissano, MD
Roberto L.V. Chiesa, MD
- 10:36–10:41** Open Repair Of TAAAs Following TEVAR Treatment Of TBAD: Technical Tips: Will This Procedure Survive The Endovascular Revolution
Michael J. Jacobs, MD
- 10:42–10:47** Retrograde Inner Branched Devices (From Cook) To Treat Aortic Arch Lesions: Indications, Value, Technical Tips And Initial Experience
Marcelo Ferreira, MD
- 10:48–10:53** Endovascular Treatment Of Ascending Aortic Diseases: What Can Be Done Currently: What Cannot And What Does The Future Hold: From A Systematic Review
Santi Trimarchi, MD, PhD
- 10:54–10:59** Update On F/B/EVAR For Degenerative And Post TBAD TAAAs: The Value Of Inner Branched Devices: Value Of The BeBack Catheter (Bentley) To Cross The Dissection Flap And For Other Purposes
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD
- 11:00–11:05** Late Results Of Patients With TAADs Treated By Open Repair Of The Ascending Aorta And Arch With A FET And Completed By The STABILISE Technique Distally
Jean-Marc Alsac, MD, PhD
- 11:06–11:12** **Panel Discussion**

- 11:12-11:17** Endovascular Procedures After Open Surgical Type A Aortic Dissection (TAAD) Repair Are Essential For Long-Term Success: Why And What Procedures Are Necessary
Götz M. Richter, MD, PhD
- 11:18-11:23** The Anatomical And Hemodynamic Bases Of Obstruction In Branch Arteries And The True Lumen With Aortic Dissections: How They Can Be Treated Before And After Closure Of The Primary Tear: What Is The Value Of Fenestration Or Septotomy
David M. Williams, MD
- 11:24-11:29** Endovascular Thermal Septotomy Of The Dissection Flap With An Electrocautery Activated Guidewire To Treat Chronic TBADs: When And How Does It Work: Complications And When It Should Be Avoided: Technical Tips And How To Avoid Pitfalls
Carlos H. Timaran, MD
Gustavo S. Oderich, MD
- 11:30-11:35** Update On The Current Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections By Cutting The Septum From Below: Yes, There Is A Downside To Other Septotomies That Cut The Septum From Above
Ramon Berguer, MD, PhD
- 11:36-11:41** In Situ Fenestration (Septotomy) Versus Multiple Chimneys For Urgent Endovascular Treatment Of Aortic Arch Pathologies: Technical Tips
Ivo Petrov, MD, PhD
- 11:42-11:47** Update On Laser Fenestrated Endografts For Aortic Emergencies: Technical Tips And Long-Term Results
Jean M. Panneton, MD
- 11:48-11:53** The Endopatch: A Promising Solution For Endovascular Repairs For Aortic Dissections: What Is It And How Does It Work: Clinical Experience
Wei Guo, MD (PowerPoint Presentation With Synched Audio)
- 11:54-12:00** **Panel Discussion**
- 12:00- 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 5 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY, DETECTION, TREATMENT AND EVAR

Moderators: *Ronald L. Dalman, MD*
Michel Makaroun, MD
Grace J. Wang, MD, MSCE

- 1:00 – 1:05** Unexpected Small Bowel Necrosis When Performing EVAR In Patients With Visceral Artery (SMA) Occlusive Disease: How To Predict It And How To Avoid It
Karan Garg, MD
Neal S. Cayne, MD
Carlos H. Timaran, MD
Frank J. Veith, MD
- 1:06 – 1:11** New Medical Therapies For AAA Disease And An Update On The Metformin Trials For Slowing Aneurysm Growth
Ronald L. Dalman, MD
- 1:12 – 1:17** **DEBATE:** The Safe-AAA Study Emphasizes The Importance Of Ongoing Surveillance And Continuing EVAR Device Risk: Some EVAR Endografts Have Been Found To Have More Late Risks Than Others
Philip P. Goodney, MD, MS
Eric A. Secemsky, MD, MSc

- 1:18 – 1:23** **DEBATE:** Patient Survival After EVAR Was NOT Improved By Compliance With Surveillance Protocols: The EVAR Surveillance Paradox: From A Systematic Meta-Analysis: What Is The Explanation
George A. Antoniou, MD, PhD, MSc
- 1:24 – 1:29** Computer Analysis Of CT Factors Determining AAA Wall Weakness/Strength Of Areas In AAAs Predicts Rupture Risk Independent Of Size And Post EVAR Neck Behavior: The ViTAA System
Randy D. Moore, MD
- 1:30 – 1:35** Value Of Properly Performed Ch/EVAR For Juxtarenal AAAs: Results From A Single Center With The Longest Available Follow-Up Confirm Long-Term Safety And Effectiveness: Technique Is Vital
Joost van Herwaarden, MD, PhD
- 1:36 – 1:41** **Panel Discussion**
- 1:42 – 1:47** Update On An Interesting New Endovascular Technology (Nectero – Intra-Sac Drug After AAA Balloon Isolation) To Slow AAA Growth: Updated Clinical Results Of The First-In-Human Trial
Andrew Holden, MBChB
Daniel G. Clair, MD
Venkatesh G. Ramaiah, MD
- 1:48 – 1:53** Short And Long-Term Results For Endovascular Therapy For Infected Aortic Aneurysms At Various Levels: An 18-Year, >163-Case Experience: EVAR Can Work
Boonprasit Kritpracha, MD
- 1:54 – 1:59** Size Thresholds For Repair Of AAAs Are Wrong On The Low Side: Data From Medicare And The VQI Indicate That Rupture Risk Only Increases With AAAs Over 6-6.9 cm
David H. Stone, MD
Sal Scali, MD
Bjoern D. Suckow, MD
- 2:00 – 2:05** Update On Long-Term Results From The Dream RCT Comparing EVAR With Open Repair For AAAs Suitable For Both: Adverse Neck Anatomy (Short, Wide, Angulated) Was Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: Neck Dilatation Only Occurs After Open Repair And In EVARs With Self-Expanding Endografts: How Should This Influence Today's Treatment
Jan D. Blankensteijn, MD
- 2:06 – 2:11** **DEBATE:** Mortality 30 Days And 3-5 Years After Endo Repair Of Juxtarenal And Complex AAAs In The UK Compass Trial (Real World) Is Double That Of Open Repairs: Why Is This So And Why Is This Different Than Results From US Single Centers And The ARC Registry
S. Rao Vallabhaneni, MD
Michael P. Jenkins, MBBS, BSc, MS
- 2:12 – 2:17** **DEBATE:** Mortality Early And 3-5 Years After Endo Repair Of Juxtarenal And Complex AAAs In The US Aortic Research Consortium (ARC) Registry Is Less Than That Reported For Comparable Open Repairs
Andres Schanzer, MD
- 2:18 – 2:23** There Is No Doubt AAA Screening Saves Lives: Do We Need Changes In The Screening Criteria
Maarit Venermo, MD, PhD
- 2:24 – 2:30** **Panel Discussion**
- 2:30 – 2:40** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 6 (Grand Ballroom East, 3rd Floor)

MORE ABOUT TBADs, AAAs AND EVAR, STANDARD AND COMPLEX: UPDATES ON PHYSICIAN MODIFIED ENDOGRAFTS (PMEGs) AND GUIDELINES

Moderators: *Maarit Venermo, MD, PhD*
Dittmar Böckler, MD
Ian Loftus, MD

- 2:40 – 2:45** Initial Experience With A Uniquely Designed Device (The Chinese Fabulous Stent) Designed To Treat TBADs: What Makes It Different And How Does It Work
Weiguo Fu, MD
- 2:46 – 2:51** Why The NICE AAA Guidelines Favoring Open Repair Over EVAR Are The Way They Are: Bias Has Played A Role As It Does In Many Things: Randomized Controlled Trials (RCTs) Can Be Misleading
Frans L. Moll, MD, PhD
- 2:52 – 2:57** Cancer Is Associated With AAAs: It's A Chicken And Egg Paradox; Which Came First, The Aneurysm Or The Cancer: Is It Related To Diagnostic And Therapeutic Radiation
Natzi Sakalihasan, MD, PhD
- 2:58 – 3:03** The Link Between Elevated Cancer Risk And EVARs: Evidence From Biological Studies And A Large Population Based Data Analysis
Bijan Modarai, PhD
- 3:04 – 3:09** What Do The New ESVS Guidelines For Elective And Emergent AAA Treatment Add To Vascular Practice In 2024: Big Changes Are Coming
Ian Loftus, MD
- 3:10 – 3:15** The SVS/ESVS/NICE/ACC/AHA Guidelines On AAA: Agreements, Conflicting Recommendations, And Omissions
Peter Gloviczki, MD
- 3:16 – 3:21** Evolving Role For Physician Modified Endografts (PMEGs) For Complex AAA Repair: Why Are Poor Results Underreported And When Are They Justified
Javairiah Fatima, MD
- 3:22 – 3:27** Hospitals Without Investigational Device Exemptions Have Worse Outcomes After PMEGs: These Are Often Unreported
Caitlin W. Hicks, MD, MS
- 3:28 – 3:33** PMEGs For Juxta-And Para-Renal Aneurysms Come Out Of The Shadows And Are Now Mainstream: When Should They NOT Be Done
Benjamin W. Starnes, MD
- 3:34 – 3:39** **DEBATE:** Population Screening With Ultrasound For Early Detection Of AAA Is Recommended For Women Age >65 Years, With A History Of Smoking Or A Family History Of AAA, And For Women Age >75 Years, With A History Of Smoking If They Are Otherwise In Good Health
Marc L. Schermerhorn, MD
- 3:40 – 3:45** **DEBATE:** Population Screening With Ultrasound For Early Detection Of AAA Is NOT Recommended For Women Age >65 Years, Even If They Are Former Or Current Smokers Or Have Cardiovascular Disease
Janet T. Powell, MD, PhD
- 3:46 – 3:56** **Panel Discussion**

SESSION 7 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC AORTIC PATHOLOGY

Moderators: *Mark A. Farber, MD*
Manju Kalra, MBBS
Thomas L. Forbes, MD

- 3:56 – 4:01** Use Of TEVARs For TBAD In Patients With Connective Tissue Disease: When Should They Be Done: How Durable Are They And When Are Open Repairs Better
Martin R. Back, MD
- 4:02 – 4:07** How To Treat Aortic Dissections With Entry Tears In The Aortic Arch: Can They Be Treated Endovascularly: Technical Tips
Santi Trimarchi, MD, PhD
- 4:08 – 4:13** With Aortic Dissections, How Can Pressures In The True And False Lumens Be Measured And How Should They Influence Treatment Decisions
David M. Williams, MD
- 4:14 – 4:19** Chronic False Lumen Expansion In Aortic Dissection Requires Complete Flow And Pressure Exclusion: How To Do It With CT Guided Interventions Including Embolization With Polymer Plugs (From Shape Memory) Or Other Methods
Götz M. Richter, MD, PhD
- 4:20 – 4:25** How To Classify Acute Aortic Intramural Hematomas (IMHs): How And When To Treat Them Safely By TEVAR: When And Why Are They So Dangerous
Jean M. Panneton, MD
- 4:26 – 4:31** Causes And Management Of Retrograde Aortic Dissection After TEVAR For TBAD
Boonprasit Kritpracha, MD
- 4:32 – 4:37** A Novel Off-The-Shelf (OTS) Endograft For All Aortic Arch Pathologies: What Makes It Unique And Promising: Early Clinical Results
Wayne W. Zhang, MD
- 4:38 – 4:43** Long-Term (>5 Years) Good Results Of The Medtronic Valiant Captiva Endografts For TEVAR In TBAD Patients: Advantages And Disadvantages
Nimesh Desai, MD, PhD
Joseph E. Bavaria, MD
- 4:44 – 4:49** Motor Evoked Potentials (MEPs) Provide Highly Reliable Information On Spinal Cord Function During Open Thoracoabdominal Aortic Aneurysm (TAAA) Repair: Advantages, Requirements And Why It Hasn't Worked For Some Groups
Michael J. Jacobs, MD
- 4:50 – 4:56** **Panel Discussion**

SESSION 8 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TYPE B AORTIC DISSECTION (uTBADs) (For Important Related Talks See Session 8 In Our 2023 Program On Our Website VEITHsymposium.org)

Moderators: *Jon S. Matsumura, MD*
William D. Jordan Jr., MD
Jean M. Panneton, MD

- 4:56 – 5:01** **DEBATE ROUND 2 (Updated From 2023):** With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients: New Data
William D. Jordan Jr., MD

- 5:02 – 5:07 DEBATE ROUND 2 (Updated From 2023):** With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset For TEVAR And Then Limiting Aortic Coverage: New Data
Mark A. Farber, MD
- DO WE NEED AN RCT COMPARING TEVAR VERSUS MEDICAL TREATMENT FOR uTBADs**
- 5:08 – 5:13** Fate Of Medically Managed Acute TBADs: A Plea For Early Repair In Most Patients – Including Those Who Appear Uncomplicated
Fabio Verzini, MD, PhD
- 5:14 – 5:19** TEVAR For Acute TBAD Significantly Reduces All-Cause Mortality At 3-Years Compared To Best Medical Management: New Data On Outcomes Of All Dissections In England: We Really Don't Need A Randomized Trial
Jonathan R. Boyle, MD
- 5:20 – 5:25** TEVAR To Treat Uncomplicated Acute/Subacute Type B Aortic Dissections (uTBADs) Must Still Be Justified By An RCT: Is An Appropriate One Possible Or Not
Colin D. Bicknell, MD
- 5:26 – 5:31** Scandinavian (SUNDAY) RCT Comparing TEVAR Versus Medical Therapy In uTBAD: Justification, Rationale And Current Status
Jacob Budtz-Lilly, MD, PhD
- 5:32 – 5:37** Status Of The Multicenter RCT (IMPROVE-AD) To Evaluate The Value Of TEVAR Versus Medical Therapy In Acute And Subacute uTBADs: Rationale And Recruitment To Date
Firas F. Mussa, MD
Panos Kougias, MD, MSc
- 5:38 – 5:43** Advances In The Endovascular Repair Of Complex Aortic Dissections: Timing Of Interventions, Adjunctive Techniques And Outcomes
Rami Tadros, MD
- 5:44 – 5:49** What Does Endovascular Aortic Repair Do To Cardiac And Coronary Artery Function: Does The Position Of The Graft In The Aorta Make A Difference: Do We Need A Compliant Endograft
Rachel E. Clough, PhD, FRCS
- 5:50 – 5:55** Re-Entry Specific Endovascular Therapy (RESET), i.e. TEVAR Plus Dealing With Re-Entry Tears: It Promotes False Lumen Thrombosis, Aortic Remodeling And Improves Outcomes: How To Do It
Jean M. Panneton, MD
- 5:56 – 6:02 Panel Discussion**
End of Program A

PROGRAM B (SESSIONS 9-16)

PROGRESS IN WEARABLE REMOTE MEASUREMENT DEVICES, VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY, SIMULATION AND COVID; NEW DEVELOPMENTS IN CAROTID DISEASE AND ACUTE STROKE TREATMENT; ABDOMINAL AORTIC BRANCH TREATMENT; NEW TECHNOLOGY CONCEPTS AND ARTIFICIAL INTELLIGENCE (AI); VASCULAR SURGERY IDENTITY, TRAINING, MANPOWER AND MENTORSHIP; UPDATES ON OPEN VASCULAR SURGERY AND TREATMENT OF AORTIC COARCTATION
Grand Ballroom West, 3rd Floor

SESSION 9 (Grand Ballroom West, 3rd Floor)

PROGRESS IN WEARABLE VASCULAR ROBOTICS, LAPAROSCOPY, GUIDANCE SYSTEMS AND SIMULATION

Moderators: *Matthew J. Eagleton, MD*
Willem Wisselink, MD
Alan B. Lumsden, MD

6:47 – 6:50 Opening Remarks
Enrico Ascher, MD

WEARABLE REMOTE VASCULAR MONITORING SYSTEMS

6:50 – 6:55 Vascular Research And Innovation Priorities In The UK Should Be Applied Everywhere: They Include Wearable Sensors, And Telehealth Systems

Celia Riga, MD

6:56 – 7:01 Remote Measurement Of Blood Flow In Any Artery Or Graft Using An Implantable Ultrasonic Sensor With Transmission To The Internet (From IntelVasc): How Does It Work, And Experimental Data

Jean Bismuth, MD

7:02 – 7:07 Inside Out: Next Generation Technology That Transmits Physical Intelligence And Parameters Continuously From Within The Patient: How Will It Help In Vascular Treatment

Barry T. Katzen, MD (PowerPoint Presentation With Synched Audio)

7:08 – 7:13 Integrating Robotic Systems Back Into Vascular Surgery: Do Not Abandon Them Yet: We Must Be Involved

Alan B. Lumsden, MD

7:14 – 7:19 Robotic And Laparoscopic Vascular Surgery: Where Do They Stand And Why Bother Continuing To Consider Them

Willem Wisselink, MD

RADIATION REDUCING IMAGING GUIDANCE TECHNIQUES

7:20 – 7:25 Updated Experience With The Fiberoptic RealShape (FORS From Philips) System: Results From The Completed Multicenter LEARN Registry: What Are Its Limitations And Can FORS Work With Very Complex Anatomy

Joost van Herwaarden, MD, PhD

7:26 – 7:31 Improved Fiberoptic Based Imaging With The FORS Lumiguide System (Philips): Fiberoptic Sensors Within A Guidewire And A Special 3D Hub Allow Imaging Guidance With Any Catheter: How Does It Work And Experience

Carlos H. Timaran, MD

7:32 – 7:37 Update On The 3D Radiation Free Electromagnetic Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: New Developments, Advantages And Limitations

Matthew J. Eagleton, MD

Francis Caputo, MD

7:38 – 7:43 Cydar Technology And Its AI Modifications Enhance The Accuracy Of Fusion For F/B/EVAR For Complex AAA Treatment: How Does It Work And Reduce Radiation: Advantages And Limitations

Murray L. Shames, MD

Ross Milner, MD

7:44 – 7:50 **Panel Discussion**

SESSION 10 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT; DIFFERING VIEWS ON TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND CAROTID SCREENING

Moderators: *Ali F. AbuRahma, MD*

Bruce A. Perler, MD, MBA

- 7:50 – 7:55** A Data-Driven Look At Interventions For Carotid Disease: Do They Represent Exuberant Enthusiasm, Financial Opportunity For Industry, Doctors And Institutions, Or A Path To Excessive Risk
Colin P. Derdeyn, MD

CORONARY DISEASE IN CAROTID STENOSIS (CS) PATIENTS

- 7:56 – 8:01** Ten-Year Results Of A Multicenter RCT Showing The Long-Term Benefit In CS Patients Of Pre CEA Coronary Angiography And Treatment In Preventing Late MIs And Death
Jean-Baptiste Ricco, MD, PhD

- 8:02 – 8:07** Asymptomatic Coronary Artery Disease Is Deadly In Patients With Carotid Stenosis (CS) Whether The CS Is Treated Invasively Or Not: An RCT Shows How The Coronary Artery Disease Can Be Quantified And Treated To Reduce Myocardial Infarction And Improve Long-Term Survival
Dainis K. Krievins, MD
Christopher K. Zarins, MD

- 8:08 – 8:13** Practice Patterns (CAS, CEA, Medical Treatment, TCAR) For Treatment Of CS Are Changing Dramatically From Those In Previous RCTs: Evidence From A Population Based Analysis
Christian A. Behrendt, MD

VALUE OF CAROTID SCREENING

- 8:14 – 8:19** The Case Against Screening For ACS (Like Lifeline): Who Profits: It May Lead To Unnecessary And Possibly Harmful Invasive Treatments
Anne L. Abbott, MD, PhD (PowerPoint Presentation With Synched Audio)

- 8:20 – 8:25** Screening For ACS: Its Main Value Is In Guiding Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques
Stavros K. Kakkos, MD, PhD
Andrew N. Nicolaides, MS, FRCS

- 8:26 – 8:32** **Panel Discussion**

DIFFERING VIEWS ON TREATMENT OF ACS AND REIMBURSEMENT POLICY

- 8:32 – 8:37** Plaque Progression In Asymptomatic Carotid Stenosis (ACS) Patients On Best Medical Therapy (BMT): Does It Mandate Invasive Therapy Or Continued BMT
Gianluca Faggioli, MD (PowerPoint Presentation With Synched Audio)

- 8:38 – 8:43** **DEBATE:** All ACS Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good And Should Not Have Been Widely Reimbursed By CMS
Anne L. Abbott, MD, PhD (PowerPoint Presentation With Synched Audio)

- 8:44 – 8:49** **DEBATE:** Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated And Reimbursed Accordingly
Bruce A. Perler, MD, MBA

8:50 – 8:55 **DEBATE:** Both Views Are Wrong: Severe ACS Has Declined As A Cause Of Ischemic Stroke To <1% Per Year: So Only <5% Of ACS Patients Should Be Treated Invasively And Reimbursed Accordingly: Can Computer Analysis Of Plaque CT Imaging Help
Robert W. Chang, MD

8:56 – 9:01 CMS Expansion Of Reimbursement For CAS For Asymptomatic Disease: An Expensive And Potentially Harmful Decision: How Could CMS Disregard The Evidence, And Why Couldn't They Wait For CREST 2 Results
Joseph L. Mills, MD

9:02 – 9:07 Is Transfemoral CAS Being Overused One Year After CMS Increased Reimbursement For Treating Asymptomatic Carotid Stenosis
Sean P. Lyden, MD

9:08 – 9:14 **Panel Discussion**

9:15 – 9:27 **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 11 (Grand Ballroom West, 3rd Floor)

MORE ABOUT CAROTID DISEASE: UPDATE ON INVASIVE TREATMENT FOR ACUTE STROKES

Moderators: *Klaus D. Mathias, MD*
Allan L. Brook, MD

9:28 – 9:33 A System For Performing TCAR Percutaneously: How Does It Achieve Flow Reversal And How Can It Be Done Safely
Wayne W. Zhang, MD

9:34 – 9:39 Acute Stroke Management: How Can A Vascular Surgeon Lead A Team That Provides Optimal Care And What Are Its Advanced Features
Laura Capoccia, MD, PhD

9:40 – 9:45 The Current Status Of Intracranial Stroke Thrombectomy: What's New With Devices And Indications: Technical Tips
Allan L. Brook, MD

9:46 – 9:51 With Acute Strokes, What Is New With Endovascular Intracranial Techniques And Indications For Arterial Clot Removal: How Can Improved Imaging, A Dedicated System With Artificial Intelligence (AI) And Intraarterial Thrombolysis With Alteplase (Genentech) Help: The Importance Of Keeping Stroke Patients Flat
Adnan H. Siddiqui, MD, PhD
L. Nelson Hopkins, MD

9:52 – 9:57 Current Optimal Treatment When Carotid Stenosis In The Neck Coexists With Intracranial Disease Or Clot
Klaus D. Mathias, MD

9:58–10:03 How Best To Treat An ICA Occlusion With Distal Embolization: Sequence And Timing Of Treatment: Site Of Treatment (OR Versus Angio Suite Versus Hybrid Room): Technical Tips
Adnan H. Siddiqui, MD, PhD
L. Nelson Hopkins, MD

10:04–10:09 With Tandem Carotid Lesions In The Neck And Supra-Aortic Trunks, How Should Acutely Symptomatic Patients Be Managed: What About Asymptomatic Patients With Such Lesions
Francesco Speziale, MD
W. Darrin Clouse, MD

10:10–10:15 Current Optimal Treatment Of Carotid Artery Dissections: When Anticoagulation And Antiplatelet Drugs; When CAS And When Open Surgery: Technical Tips
Klaus D. Mathias, MD

10:16-10:21 How Should Acute Stroke Severity (NIHSS) Influence Timing To Therapeutic Intervention: For TPA Use; For CEA And CAS; For Intracranial Arterial Clot Removal: It Matters To Neurologic Outcomes
Hernan A. Bazan, MD

10:22-10:30 **Panel Discussion**

SESSION 12 (Grand Ballroom West, 3rd Floor)

PROGRESS IN THE TREATMENT OF AORTIC AND AORTOILIAC OCCLUSIVE DISEASE; HYPOGASTRIC REVASCULARIZATION

Moderators: *Daniel G. Clair, MD*
Wayne W. Zhang, MD
Zhong Chen, MD

10:30-10:35 The VORTEC Technique For Aortofemoral Bypass: What Is It And How To Do It: Why Is It Especially Valuable For Heavily Calcified And Scarred Aortas
Mario L. Lachat, MD

10:36-10:41 What Is New In The Treatment Of External Iliac Artery Endofibrosis In Committed Cyclists: Is There A Role For Endovascular Treatment
Margaret Tracci, MD, JD

10:42-10:47 Iliac Endofibrosis In Elite Cyclists: What Are Its Symptoms Despite Normal Pulses: Diagnosis Is Difficult: Diagnostic Workup: Surgical Treatment And Prognosis
Jason T. Lee, MD

10:48-10:53 **DEBATE:** How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go: How To Do It And What Is The Role Of Lysis
David J. Minion, MD

10:54-10:59 **DEBATE:** Not So: Open Or Hybrid Repairs Are Best For Complex Juxtarenal Aortoiliac Occlusive Disease: Technical Tips
Yamume Tshomba, MD

11:00-11:05 Value Of Shockwave Intravascular Lithotripsy (IVL) For Calcified Aortoiliac Occlusive Disease Treatment And For Facilitating Large Bore Access With Narrowed Calcified Iliac Arteries
Daniel G. Clair, MD

11:06-11:12 **Panel Discussion**

COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE

11:12-11:17 Long-Term Outcomes Of The CERAB Technique In Patients With Aortoiliac Occlusive Disease: Advantages, Limitations, And Stent-Graft Choice: How Can CERAB Be Used To Treat Juxtarenal Occlusions
Michel Reijnen, MD, PhD
Peter C.J. Goverde, MD

11:18-11:23 The CERAB Technique: From A Niche Procedure To A Better General Solution For Complex Aortoiliac Occlusive Disease Based On The Updated Results Of The Physician Initiated Multicenter BeGlory Registry: Technical Tips And Precautions
Maria A. Ruffino, MD

11:24-11:29 Impact Of Female Gender And Smaller Arteries On Outcomes Of Endovascular Treatment Of Aortoiliac Occlusive Disease: When Is Open Repair Indicated
Franco Grego, MD

11:30-11:35 Treatment Of Isolated Infrarenal And Pararenal Aortic Stenosis: Why Results Are Worse In Women: When Stents; When Stent-Grafts; When Open Bypasses
Sigrid Nikol, MD

- 11:36–11:41** Radiation Free CERAB Procedures Are Possible Using FORS Technology (Philips) With Its 3-D Hub: How Is It Done And Technical Tips: Clinical Experience In Over 20 Patients
Barend M.E. Mees, MD, PhD
- 11:42–11:47** Can Mesh Covered Stents Replace Stent-Grafts For The Treatment Of Complex Iliac Occlusive Lesions: Advantages And Disadvantages
Piotr Myrcha, MD
- 11:48–11:53** How Can The VORTEC Technique Be Used To Simplify Hypogastric Revascularization With Open Repair Of Difficult Iliac Aneurysms: How To Do It
Zoran Rancic, MD, PhD
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 13 (Grand Ballroom West, 3rd Floor)

NEW CONCEPTS; MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE (AI); TO DECREASE RADIATION (See Also Sessions 9 And 90)

Moderators: *W. Darrin Clouse, MD*

Kak Khee Yeung, MD, PhD

- 1:00 – 1:05** Revolutionizing Vascular Surgery: Navigating The AI And Multiomics Frontiers For Precision Care: Advantages And Limitations
Sherif A.H. Sultan, MD, PhD
- 1:06 – 1:11** Why RCTs In Vascular Surgery In The Era Of AI Are Unnecessary, Useless And Possibly Unethical
Willem Wisselink, MD
- 1:12 – 1:17** What Is The VASCUL-AID Platform Which Uses AI To Predict Cardiovascular Disease Progression In AAA And Lower Extremity Lesion Patients (PAD): Interesting Findings To Date
Kak Khee Yeung, MD, PhD
- 1:18 – 1:23** Focus On Radiation Protection During Simulation-Based Training Improves Both Correct Behavior And Procedural Performance: Proven By A Randomized Comparison
Lars B. Lonn, MD, PhD (PowerPoint Presentation With Synched Audio)
- 1:24 – 1:29** Small Tips And Modifications In Radiation Safety Can Make A Huge Impact On Staff Exposure: What Are They And How Can They Be Enforced
Maarit Venermo, MD, PhD
- 1:30 – 1:35** Use Of Virtual Reality 3-D Visualization With A Headset For Preoperative Optimization For Treatment Of Visceral Artery Aneurysms
Dominique Fabre, MD, PhD
- 1:36 – 1:41** Benefit Of AI And AAA Volume Measurements After EVAR And F/B/EVAR: How Do They Improve Care
Stephan Haulon, MD
- 1:42 – 1:47** Is Image Fusion Advanced Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question And Do We Need A Trial
Rachel E. Clough, PhD, FRCS
- 1:48 – 1:53** Update On Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease And Predicting Stroke Risk With Carotid Disease; How Does It Work And How Reliable Is It
Ravi K. Veeraswamy, MD

- 1:54 – 1:59** Update On How An AI Based Prediction Of Rupture Risk Is Better Than Size Based Predictions
Jes S. Lindholt, MD
- 2:00 – 2:05** Remote Endovascular Proctoring And Mentoring Using An Augmented Reality Virtual Platform: How Does It Work And Experience
Cherrie Z. Abraham, MD

2:06 – 2:12 Panel Discussion

SESSION 14 (Grand Ballroom West, 3rd Floor)

ISSUES IMPORTANT TO VASCULAR SURGERY'S INDEPENDENCE, IDENTITY AND TRAINING; SHOULD WE GET A COVID-19 VACCINATION

Moderators: *James C. Stanley, MD*
Keith D. Calligaro, MD
Jerry Goldstone, MD

- 2:12 – 2:17** Why Vascular Surgery Needs To Have An Independent Board And What Is The SVS Doing To Pursue This Goal
Joseph L. Mills, MD
- 2:18 – 2:23** What Is The ABVS Doing To Pursue An Independent Board And Why Hasn't It Done More
Timur P. Sarac, MD
Jeffrey H. Hsu, MD
Sean P. Lyden, MD
Alan M. Dietzek, MD
- 2:24 – 2:29** An Independent Board Of Vascular Surgery And Why It Has Been So Helpful: The French Experience
Jean Pierre Becquemin, MD
- 2:30 – 2:35** Five Issues Affecting Vascular Surgeons' Bargaining Power: Would An Independent Vascular Board Help
Margaret Tracci, MD, JD
- 2:36 – 2:41** Status Of Cardiology's Independent Board For Cardiovascular Medicine: What Will Be Its Impact On Vascular Surgery And How Would An Independent Vascular Surgery Board Counteract This
Alan M. Dietzek, MD
- 2:42 – 2:47** The SVS Public Marketing Initiative: Why It Will Help Overcome Vascular Surgery's Clouded Identity: In View Of Cardiology's Initiative To Obtain An Independent Board, Shouldn't Vascular Surgery Get One Too
Matthew J. Eagleton, MD
Keith D. Calligaro, MD
Joseph L. Mills, MD
- 2:48 – 2:53** The Importance Of Mentorship In Vascular Surgery: How Best To Achieve It
Malachi Sheahan, MD
- 2:54 – 2:59** How To Handle Bad Clinical Outcomes And Other Professional And Personal Adversity: It Really Matters For A Vascular Surgeon/Specialist
John F. Eidt, MD
- 3:00 – 3:05** Evolution And Current Status Of Integrated Vascular Surgery Residency (0+5) Training: Advantages And Limitations: A View From One Of The First Such Trainees
Daniel K. Han, MD
- 3:06 – 3:11** Important Developments In Vascular Surgery Training Programs: Changes In Numbers And Quality Of 0+5 And 5+2 Trainees; Why We Need More Qualified Vascular Surgeons And How Are We Going To Get Them
Dawn M. Coleman, MD

- 3:12 – 3:17** How Safe And Effective Are Current COVID-19 Drugs For Vaccination: When And How Often Should Vascular Surgeons/Specialists Get Them If They Are <50, >50, >65 Or >75
Clayton J. Brinster, MD
- 3:18 – 3:24** **Panel Discussion**
- 3:25 – 3:35** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 15 (Grand Ballroom West, 3rd Floor)
PROGRESS IN THE TREATMENT OF VISCERAL AND RENAL ARTERY DISEASE (For Important Related Talks See Session 15 In Our 2023 Program On Our Website VEITHsymposium.org)

Moderators: *Dawn M. Coleman, MD*
Timur P. Sarac, MD

- 3:36 – 3:41** Endovascular Mesenteric Artery Revascularization: Has It Improved Outcomes Of Acute Mesenteric Ischemia: Stents Versus Covered Stents
Manju Kalra, MBBS
- 3:42 – 3:47** Natural History Of Untreated Visceral And Renal Artery Aneurysms (Renal, Splenic, Celiac, Etc.): From Large Series With Mid-To Long-Term Follow Up
Caron B. Rockman, MD
- 3:48 – 3:53** Multidisciplinary Consensus Statement On The Management Of Pediatric Renovascular Hypertension, Renal Artery Stenosis And Midaortic Syndrome: Optimal Conduits, Techniques And Results
Dawn M. Coleman, MD
James C. Stanley, MD
- 3:54 – 3:59** Treatment Of Visceral And Renal Artery Aneurysms: Technical Tips And When To Use Coils, Covered Stents Or Uncovered Stents: How To Maintain Critical Arterial Flow
Paulo E. Ocke Reis, MD, PhD
- 4:00 – 4:05** Why Is Open Repair Always Indicated To Treat Long Complex SMA Occlusions: Technical Tips
Armando Mansilha, MD, PhD
- 4:06 – 4:11** When Should SMA Endovascular Embolectomy Be The Standard Of Care: How To Do It
Loay S. Kabbani, MD, MHSA
- 4:12 – 4:17** Visceral Artery Aneurysms: When To Treat Invasively, At What Size: When Endo, When Open
Rabih A. Chaer, MD
- 4:18 – 4:23** Open Versus Endovascular Treatment For Visceral Artery Aneurysms And Acute Mesenteric Ischemia: When Is Open Surgery Mandatory
Timur P. Sarac, MD
- 4:24 – 4:29** Gastroduodenal Aneurysms Associated With Celiac Artery Occlusion – Patterns, Treatment (Endo Versus Open); Technical Tips To Maintain Flow Through The Gastroduodenal And Results
Keith D. Calligaro, MD
Samy S. Nitecki, MD
- 4:30 – 4:36** **Panel Discussion**

SESSION 16 (Grand Ballroom West, 3rd Floor)
UPDATE ON OPEN VASCULAR SURGICAL PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS (For Important Related Talks See Session 16 In Our 2023 Program On Our Website VEITHsymposium.org)

Moderators: *R. Clement Darling III, MD*
James H. Black, III, MD
Peter Gloviczki, MD

OPEN VASCULAR SURGERY

- 4:36 – 4:41 What Are The Symptoms And What Is Current Open Surgical Treatment For Arterial Nutcracker Syndrome (Compression Of The Duodenum By The SMA)
Keith D. Calligaro, MD
- 4:42 – 4:47 What Is ERAS (Early Recovery After [Open Aortic] Surgery): How To Do It With AAAs And What Are Its Advantages And Limitations
W. Anthony Lee, MD
- 4:48 – 4:53 Strategies And Technical Challenges In The Open Treatment Of Large TAAAs In Patients With Connective Tissue Disorders
James H. Black, III, MD
- 4:54 – 4:59 How To Perform All Vascular Operations Through Small Incisions: Technical Tips, Why Is It Advantageous And Results: When Is It Contraindicated
Robert M. Proczka, MD, PhD
- 5:00 – 5:05 The Role Of Open AAA Repair In The Era Of F/EVAR And EVAR: Technical Tips
Francis Caputo, MD
- 5:06 – 5:11 The Right Retroperitoneal Approach For Open AAA Repair: When To Do It, Advantages And Technical Tips
Ashraf Mansour, MD
- 5:12 – 5:17 Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign
Kimihiro Komori, MD, PhD
- 5:18 – 5:24 **Panel Discussion**

UPDATE ON COARCTATION TREATMENT

- 5:24 – 5:29 Endovascular Repair Of Aortic Coarctation: Balloon Angioplasty Versus Bare Stents Versus Covered Stents And When Is Open Repair Necessary
Tilo Kölbel, MD, PhD
- 5:30 – 5:35 Open And Endovascular Treatment Of Aortic Arch Aneurysms Following Aortic Coarctation Repairs
Germano C.G. Melissano, MD
Andrea Kahlberg, MD (Presenter)
Roberto L.V. Chiesa, MD
- 5:36 – 5:41 Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists
Jeffrey J. Siracuse, MD, MBA
- 5:42 – 5:47 Technical Tips And Lessons Learned To Make In Situ Vein Bypasses More Effective And Better
R. Clement Darling III, MD
- 5:48 – 5:53 Anterior Lumbar Spine Exposure: Technical Tips And How To Avoid Pitfalls
Timothy K. Liem, MD, MBA
- 5:54 – 5:59 **Panel Discussion**
- End of Program B**

PROGRAM C-1 (SESSIONS 17-18)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH

Trianon Ballroom, 3rd Floor

SESSION 17 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1

Moderator: *Michael R. Jaff, DO*

- 7:00 – 7:05 Introduction To The Symposium
Frank J. Veith, MD

- 7:05 – 7:15** Welcome And Introduction
Michael R. Jaff, DO
- 7:15 – 7:25** The Basics Of Pulmonary Embolism Diagnosis: What Is The Role Of The History, Exam, Biomarkers
Raghu Kolluri, MD
- 7:25 – 7:35** Echocardiography Is All You Need To Manage Acute Submassive PE
David M. Dudzinski, MD
- 7:35 – 7:45** CTA Is All You Need To Manage Acute Submassive PE
Brian B. Ghoshhajra, MD, MBA
- 7:45 – 7:55** Testing For Cancer And Other Hypercoagulable States In PE: Why, When, And What Tests
Aditya Sharma, MD
- 7:55 – 8:10** Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember
Geno J. Merli, MD
- 8:10 – 8:25** An Overview Of Clinical Trials For PE: Will Any Of Them Move The Needle
Rachel Rosovsky, MD, MPH
- 8:25 – 8:35** Intravenous Thrombolytic Therapy For PE: Why, When, And At What Dose
Lauren Glassmoyer, MD
- 8:35 – 8:45** Ultrasound-Assisted Pharmacomechanical Thrombolysis: Emerging Data To Define Use In PE
Assaf Graif, MD
- 8:45 – 8:55** Pharmacomechanical Thrombolysis With The BASHIR™ Catheter: Unique And Differentiated Approach
Eric A. Secemsky, MD, MSc
- 8:55 – 9:05** Percutaneous Mechanical Thrombectomy Without Lytics: The FlowTrieve System
Mitchell D. Weinberg, MD
- 9:05 – 9:15** Percutaneous Mechanical Thrombectomy Without Lytics: The Indigo System
Robert A. Lookstein, MD, MHCDL
- 9:15 – 9:25** Large Bore Aspiration Thrombectomy—Tips, Tricks And Pearls
Gary M. Ansel, MD
- 9:25 – 9:40** **Panel Discussion**
Moderator: *Michael R. Jaff, DO*
Panelists: Gary M. Ansel, MD
Brian B. Ghoshhajra, MD, MBA
Lauren Glassmoyer, MD
Assaf Graif, MD
Raghu Kolluri, MD
Robert A. Lookstein, MD, MHCDL
Geno J. Merli, MD
Rachel Rosovsky, MD, MPH
Eric A. Secemsky, MD, MSc
Aditya Sharma, MD
Mitchell D. Weinberg, MD
- 9:40– 10:10** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 18 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2

Moderator: *Michael R. Jaff, DO*

- 10:10–10:20** The AngioVac Strategy For The Treatment Of PE
Christopher J. Kwolek, MD, MBA
- 10:20–10:30** ECMO-Assisted Pulmonary Embolectomy In Massive PE: Can It Replace Open Surgical Thrombo-Embolectomy
Animesh Rathore, MD
- 10:30–10:40** Do Statins Matter In The Treatment Of Patients With PE
Anthony J. Comerota, MD

- 10:40–10:55** Your Referring Docs Think Heparin Is All They Need To Offer For PE – How To Tell The Intervention Story
Patrick Troy, MD
- 10:55–11:10** Pulmonary Denervation: A New Frontier In The Treatment Of Pulmonary Hypertension
Mark G. Davies, MD
- 11:10–11:25** Balloon Pulmonary Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream
Kenneth Rosenfield, MD
- 11:25–11:35** The Team Approach To PE Management: The National PERT Consortium
Rachel Rosovsky, MD, MPH
- 11:35–12:00** Challenging The Experts: Interactive Q&A
Moderator: *Michael R. Jaff, DO*
Panelists: Anthony J. Comerota, MD
Mark G. Davies, MD
Christopher J. Kwolek, MD, MBA
Robert A. Lookstein, MD, MHCDL
Animesh Rathore, MD
Kenneth Rosenfield, MD
Rachel Rosovsky, MD, MPH
Eric A. Secemsky, MD, MSc
Patrick Troy, MD
- 12:00– 1:00** **Lunch Break – Rhineland Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)
End of Program C-1

PROGRAM C-2 (SESSIONS 19-22)
INTERESTING TOPICS RELATED TO LOWER
EXTREMITY OCCLUSIVE DISEASE AND ITS
TREATMENTS

Trianon Ballroom, 3rd Floor

SESSION 19 (Trianon Ballroom, 3rd Floor)

HOT NEW TOPICS RELATED TO LOWER
EXTREMITY OCCLUSIVE DISEASE AND ITS
TREATMENTS – MEDICAL AND NATURAL HISTORY
ISSUES

Moderators: *William D. Jordan Jr., MD*
Vincent L. Rowe, MD

- 1:00 – 1:05** Personalized Anticoagulation For Lower Extremity Revascularization Using The Distinctive Utilization Of Antiplatelets Protocol To Decrease Thrombosis (Failure) Rates: How To Do It
Anahita Dua, MD, MS, MBA
- 1:06 – 1:11** Why Are Patients Who Undergo Lower Extremity Revascularization At Risk For Major Bleeding: How To Estimate That Risk And What Should Be Done To Decrease It
Christian A. Behrendt, MD
- 1:12 – 1:17** Frailty With CLTI: How Best To Measure It And Can It Improve With Revascularization
Mark G. Davies, MD
- 1:18 – 1:23** How Atherosclerosis In Peripheral Arteries Differs From That In The Coronary Arteries: What Are The Therapeutic Implications
Janet T. Powell, MD, PhD
- 1:24 – 1:29** Premature Peripheral Artery Disease: What Factors Predispose To It: How Should Its Treatment Differ: How Does It Influence Treatment Outcomes
Olamide Alabi, MD
- 1:30 – 1:35** Open And Endo Revascularization In Young Patients With PAD: What Works, What Doesn't, And How Should Treatment Be Modified
William P. Robinson, MD

- 1:36 – 1:41** 'Low-Flow State' Induced Limb Ischemia: What's The Etiology: Is The Incidence Increasing In The Era Of ECMO, IMPELLA, LVADs And Heart Transplantation: How Should It Be Treated
Sateesh C. Babu, MD
- 1:42 – 1:47** Renal Failure In CLTI Patients Should Not Be A Contraindication To Limb Salvage Attempts
Vincent L. Rowe, MD
- 1:48 – 2:04** **Panel Discussion**

SESSION 20 (Trianon Ballroom, 3rd Floor)

MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT – EVALUATING ARTERIAL ANATOMY AND TREATMENT OUTCOMES WITH CLTI

Moderators: *Marianne Brodmann, MD*
Caron B. Rockman, MD

- 2:04 – 2:09** How To Accurately Evaluate Availability And Nonavailability Of Ipsilateral Or Contralateral Great Saphenous Vein For Use For Potential Bypasses In Patients Being Treated For Severe CLTI: How Can One Determine Optimal Treatment
Caron B. Rockman, MD
- 2:10 – 2:15** Value Of Optical Coherence Tomography (OCT) In Treating BTK Arterial Lesions: How Does It Work And Indications
Lee Bouwman, MD, PhD
- 2:16 – 2:21** The Value Of Distal Angiography, Selective And Subselective, In The Treatment Of Lesions Causing CLTI
Jos C. van den Berg, MD, PhD
- 2:22 – 2:27** The Japanese SPINACH Registry Confirms That Open Bypasses Are Superior To Endovascular Treatments In CLTI Patients When Ischemia And Infection Are Advanced
Nobuyoshi Azuma, MD (PowerPoint Presentation With Synched Audio)
- 2:28 – 2:33** What Is The Role Of IVUS In Peripheral Arterial Endovascular Procedures: When Is It Better Than Contrast Arteriography And When Can It Replace It
Hany M. Zayed, MD
- 2:34 – 2:39** What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology (ABIs And PVRs), Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters
Mitchell D. Weinberg, MD
Ido Weinberg, MD, MSc
- 2:40 – 2:45** How Should We Define Success For CLTI Treatment: What Criteria Are Best: The UK Perspective: Why Is It Different
Jonathan R. Boyle, MD
- 2:46 – 2:52** **Panel Discussion**
- 2:52 – 3:00** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 21 (Trianon Ballroom, 3rd Floor)

HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS

Moderators: *Neal S. Cayne, MD*
Gary M. Ansel, MD

- 3:00 – 3:05** Technical Tips For Vessel Prep For DCBs Or DESs: It Is Different And Not Simple: How To Do It And How Important Is It
Erwin Blessing, MD

- 3:06 – 3:11** Current Comparative Value Of Paclitaxel Coated DCBs Versus Uncoated Balloons In Below The Knee (BTK) Arteries: The SAMBA Trial Shows That DESs Can Work In This Location
Gunnar Tepe, MD
- 3:12 – 3:17** When Are Polymer Based Paclitaxel Eluting Stents (Eluvia, Boston Scientific) Superior To Other Endo Treatments For Lower Extremity Lesions
Yann Gouëffic, MD, PhD
- 3:18 – 3:23** Update On The Advantages Of The Chocolate Wire Constrained Uncoated Balloon (From Medtronic) For Treating Popliteal And BTK Lesions
Gunnar Tepe, MD
- 3:24 – 3:29** Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion, Getting A Resistant Balloon To Go Over The Wire And Tips For Retrograde Access
Marco G. Manzi, MD
- 3:30 – 3:35** Propensity Matched Comparison Of Uncoated And Paclitaxel-Coated Balloon Angioplasty For Isolated Popliteal Lesions Excluding Bail-Out Stenting: The DCBs Are Better
Fabrizio Fanelli, MD
Thomas Zeller, MD
- 3:36 – 3:42** **Panel Discussion**
- 3:42 – 3:47** Outcomes Following Profunda Revascularization Using Atherectomy And DCB Angioplasty: Technical Tips And Comparison With Open Surgery
Giovanni B. Torsello, MD
- 3:48 – 3:53** First-In-Human Experience With The Efemoral Bioresorbable Scaffold And New Sirolimus DCB (Provision DCB From BD) In FemPop Disease
Andrew Holden, MBChB
- 3:54 – 3:59** Why The Zilver PTX DES (Cook) Is A Durable Effective Treatment For Long FemPop Lesions: Based On Worldwide Trials And Experience
Charles J. Bailey, MD
- 4:00 – 4:05** Non-Aspiration Based Mechanical Thrombo-Embolectomy With The Pounce (From Surmodics) Or Rotarex (From BD) Devices: How Do They Work And How They May Lead To More Concrete Procedural End Points And Improved Value Analysis
Gary M. Ansel, MD
- 4:06 – 4:11** Local Anesthetic Injection Into A Lesion Site Facilitates Angioplasty (PTA) And Stent Placement: How To Do It
Andrej Schmidt, MD
- 4:12 – 4:17** Technical Tips For A Successful BTK Intervention In Patients With CLTI Including How To Perform An Antegrade Femoral Artery Puncture And Pass The Guidewire Easily Into The SFA And Not The Profunda
Ali Amin, MD, RVT
- 4:18 – 4:23** **Panel Discussion**

SESSION 22 (Trianon Ballroom, 3rd Floor)

MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE, CLTI AND ITS TREATMENTS

Moderators: *Brian G. DeRubertis, MD*
Caitlin W. Hicks, MD, MS

- 4:24 – 4:29** How To Evaluate The Need For Below The Ankle (BTA) Recanalization In CLTI Patients: When Is It Important To Achieve Foot Healing: Technical Tips To Do It And How Durable Is Its Patency
Lorenzo Patrone, MD (PowerPoint Presentation With Synched Audio)

- 4:30 – 4:35** Lymphatic Embolization For Postoperative Groin Wound Leaks: How To Do It And How Effective Is It
Lindsay Machan, MD
- 4:36 – 4:41** When Is Endovascular Treatment For CLTI Justified And Better For Patients Classified As “Bypass Preferred” In The Global Vascular Guidelines: What Are The Guidelines Missing
Kimihiko Komori, MD, PhD
- 4:42 – 4:47** A Radiologist's View Of Open Bypass Versus Endovascular As First Treatment For CLTI: Bypasses Still Have An Important Role
Konstantinos Katsanos, MSc, MD, PhD
- 4:48 – 4:53** How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): How Does It Help
Jos C. van den Berg, MD, PhD
- 4:54 – 4:59** Do Diabetic Patients With CLTI And Extensive Foot Necrosis Have Time For An Endovascular First Strategy: Primary Open Bypass Is Better Treatment In This Setting
Katariina M. Noronen, MD
- 5:00 – 5:05** Does Intravascular Lithotripsy (IVL) (Shockwave) Eliminate The Need For Other Vessel Prep
Lawrence A. Garcia, MD
- 5:06 – 5:11** **Panel Discussion**
- 5:12 – 5:17** Value Of Redo Tibial Bypasses: Technical Tips For Facilitating - Some Old And Some New Tricks
Evan C. Lipsitz, MD, MBA
- 5:18 – 5:23** Experience With >1500 Retrograde Recanalization For Chronic Total Occlusions (CTOs); What Predicts Technical Success And What Predicts Periprocedural Complications: Are Re-Entry Devices Ever Helpful
Erwin Blessing, MD
- 5:24 – 5:29** Guillotine TMA After Arterial Revascularization: When And Why Is It Helpful With CLTI And How Should It Be Done
Miguel F. Montero-Baker, MD (PowerPoint Presentation With Synched Audio)
- 5:30 – 5:35** A New Technology (From AOTI) Combining Local Oxygen Therapy With Cycled Compression And Humidification Enhances Healing Of Diabetic Wounds And Ischemic Ulcers After Revascularization
Anil P. Hingorani, MD
Enrico Ascher, MD
- 5:36 – 5:41** When Lower Extremity Interventions Are Required In Patients With Prior EVAR Or Kissing Iliac Stents, How Can Contralateral Femoral Access Be Used: Technical Tips
Dipankar Mukherjee, MD
- 5:42 – 5:47** Alternate Anatomic Approaches To Lower Extremity Arteries When Standard Approaches Are Prevented By Scarring Or Infection
Neal S. Cayne, MD
Enrico Ascher, MD
Frank J. Veith, MD
- 5:48 – 5:53** Effects Of Atherectomy On Immediate Luminal Gain In Patients With In-Stent Restenosis/Thrombosis: Which Atherectomy Device Is Best
Joseph J. Ricotta II, MD, MS
- 5:54 – 5:59** How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries
Enrico Ascher, MD
Frank J. Veith, MD
- 5:59 – 6:00** **End of Program C-2**
(No formal Panel Discussion will be held. Comments and Questions should be addressed to the Speakers on an individual basis later in the meeting.)

WEDNESDAY, NOVEMBER 20, 2024

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor

6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor

6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT WEDNESDAY PROGRAMS

PROGRAM D (SESSIONS 23-30)

Progress In Lower Extremity Occlusive Disease And Its Treatment

6:40 A.M. - 6:05 P.M.

Location: Grand Ballroom East, 3rd Floor

PROGRAM E (SESSIONS 31-38)

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest; Outpatient And Office Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence Based Medicine

6:40 A.M. - 6:05 P.M.

Location: Grand Ballroom West, 3rd Floor

PROGRAM F (SESSIONS 39-46)

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/EVAR), Multilayer Bare Stents, Infraarenal AAAs And Standard EVAR, And Hot New Aortic Topics

6:50 A.M. - 6:10 P.M.

Location: Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 23-30)

PROGRESS IN LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT

Grand Ballroom East, 3rd Floor

SESSION 23 (Grand Ballroom East, 3rd Floor)

GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI

Moderators: *Enrico Ascher, MD*

Andrej Schmidt, MD

Christopher K. Zarins, MD

6:40 – 6:45 How Do Prior Endovascular Interventions Affect Future Lower Extremity Bypass Outcomes For CLTI: Why Do The Results Of The BEST-CLI Trial Make This More Important

Kenneth Rosenfield, MD

Alik Farber, MD, MBA

Matthew T. Menard, MD

6:46 – 6:51 The Effect Of Optimal Medical Therapy On Outcomes In Patients With CLTI In The BEST-CLI Trial: What Should This Therapy Be And How Should It Be Monitored

Vikram S. Kashyap, MD

6:52 – 6:57 Five-Year Mortality In Medicare Patients Undergoing Interventions For CLTI And IC Is Worse Than We Thought: 67% For CLTI And 33% For IC

Jeffrey J. Siracuse, MD, MBA

6:58 – 7:03 **DEBATE:** An Endo First Approach Is Best For Treating CLTI In Almost All Patients: The Role For Open Bypasses Is Very Limited (What Percent): Why BEST-CLI And BASIL 2 Have Not Changed My Practice

Christopher J. Abularrage, MD

- 7:04 – 7:09** **DEBATE:** Open Bypass Should Be The First Treatment For Many CLTI Patients: When Is This So And In What Percent Of CLTI Patients
Michael S. Conte, MD
- 7:10 – 7:15** Is The Open Surgery First Or Endovascular First Approach Controversy Still Alive For CLTI: What Percentage Of An Interventionalist's Patients Should Be Treated First By Open Surgery
Marianne Brodmann, MD
- 7:16 – 7:21** What Causes Small Foot Arteries To Have Decreased Blood Flow Resulting In CLTI: Medial Arterial Calcification (MAC) Causes Increased Vascular Stiffness And Decreased Blood Flow; Atheromatous And Non Atheromatous Lesions Further Obstruct Blood As Shown Pathologically: Can Any Of These Be Treated
Roberto Ferraresi, MD
- 7:22 – 7:27** What Are The Best Current Techniques For Revascularizing BTK And Below-The-Ankle (BTA) Lesions Causing CLTI: Is Open Bypass Ever The Best
Stefan Müller-Hülsbeck, MD
- 7:28 – 7:33** Microembolization During Complex Endovascular Procedures Is Causing More Damage Than We Think To The Already Compromised Pedal Runoff: Is Paclitaxel A Causal Agent
Peter A. Schneider, MD
- 7:34 – 7:39** Is Preop CT Fractional Flow Reserve (FFR_{CT}) Guided Coronary Revascularization Beneficial In Patients Requiring Invasive Treatment For Lower Extremity (LE) Lesions: An RCT Comparing Standard Care Versus Such Revascularization Is Showing The Benefit Of The Latter: What Is The Best Time For The Coronary Procedure—Before Or After The LE Treatment
Christopher K. Zarins, MD
Dainis K. Krievins, MD
- 7:40 – 7:45** Radial-to-Peripheral Interventions For Lower Extremity Arterial Lesions (PAD): An Update On Available Tools And Techniques And Precautions: What's Possible And What's Not
Craig M. Walker, MD
- 7:46 – 7:53** **Panel Discussion**

SESSION 24 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE)

Moderators: *Craig M. Walker, MD*
Ramon L. Varcoe, MBBS, MS, PhD
Peter A. Schneider, MD

PROGRESS IN ATHERECTOMY

- 7:53 – 7:58** Which Vascular Specialists Are Performing Tibial Atherectomies And Angioplasties For Intermittent Claudication And Are There Suboptimal Outcomes: Is Atherectomy Usage Overall Being Abused
Caitlin W. Hicks, MD, MS
- 7:59 – 8:04** Update On Atherectomy Devices: Do They Still Have A Role In 2024: Which One Or Ones Are Best: Has Their Benefit Been Proven
Todd R. Vogel, MD, MPH
- 8:05 – 8:10** Atherectomy In Patients With CLTI, In Stent Restenosis (ISR) And Diabetes: When Is It Helpful; How Durable Is It: Which Devices Are The Best
Ignacio Escotto, MD

- 8:11 – 8:16** The Objective Benefits Of Directional Atherectomy In Treating Lower Extremity Occlusive Lesions Are Real: When And How Should It Be Used And When Should It Not
Andrej Schmidt, MD
Dierk Scheinert, MD
Thomas Zeller, MD
- 8:17 – 8:22** What Is The Evidence That Atherectomy Is Effective In Femoropopliteal Interventions
Eric A. Secemsky, MD, MSc
- DRUG ELUTING STENTS (DESS) FOR BTK LESIONS**
- 8:23 – 8:28** For BTK Lesions, Results Justify A Change In The Role Of Stenting From Bailout Use To Primary Stenting: For Which Lesions And With Which Stents
Marco G. Manzi, MD
- 8:29 – 8:34** An Update Of The 2-Year Results And Economic Cost Effectiveness Analysis Of The LIFE-BTK Randomized Controlled Comparison Of Abbott’s Esprit Drug-Eluting Resorbable Stent (DERS) With Plain Old Balloon Angioplasty (POBA): When Will DERSs Make A Difference
Ramon L. Varcoe, MBBS, MS, PhD
Sahil A. Parikh, MD
Brian G. DeRubertis, MD
- 8:35 – 8:40** Update On Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5 Years: From The DISAPEAR Registry And A Meta-Analysis Of Other Bioresorbable BTK Stent Results
Steven Kum, MD
- 8:41 – 8:46** Updated Experience With Everolimus And Other Nonabsorbable DESs To Treat Infrapopliteal BTK Lesions – Long And Short – Causing CLTI: What Are The Stents And When Do They Help: Why Will The DERSs Be Better
Robert A. Lookstein, MD, MHCDL
- 8:47 – 8:52** Late-Breaking Final Patency And Wound Healing Results With A 3-French Compatible Microstent (From Micro Medical) Versus POBA For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: From The STAND RCT
Robert E. Beasley, MD
Marco G. Manzi, MD
- 8:53 – 9:00** **Panel Discussion**
- SESSION 25 (Grand Ballroom East, 3rd Floor)
LOWER EXTREMITY TOPICS RELATED TO DRUG COATED BALLOONS (DCBs), AND DRUG ELUTING STENTS (DESS) AND OTHER INTERWOVEN (SUPERA) STENTS
- Moderators:** *Kenneth Ouriel, MD, MBA*
Sahil A. Parikh, MD
Michael S. Conte, MD
- 9:00 – 9:05** One View On The Final Result Of The Scare And Concern That Paclitaxel Coated Devices For Lower Extremity Treatments Increased Mortality And Amputation Rates: The Case Is Closed: What Were Its Costs
Peter A. Schneider, MD
- 9:06 – 9:11** Another View On The Final Word: Is There Still Any Validity To The Increased Amputation And Mortality Rate Signals After Use Of Paclitaxel Coated Devices In The Lower Extremity: How Can We Explain These Signals In Older Studies And Their Disappearance In More Recent Data: The Case Is Not Yet Fully Closed
Konstantinos Katsanos, MSc, MD, PhD

- 9:12 – 9:17** Update On DCBs For BTK Angioplasty: RCT Comparing A Paclitaxel DCB (Litos From Acotec) Versus A Sirolimus DCB (Magic Touch From Concept Medical): Update On Enrollment And Data In The DEBATE BTK DUELL RCT And The XTOSI Study
Francesco Liistro, MD
Edward T. Choke, MBBS, PhD
- 9:18 – 9:23** Progress With A Sustained Release Sirolimus DCB For FemPop Lesions: 1-Year Results With The Magic Touch DCB Compared To A Paclitaxel DCB: From The SIRONA Study
Dierk Scheinert, MD
Andrej Schmidt, MD
Thomas Zeller, MD
Marianne Brodmann, MD
- 9:24 – 9:29** Adventitial Drug Delivery With The BullFrog Device (From Mercator MedSystems) And The Spur Device (From Reflow): How Do They Work And How Will We Know They Improve Results
William A. Gray, MD
- 9:30 – 9:35** To Reduce Injury In Post Balloon PTA Dissections: The Value Of Stents, Tacks, Etc.
Michael K.W. Lichtenberg, MD
- 9:36 – 9:41** Late Breaking Information Shows That Higher Dose Of Statins Greatly Lessens The Risk Of SFA Stent Restenosis: Is It True With DESs
Timothy W.I. Clark, MD
- 9:42 – 9:47** The Light And Darkness Of Fluoropolymer-Based Limus DESs In The Treatment Of Femoropopliteal Lesions
Osamu Iida, MD, PhD (PowerPoint Presentation With Synched Audio)
- 9:48 – 9:53** Updated And Long-Term Follow-Up Results With The Vasculomimetic Interwoven Supera Stent In Angulated And Tortuous Lower Extremity Anatomies
Rajiv Parakh, MBBS, MS
- 9:54 – 9:59** Are DESs Ever Associated With Aneurysmal Degeneration: Is It Related To The Drug (Paclitaxel Or Limus) Or To The Fluoropolymer Excipient To Which The Drug Is Attached
Osamu Iida, MD, PhD (PowerPoint Presentation With Synched Audio)
- 10:00–10:08** **Panel Discussion**
- 10:08–10:18** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 26 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs

Moderators: *John R. Laird, MD*
Dierk Scheinert, MD
Sean P. Lyden, MD

NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs

- 10:18–10:23** How Should We Move Forward With Limus Coated Devices After FDA Has Cleared Paclitaxel Coated Devices: Are There Promising Results Currently With Limus Coated DCBs
Marianne Brodmann, MD

- 10:24-10:29** 4-Year Results Of An RCT Comparing Surveil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating FemPop Lesions: From The TRANSCEND Trial
Peter A. Schneider, MD
- 10:30-10:35** Paclitaxel-Eluting Devices Decrease Major Amputation Rates In Peripheral Arterial Disease Without Increasing Mortality: From The French Nationwide DETECT Study
Yann Gouëffic, MD, PhD
- 10:36-10:41** Update On The Randomized Head-To-Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 5-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages
Dierk Scheinert, MD
Sabine Steiner, MD
- 10:42-10:47** Update On The BioMimics 3D Spiral Flow Prosthetic Graft From Veryan Medical: Does It Prevent Neointimal Hyperplasia And Improve Patency: 3-Year Results With FemPop Lesions
Robert E. Beasley, MD
- 10:48-10:53** One Year Results Of The SPORTS RCT – Comparing DESs (Eluvia – Boston Scientific) Versus Bare Metal Stents (BMSs) Versus DCBs: Which Device Is Best And In What Circumstances
Gunnar Tepe, MD
- 10:54-10:59** Updated 5-Year Results Of The IMPERIAL RCT Head-To-Head Comparison Of The Eluvia DES (Boston Scientific) With The Zilver PTX DES (Cook): Both Are Safe And Effective: What Are The Differences
Stefan Müller-Hülsbeck, MD
William A. Gray, MD
Thomas Zeller, MD
- 11:00-11:05** 1-Year Results Of The DEBATE-BTK SHOCK RCT Evaluating The Impact Of Lithotripsy Prior To DCB Treatment In Diabetic Patients Undergoing BTK Revascularization
Francesco Liistro, MD
- 11:06-11:11** Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With De Novo Or Recurrent FemPop Lesions Through 3 Years In The ILLUMENATE US And European RCTs
Sean P. Lyden, MD
Marianne Brodmann, MD
Sahil A. Parikh, MD
William A. Gray, MD
- 11:12-11:18** **Panel Discussion**
NEW INFORMATION ON BTK DCBs AND DESs
- 11:18-11:23** Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter
Francesco Liistro, MD
- 11:24-11:29** When, How And With What Devices Are Endovascular Treatments The Best Way To Treat BTK Disease Causing CLTI
Brian G. DeRubertis, MD
- 11:30-11:35** 5-Year Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency Versus POBA To Treat BTK Lesions
Francesco Liistro, MD
Wei Guo, MD

- 11:36–11:41** Sirolimus DCBs For Infrapopliteal Interventions: The Cordis/MedAlliance Soluton 4BTK IDE Trial Update: Overseas Results Have Been Promising
Patrick J. Geraghty, MD
George L. Adams, MD
Michael K.W. Lichtenberg, MD
- 11:42–11:47** How Does The LIFE BTK Study With Esprit Bioresorbable DES (From Abbott) Change The BEST-CLI Conclusions For BTK Lesions
Lawrence A. Garcia, MD
- 11:48–11:53** Below-The-Ankle Endo Interventions In 2024: Techniques, Devices And Should Balloons Be Drug Coated Or Not
Marianne Brodmann, MD
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 27 (Grand Ballroom East, 3rd Floor)

PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: OPTIONS TO SAVE THE “NO OPTION FOR TREATMENT” LIMB AND THE “DESERT FOOT”

Moderators: *Richard F. Neville, MD*
Marco G. Manzi, MD
Roberto Ferraresi, MD

- 1:00 – 1:05** Successful Bypasses To Foot Arteries And Their Branches Allowed Limb Salvage In What Were Thought To Be 'No Option For Treatment' CLTI Patients
Enrico Ascher, MD
Frank J. Veith, MD
- 1:06 – 1:11** What Presently Defines A No Option Or Desert Foot Before Or After Failed Endo Or Open Treatments: Under What Conditions Are Further Extreme Limb Salvage Procedures Possible
Peter A. Schneider, MD
- 1:12 – 1:17** No Option CLTI Is Often A Misnomer: What Diagnostic And Therapeutic Procedures Can Result In Successful Limb Salvage In Many Of These Patients
Hisham Rashid, FRCS

VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES

- 1:18 – 1:23** Why PTFE Bypasses To Infrapopliteal Arteries Have Been A Controversial Procedure For More Than 40 Years – And Why They Continue To Be
Matthew T. Menard, MD
- 1:24 – 1:29** Long-Term Multicenter Outcomes Show That Prosthetic (PTFE) Bypasses To Tibial And Peroneal Arteries Are Worthwhile
Hasan H. Dosluoglu, MD
Richard F. Neville, MD
Enrico Ascher, MD
Frank J. Veith, MD

UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI

- 1:30 – 1:35** Value Of Open Surgical Vein ArterIALIZATION: When And How It Can Be Useful: Technical Tips From The First One To Make It Work
Pramook Mutirangura, FRCS (PowerPoint Presentation With Synched Audio)

- 1:36 – 1:41** Why Foot Vein Arterialization Can Save Limbs With Truly No Other Option: What Is The Physiology That Allows Successful Arterialization Into Small Veins And The Capillary Bed: What Is Necessary For This To Occur
Roberto Ferraresi, MD
- 1:42 – 1:47** Update On The PROMISE Trials And Registry Results In No Option CLTI Patients With Foot Gangrene Shows That Deep Vein Arterialization (DVA) Using The LimFlow Device Can Produce Wound Healing And Limb Salvage: When Does It Work And When Doesn't It: Are There Drawbacks
Daniel G. Clair, MD
Hany M. Zayed, MD
Andrej Schmidt, MD
Daniela Branzan, MD
- 1:48 – 1:53** Technical Advances In (DVA) With The LimFlow Device: Improved Access, Better Post Procedural Care And Wound Management Are Essential
Anahita Dua, MD, MS, MBA
- 1:54 – 1:59** Technical Tips For DVA: The Most Important Part Starts After The Procedure
Erwin Blessing, MD
- 2:00 – 2:05** Deep Venous Arterialization (DVA): Advantages Of Open Surgical Versus Endovascular Procedures Based On A Single Center Experience
Richard F. Neville, MD
- 2:06 – 2:11** Novel Uses Of Selective Superficial Venous Arterialization To Achieve Lower Limb Salvage: Techniques, Indications, Precautions And Results
Patrick J. Geraghty, MD
- 2:12 – 2:17** Hybrid Superficial Venous Arterialization For No Option CLTI: Technical Tips: Causes And Patterns Of Failure - Which Is Common
Miguel F. Montero-Baker, MD
- 2:18 – 2:24** **Panel Discussion**

SESSION 28 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN PROSTHETIC GRAFTS; STENT-GRAFTS; PERCUTANEOUS ENDOVASCULAR BYPASSES; STENT OCCLUSIONS AND TREATMENT OF IN STENT RESTENOSIS (ISR)

Moderators: *Timothy M. Sullivan, MD*
Patrick J. Geraghty, MD
Anahita Dua, MD, MS, MBA

NEW CONCEPTS RE PTFE GRAFTS AND STENT-GRAFTS

- 2:25 – 2:30** Heparin-Bonded Expanded PTFE Grafts For BTK Bypasses: What Is The Evidence That They Are Better And Are Propaten (Gore) Grafts The Best For Extensive FemPop Disease: Based On An RCT And A Systemic Review And Meta-Analysis
Yann Gouëffic, MD, PhD
- 2:31 – 2:36** Less Invasive And More Effective Hybrid Method For Restoring Patency To Occluded PTFE Bypasses Using A Fluoroscopically Guided Adherent Clot Remover (From Edwards)
Neal S. Cayne, MD
Frank J. Veith, MD
- 2:37 – 2:42** 5-Year Results Of Viabahn Stent-Graft For Complex FemPop Lesions: Technical Tips, Advantages And Limitations
Osamu Iida, MD, PhD (PowerPoint Presentation With Synched Audio)

PERCUTANEOUS FEMPOP BYPASSES

- 2:43 – 2:48** 3-Year Results With Percutaneous (PQ) Transvenous FemPop PTFE Bypasses Using The Torus 2 Endograft (From Endologix): How Is It Done And Updated Results From The US DETOUR Trial: Does It Have Limitations
Sean P. Lyden, MD
Daniel G. Clair, MD
Peter A. Schneider, MD
- 2:49 – 2:54** 5-Year Results With Percutaneous Transvenous PTFE FemPop Bypass (PQ From Endologix) The DETOUR 1 TRIAL: Will Open Bypasses Become Obsolete
Dainis K. Krievins, MD
- 2:55 – 3:00** Percutaneous Extravascular FemPop PTFE Bypasses Without Traversing The Vein: Technique And 6-Year Experience In Patients: Is It More Cost Effective: What Are The Limitations
Pierre G. Sarradon, MD
Jean Pierre Becquemin, MD

STENT OCCLUSIONS AND TREATMENT OF IN STENT RESTENOSIS (ISR)

- 3:01 – 3:06** Treatment Of SFA In Stent Occlusions: Technique Of Direct Stent Puncture: And Value Of The Excimer Laser To Cross And Treat The Occlusions: How Is It Done And Advantages
Craig M. Walker, MD
- 3:07 – 3:12** What Are The Best Current Treatment Options For ISR: What Are The Results Including Recurrence Rates
Stefan Müller-Hülsbeck, MD

ROLE OF OPEN PTFE BYPASSES IN CLTI

- 3:13 – 3:18** In The Endovascular Era, What Is The Current Role Of Open Bypasses In A Limb Salvage Program: What Percentage Of CLTI Patients Will Need One At Some Time In Their Course And What Percentage Of Those Will Require A PTFE Graft
Niten Singh, MD
- 3:19 – 3:39** **Panel Discussion And Break**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 29 (Grand Ballroom East, 3rd Floor)

LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES

Moderators: *Brian G. DeRubertis, MD*
Marco G. Manzi, MD
Frank J. Veith, MD

- 3:40 – 3:45** An Important Multicenter Propensity Matched Comparison Of Endo Versus Open Infrainguinal Treatment For CLTI Shows That Open Treatment Is Superior And Supports The Main Finding Of BEST-CLI
Jean-Baptiste Ricco, MD, PhD
- 3:46 – 3:51** How To Reconcile The Different Primary Outcomes And Main Conclusion Of The BEST-CLI And BASIL-2 RCTs
Michael S. Conte, MD
- 3:52 – 3:57** How The Data From BEST-CLI And BASIL-2 Can Be Combined To Produce Conclusions Superior To Those Of Either Trial Alone
Alik Farber, MD, MBA
Andrew W. Bradbury, MD
Matthew T. Menard, MD
Kenneth Rosenfield, MD

- 3:58 – 4:03** New Subanalysis Findings From The BEST-CLI RCT Are Critically Important To The Treatment Of CLTI Patients: Open Surgical Bypass Operations Still Have A Critical Role: Open Versus Endo Treatment Of Infrapopliteal Disease: Does Endo Treatment Burn Bridges
Matthew T. Menard, MD
Alik Farber, MD, MBA
Kenneth Rosenfield, MD
- 4:04 – 4:09** Findings From BASIL-3, An RCT Comparing Clinical And Cost Effectiveness Of 3 Treatment Modalities For CLTI From FemPop Disease: POBA Versus DCBs Versus DESs
Andrew W. Bradbury, MD
- METHODS FOR EVALUATING FOOT PERFUSION**
- 4:10 – 4:15** Foot Perfusion Measurements Are The Best Method To Evaluate Treatment Effectiveness For CLTI: What Methods Are Available And Best
Werner Lang, MD
- 4:16 – 4:21** How And Why To Measure Foot Perfusion During And After Endo Treatments: Hyperspectral Imaging, O₂ Sensors, Etc.: When Is The Angiosome Concept Helpful; When Not
Marianne Brodmann, MD
- 4:22 – 4:27** New Methods For Evaluating The Significance Of Lower Extremity Arterial Lesions And Foot Perfusion Using Fractional Flow Reserve (FFR) And MRI; How They Work And Their Value In Assessing Therapeutic Success
Bijan Modarai, PhD
- 4:28 – 4:35** **Panel Discussion**

SESSION 30 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)

Moderators: *Matthew T. Menard, MD*
Caitlin W. Hicks, MD, MS
Thomas S. Maldonado, MD

INTERMITTENT CLAUDICATION (IC)

- 4:36 – 4:41** At 2 Years After Endovascular Interventions For IC, Only 32% Of Patients Were Free From Recurrent IC: From A VQI Multicenter Study: What Are The Implications
Peter F. Lawrence, MD
- 4:42 – 4:47** Decreasing Unnecessary And Potentially Harmful Endovascular Procedures In Patients With IC Which Are Almost Never Justified And Should Not Be Reimbursed
Caitlin W. Hicks, MD, MS
- 4:48 – 4:53** Under What Circumstances Could Tibial Endo Interventions Possibly Be Justified For IC
Sahil A. Parikh, MD
- 4:54 – 4:59** When Do Outcomes For Lower Extremity Revascularizations Justify Their Use For IC In Patients >80 And >90
Jeffrey J. Siracuse, MD, MBA
- 5:00 – 5:04** **Panel Discussion**

ACUTE LIMB ISCHEMIA (ALI) (See Also Session 63)

- 5:04 – 5:09** When And Why Is ALI Best Treated By Open Surgery: When Are Endovascular Treatments Best
Peter Henke, MD

- 5:10 – 5:15** The PROMOTE-ALI Study Shows That Open Surgery Is Still Number One In The Treatment Of ALI
Katariina M. Noronen, MD
- 5:16 – 5:21** **DEBATE:** ALI Is Always Best Treated Endovascularly: Why And What Techniques May Be Required
Ali Amin, MD, RVT
- 5:22 – 5:27** **DEBATE:** When Is Open Surgery Required To Treat ALI: When Is Mechanical Thrombectomy And Thrombo-Aspiration The Best Treatment: When Should Lytics Be Used: Based On A Systematic Review And Meta-Analysis
Yann Gouëffic, MD, PhD
- 5:28 – 5:33** Characteristics Of All The Commercial Systems For Mechanically Removing Clot To Treat ALI: What Are The Advantages And Disadvantages Of Each
Jos C. van den Berg, MD, PhD
- 5:34 – 5:39** What Is New With Penumbra Indigo Clot Aspiration Systems: Improved Mechanical Catheter And Computer Based Clot Removal Indigo Systems: Modulated Pulsed Aspiration Technology (Lightning Bolt) For The Treatment Of Acute Arterial Clot: How It Works And Why It Improves Clot Removal In Various Vascular Beds: Is Open Surgery Ever Needed
James F. Benenati, MD
- 5:40 – 5:45** New Findings From The STRIDE Multicenter Trial: Mechanical Suction Thrombectomy With The Indigo Aspiration System (Penumbra) Had Few Complications And Excellent Limb Salvage: When Was It Contra-indicated And When Was Angioplasty, Stenting Or Bypass Necessary
Thomas S. Maldonado, MD
- 5:46 – 5:51** Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: What Devices Are Available And What Are Their Advantages And Limitations
Patrick E. Muck, MD
- 5:52 – 5:57** Time To Perfusion In ALI: Which Is Faster, Lightning Bolt 7 (Penumbra) Or Open Surgical Embolectomy: When Is Open Surgery Necessary In 2024
Sean P. Lyden, MD
- 5:58 – 6:05** **Panel Discussion**
End of Program D

PROGRAM E (SESSIONS 31-38)

NEW DEVELOPMENTS IN MEDICAL TREATMENTS AND NEW DRUGS; PROGRESS IN ANTI-ATHEROGENIC AND ANTI-HYPERTENSIVE TREATMENTS; MANAGEMENT OF ENDOLEAKS; RECORDED LIVE CASES FROM LEADING CENTERS IN THE US AND EU; ISSUES OF INTEREST; OUTPATIENT AND OFFICE BASED VASCULAR TREATMENT; TOPICS RELATED TO GOVERNMENT, REIMBURSEMENT, THE SVS, VQI, FDA, GUIDELINES, TRIALS AND EVIDENCE BASED MEDICINE
Grand Ballroom West, 3rd Floor

SESSION 31 (Grand Ballroom West, 3rd Floor)

ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND RIVAROXABAN

Moderators: *Caron B. Rockman, MD*
Michael R. Jaff, DO

- 6:40 – 6:45** Postop Myocardial Infarctions (MIs) In Vascular Patients: What Are The New Options For Diagnosis, Prevention And Treatment
Peter Henke, MD
- 6:46 – 6:51** What Is The Best Current Method For Evaluating The Heart In Patients Undergoing Open And Endovascular Surgery: When Is A Stress Test An Important Tool
David H. Stone, MD
- 6:52 – 6:57** New Findings From The VOYAGER PAD And COMPASS RCTs With Low Dose Rivaroxaban (Xarelto [Janssen/J&J]) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open)
Marianne Brodmann, MD
Sebastian E. Debus, MD, PhD
- 6:58 – 7:03** How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials
Anthony J. Comerota, MD
- 7:04 – 7:09** **DEBATE:** LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show
Sherif A.H. Sultan, MD, PhD
- 7:10 – 7:15** **DEBATE:** Not So: Update On LDL-C Lowering With Statins And Other Drugs: They Are Proven To Stabilize And Shrink Plaques And Decrease Morbid Vascular Events: Stopping Statins Increases Patients' Risk Of MI And Death
Ron Waksman, MD
- 7:16 – 7:21** The Risk Of Arteriosclerosis And Its Complications Are Increased By LDL Cholesterol (LDL-C) Levels, Elevated Lp(a) And Inflammation: What Are The Best Medical Strategies To Decrease These Parameters: Statins, Adjunctive LDL-C Lowering Drugs Inclisiran, Bempedoic Acid, Ezetimibe, PCSK-9 Inhibitors, Lepodisiran, Colchicine, Olezarsen, Etc. And Anti-Inflammatories: How They Should Be Administered
Richard Bulbulia, MA, MD
- 7:22 – 7:27** Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured
J. David Spence, MD
- 7:28 – 7:33** An Interesting New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work
Nicholas Kipshidze, MD, PhD
- 7:34 – 7:42** **Panel Discussion**

SESSION 32 (Grand Ballroom West, 3rd Floor)

CATHETER BASED TREATMENTS FOR RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, CORONARY DESs, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS

Moderators: *Ron Waksman, MD*
Lindsay Machan, MD

**UPDATE ON RENAL DENERVATION FOR
HYPERTENSION**

- 7:42 – 7:47** Renal Denervation For Resistant Hypertension Really Works As Shown By RCTs: What Are The Techniques And Devices: When Should They Be Used
Eric A. Secemsky, MD, MSc
- 7:48 – 7:53** The Role Of Pressure Wires And IVUS In The Assessment Of Renal Artery Stenosis In The Treatment Of Hypertension And Other Conditions
Lindsay Machan, MD
- 7:54 – 7:59** Effect Of Increased Hydration And Protein Intake On Lower Extremity Arteriosclerotic Ischemia With Intermittent Claudication And CLTI: What Is The Evidence And The Mechanism: Will It Change The Game And Decrease The Need For Stents And Bypasses
Juan C. Parodi, MD (PowerPoint Presentation With Synched Audio)
Samuel Fernandez, MD

**OTHER TOPICS RELATED TO VASCULAR DISEASE AND
ITS TREATMENT**

- 8:00 – 8:05** When And To What Level Can Postoperative Anemia Be Tolerated After Major Vascular Surgery: When Should It Be Corrected By Transfusion And Do Cardiac Comorbidities Make A Difference
Panos Kougias, MD, MSc
- 8:06 – 8:11** New Developments In Methods To Prevent Kidney Damage From Iodinated Contrast Agents
Roxana Mehran, MD
- 8:12 – 8:17** How Important Is Inflammation As Determined By C-Reactive Protein (CRP) Levels In Predicting Adverse Cardiac Events: What Drugs Can Lower This Risk
Ron Waksman, MD
- 8:18 – 8:23** When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks: Why Does The Duration Of Cessation Matter
Jeffrey J. Siracuse, MD, MBA
- 8:24 – 8:29** In Patients Undergoing Carotid Endarterectomy (CEA), What Should Best Medical Therapy (BMT) Be: Should Clopidogrel Be Part Of This BMT And Should It Be Continued During The Perioperative Period
Timothy M. Sullivan, MD
- 8:30 – 8:35** How To Manage Patients With Recent Coronary DESs Who Require Vascular Operations Or Interventions: What To Do About Antiplatelet Medications: How Long To Wait Before Stopping Safely: What To Do With Urgent Or Emergent Cases To Avoid DES Thrombosis
Caron B. Rockman, MD
- 8:36 – 8:42** **Panel Discussion**
- 8:42 – 8:54** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 33 (Grand Ballroom West, 3rd Floor)

**PROGRESS IN MANAGING ENDOLEAKS:
UNDERSTANDING THEIR CONSEQUENCES AND
PREDICTING, PREVENTING AND TREATING THEM**
(For Important Related Talks See Session 33 In Our 2023
Program On Our Website VEITHsymposium.org)

Moderators: *Timur P. Sarac, MD*
Luis A. Sanchez, MD
Mark W. Mewissen, MD

ALL ENDOLEAKS AFTER EVAR

- 8:54 – 8:59** Update On The Optimal Management Of Endoleaks: Key Points From A Systematic Review
Bernardo C. Mendes, MD

- 9:00 – 9:05 Dynamic CT Scanning – The Gold Standard For Evaluating Endoleaks: Technical Requirements And How To Make It Help In Diagnosis And Treatment
Alan B. Lumsden, MD
- 9:06 – 9:11 How To Improve Endoleak Detection And Finding Its Source With Contrast Enhanced Sonography
Thanila A. Macedo, MD

TYPE 1 ENDOLEAKS

- 9:12 – 9:17 Major Systemic Trauma Can Lead To High-Flow (Type 1) Endoleaks In EVAR Patients: Can They Occur With Endografts Fixed By Hooks Or Barbs And What Is The Best Treatment
Francesco Setacci, MD
Carlo Setacci, MD
- 9:18 – 9:23 Update On Embolization Treatment For Type 1 Endoleaks After EVAR: Indications And Technical Tips To Make It Work Successfully: Contraindications
Robert A. Morgan, MD
- 9:24 – 9:29 How Can Type I Endoleaks Cause Sac Pressurization (Endotension) Without Contrast Visualization: How To Detect And Treat It: What Else Can Cause Endotension
Kenneth Ouriel, MD, MBA
- 9:30 – 9:35 How To Treat Type 1 Endoleaks After EVAR: When Cuff, When F/EVAR, When Chimney, When Open Conversion: What About Embolization
Matteo Orrico, MD
Nicola Mangialardi, MD
- 9:36 – 9:41 **Panel Discussion**

TYPE 2 ENDOLEAKS AFTER EVAR

- 9:41 – 9:46 Most Type 2 Endoleaks After EVAR Should Be Left Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: What Are The Exceptions
Hence J.M. Verhagen, MD, PhD
- 9:47 – 9:52 When Should We Reintervene And Keep Reintervening For Persistent Type 2 Endoleaks: What Factors With Persistent Type 2 Endoleaks Are Predictors Of AAA Rupture
Naoki Fujimura, MD, PhD
- 9:53 – 9:58 When Do Type II Endoleaks Cause Type I Endoleaks After Standard EVAR: How To Best Diagnose And Treat Them: Does One Need Proximal Aortic Control If Treatment Is Open Conversion
Randall R. De Martino, MD
- 9:59-10:04 The Role Of Mural Thrombus In The Development Of Late Type II Endoleaks: How Best To Prevent Them And Treat Them
Natzi Sakalihan, MD, PhD
- 10:05-10:10 Patients On Anticoagulation Are More Likely To Develop Endoleaks After EVAR: How Does It Influence The Outcome Of Endoleak Treatment And Should It Be Stopped If Possible
Faisal Aziz, MD
- 10:11-10:16 How Can 3D Fusion And ASSIST Guidance (GE) Help In Type 2 Endoleak Treatment By Any Approach: How To Do It
Mark W. Mewissen, MD
- 10:17-10:22 **Panel Discussion**
- 10:23-10:28 Transcaval Approach For Endoleak Embolization: A Minimally Invasive Hot Needle Approach And Other Technical Tips Including How To Close The Aortic Access Site
Sean P. Lyden, MD

- 10:29–10:34** Transgraft Treatment Of Type 2 Endoleaks After EVAR: When And How To Do It
James F. McKinsey, MD
- 10:35–10:40** The Latest Advances In The Treatment Of Type 2 Endoleaks: A New Technique With The Taurus Device Will Be Better: What Is It And Results
Zvonimir Krajcer, MD
- 10:41–10:46** Innovative Type 2 Endoleak Obliteration Via Collateral Networks: Technical Tips
Palma M. Shaw, MD, MBA
- 10:47–10:52** An Algorithm For Diagnosing And Treating Challenging Endoleaks After F/B/EVAR For TAAAs
Thomas F. Lindsay, MDCM
- 10:53–11:00** **Panel Discussion**

SESSION 34 (Grand Ballroom West, 3rd Floor)

ISSUES IMPORTANT TO VASCULAR SURGEONS/ SPECIALISTS

Moderators: *Kim J. Hodgson, MD*
Thomas L. Forbes, MD

- 11:00–11:05** A Tribute To James S. T. Yao, MD, PhD (1932–2023)
Jon S. Matsumura, MD
- 11:06–11:11** How Human Behavior – Even With Vascular Surgeons/Specialists – Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better
Scott L. Stevens, MD

ISSUES RE EVIDENCE BASED PRACTICE

- 11:12–11:17** RCTs Are Too Often Underpowered With Other Serious Flaws: So They Are Misused As Evidence, Negatively Influencing Practice And Innovation In Health Care
Frans L. Moll, MD, PhD
- 11:18–11:23** Why Systematic Reviews, Meta-Analyses And RCTs Can Be Misleading: What To Do About It: Does Current Wisdom Help
Janet T. Powell, MD, PhD
- 11:24–11:29** Answering The Current Big Questions: Vascular Surgeons/Specialists Need To Develop High Quality Evidence To Improve Care: How And Why To Do It
Jens Eldrup-Jorgensen, MD

ISSUES IMPORTANT TO VASCULAR SURGEONS/ SPECIALISTS

- 11:30–11:35** How Can Vascular Surgeons/Specialists Become Successful Entrepreneurs: What To Do And What Not To Do
Jeffrey H. Lawson, MD, PhD
- 11:36–11:41** The Distracted Surgeon: Lessons Learned From Running Multiple Rooms: Is It Really More Efficient Or A Bad Practice Resulting In Poor Patient Care
Patrick A. Stone, MD

ISSUES IN VASCULAR TRAINING

- 11:42–11:47** Optimal New Training Paradigm For Vascular Surgeons: 0+5 Vascular Surgery Residency Followed By 2 Years Of Cardiac Surgery Residency Training: Why Is It Better Than 2 Extra Years Of Laboratory Research
Alan B. Lumsden, MD
- 11:48–11:53** Obtaining Cardiac Surgery Training After Vascular Surgery Training: I Did It, So It's Possible: Is It Worthwhile: Advantages And Disadvantages
Jennifer L. Perri, MD, MBA
- 11:54–12:00** **Panel Discussion**

**12:00- 1:00 Lunch Break – Rhinelander Gallery, 2nd Floor
Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 35 (Grand Ballroom West, 3rd Floor)

**RECORDED LIVE CHALLENGING CASES AND
INNOVATIVE TECHNIQUES FROM THE PLINIO
ROSSI AND LINC COMPONENTS**

Moderators: *Fabrizio Fanelli, MD*
Andrew Holden, MBChB
Francesco Setacci, MD

THE PLINIO ROSSI COMPONENT

- 1:00 – 1:08** DES Versus DCB+BMS Versus BMS+DCB Versus DCB+DES: The Winner Is: Evaluation Of The Different Treatment Strategies With A Focus On The Now Increasingly Common Combination Of DCB Plus BMS
Fabrizio Fanelli, MD
- 1:08 – 1:16** Preservation Of Left Subclavian Artery In TEVAR With Off-The-Shelf Branch Stent-Graft Technology
Dittmar Böckler, MD
- 1:16 – 1:24** The Knickerbocker Technique – An Underutilized And Highly Effective Strategy For False Lumen Management In Chronic Aortic Dissection
Andrew Holden, MBChB
- 1:25 – 1:30** **Panel Discussion**

THE LINC COMPONENT

Moderators: *Dierk Scheinert, MD*
Andrej Schmidt, MD
Daniela Branzan, MD

- 1:30 – 1:39** Recorded Case: Tibial Reconstruction With Enhanced Local Drug Delivery Using The Temporary Spur Stent System
Andrej Schmidt, MD
- 1:40 – 1:45** Distal Micro-Embolization During Complex Endovascular Procedures – The Underestimated Threat
Peter A. Schneider, MD
- 1:46 – 1:55** Endovascular Reconstruction Of A Highly Calcified, Obstructed Tibial Trifurcation With Multivessel Distal Protection
Andrej Schmidt, MD
- 1:55 – 1:59** **Panel Discussion**

SESSION 36 (Grand Ballroom West, 3rd Floor)

**MORE ISSUES IMPORTANT IN VASCULAR
SURGERY: HISTORY, PRACTICE PATTERNS, VALUE
OF GUIDELINES AND RCTs, MALPRACTICE,
SCIENCE, TRAINING AND HUMAN BEHAVIOR**

Moderators: *Jack L. Cronenwett, MD*
Jerry Goldstone, MD

- 2:00 – 2:05** A Tribute To Hans-Henning Eckstein, MD, PhD (1955-2024)
Sebastian E. Debus, MD, PhD (PowerPoint Presentation with Synched Audio)

VASCULAR HISTORY

- 2:06 – 2:11** Einstein And Nissen: A New York Story About An AAA Wrapped In Cellophane
Frank J. Criado, MD
- 2:12 – 2:17** The SVS Digital History Archive: What Is It, Why It Is Important And Should Vascular Surgeons Contribute To It And Use It
Jerry Goldstone, MD

2:18 – 2:23 Multispecialty Vascular Care Departments Or Units Within Institutions Are Best For Patients And Physicians: How Should The Dominant Specialty And Leader Be Chosen: How Should Rewards Be Distributed
Samuel R. Money, MD, MBA

VASCULAR SURGERY'S ROLE AND RECOGNITION

2:24 – 2:29 Vascular Surgery's Identity And Role Is Usually In A Subservient Position Within A Heart And Vascular Unit: What Should Be Done To Correct This Inequity In The Interest Of Better Patient Care
Timur P. Sarac, MD

2:30 – 2:35 Vascular Surgery Needs An Independent ABMS Approved Board And Associated RRC To Thrive As A Specialty In The Medical Hierarchy And To Have Its Value Appropriately Recognized
Sean P. Lyden, MD

2:36 – 2:41 The Negative Impact Of Hospital Administrators On Vascular Surgery And Vascular Surgeons' Careers: Why Is It Happening, Why Is It Worse For Vascular Surgeons Than Other Specialists And What Can Be Done To Counteract It
Samuel R. Money, MD, MBA

2:42 – 2:47 The Role Of Women In Vascular Surgery: What Has It Been And Where Is It Going
Cynthia K. Shortell, MD

2:48 – 2:56 **Panel Discussion**

ISSUES RE THE CONFLICT BETWEEN ETHICS AND FINANCES

2:56 – 3:01 Simultaneous Overuse And Undertreatment Of Patients With PAD And CLTI: Why The Problem Exists And What Should Be Done To Fix It
Joseph L. Mills, MD

3:02 – 3:07 Physician And Industry Responsibility In Overuse Of Technology (Atherectomy, CAS, EVAR, Etc.): Especially Important In View Of The Recent Media Spotlight On This Issue
Murray L. Shames, MD

UNIONIZATION FOR VASCULAR SURGEONS

3:08 – 3:13 Why Vascular Surgeons Should Unionize: The Pros And Cons
Enrico Ascher, MD

3:14 – 3:19 Racial And Ethnic Disparities In Clinical Trials And The Treatment Of CLTI: What Are The Causes And What Can Be Done About Them
Vincent L. Rowe, MD

3:20 – 3:32 **Panel Discussion And Break**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 37 (Grand Ballroom West, 3rd Floor)

MORE ISSUE-RELATED TOPICS IMPORTANT TO VASCULAR SURGEONS AND VASCULAR SPECIALISTS; ISSUES RELATED TO OUTPATIENT CENTERS OR OFFICE BASED LABS (OBLs)

Moderators: *Anton N. Sidawy, MD, MPH*
Krishna Jain, MD

3:32 – 3:37 Vascular Spinoff Revenue In Tertiary Healthcare Systems: Substantially More Downstream Benefits From Vascular Surgeons: How To Make Hospital Administrators Appreciate The Value Of Vascular Surgeons And Reward Them Appropriately
Joseph V. Lombardi, MD, MBA

- 3:38 – 3:43** The Significant Burden Of Iatrogenic Vascular Injury On The Vascular Surgery Workforce At A Tertiary Care Center: What Can And Should Be Done To Offset This Problem
Caron B. Rockman, MD
- 3:44 – 3:49** Current Medicare Reimbursement For Complex AAAs (F/B/EVAR) Is Inadequate For Physicians And Less Profitable For Hospitals: How Does It Harm Vascular Surgery
Samuel R. Money, MD, MBA
- 3:50 – 3:55** How And Why Aortic And Lower Extremity Artery Gender Differences Matter In The Treatment Of Vascular Disease: What Can Be Done To Offset This Problem
Linda M. Harris, MD
- 3:56 – 4:01** The Value Of Telehealth In Vascular Surgery: Reimbursement Issues And When Is It Misleading
Misty D. Humphries, MD, MAS

ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs

- 4:02 – 4:07** The Ever-Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It's Happening And Where Is It Going
Sean P. Roddy, MD
Robert M. Zwolak, MD, PhD
- 4:08 – 4:13** Limb Preservation Centers: Benefit To Patients, Physicians And Health Care Systems: How To Create One
Krishna Jain, MD
- 4:14 – 4:19** How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable And Still Allow Vascular Surgeons To Only Work From 8 AM To 5 PM
Mark A. Mattos, MD
- 4:20 – 4:25** How To Make Outpatient Vascular Treatment Facilities (OBLs, ASCs) Safe, Effective And Profitable Without Doing Unjustified Procedures: How Can They Make Uniquely Important Vascular Research Contributions
Christopher J. Kwolek, MD, MBA
Enrico Ascher, MD
- 4:26 – 4:32** **Panel Discussion**

SESSION 38 (Grand Ballroom West, 3rd Floor)

UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; IMPROVING VASCULAR CARE QUALITY; FIXING FALSE TESTIMONY; FLAWED PEER REVIEW; FDA IMPROVEMENTS; LEARNING HEALTH SYSTEMS

Moderators: *Sean P. Roddy, MD*
Jack L. Cronenwett, MD
Kim J. Hodgson, MD

VASCULAR REIMBURSEMENT ISSUES

- 4:32 – 4:37** What's Happening With Vascular Surgeon Reimbursement In 2024 And What Are The Prospects For 2025: For Hospital And OBL Procedures
Sean P. Roddy, MD
- 4:38 – 4:43** Current Medicare Reimbursement For Ch/EVAR And F/EVAR Is Inadequate: The Situation Is Untenable: How Did We Get There And Can The Problem Be Fixed
Clayton J. Brinster, MD

4:44 – 4:49 Reimbursement For Vascular Procedures Under CMS Is Deeply Flawed And Subject To The Bias Of Others: It Results In Unethical Compensatory Behavior: What Can Be Done About It
Sean P. Roddy, MD

ISSUES RE QUALITY OF VASCULAR CARE

4:50 – 4:55 New Developments In And Benefits From VQI Participation: It Will Make For Better Doctors And Vascular Care And It Will Cut Hospital Costs
Jens Eldrup-Jorgensen, MD

4:56 – 5:01 The SVS/ACS Vascular Verification Program (VVP) To Assure Quality Vascular Care In Inpatient And Outpatient Programs: What Is It And How Will It Help Vascular Surgery
Anton N. Sidawy, MD, MPH

5:02 – 5:07 How Can The Insurance Industry Improve The Quality And Appropriateness Of Vascular Care And Help Vascular Surgery Survive In A Competitive World
Russell H. Samson, MD, RVT

PUNISHING FALSE TESTIMONY

5:08 – 5:13 How Do We Hold Physicians Who Provide False Or Misleading Testimony Against Vascular Surgeons Accountable: Has The SVS Committee On This Topic Ever Done Anything To Do What Should Be Done
O. William Brown, MD, JD

5:14 – 5:20 **Panel Discussion**

PEER REVIEW RELATED ISSUES

5:20 – 5:25 Our System Of Peer Reviews Is Flawed: Within Hospitals; Within Journal Reviews: How Might Artificial Intelligence (AI) Improve Them
Timothy M. Sullivan, MD

5:26 – 5:34 What Is An Impact Factor For A Peer Reviewed Journal Or An Article: What Is Plum X And H-Index: How Are They Calculated And Why Are They Important: What Constitutes Plagiarism – It's Not Simple (8-Minute Presentation)
Peter F. Lawrence, MD
Peter Gloviczki, MD

FDA RELATED ISSUES

5:35 – 5:40 I Was From The Government And I'm Here To Help: FDA Resources To Assure Safe And Effective Medical Devices In Vascular Disease: What Is The LEAF Initiative To Assure That Trials Are Appropriate For FDA Approval
Robert E. Lee, MD
Philip P. Goodney, MD, MS

5:41 – 5:46 Why Do IDEs Fail To Get FDA Approval: Updates To The FDA 510 (K) Program And Why They Are Important
Valerie M. Merkle, PhD

5:47 – 5:52 Different Perspectives From Industry And The FDA Regarding The Importance Of Innovation, Engineering And Financial Rewards That Influence Innovation
Dorothy B. Abel, BSBME

5:53 – 5:58 What Is A Learning Health System And Why Should It Matter To Vascular Surgery
Charles C. Miller, PhD

5:59 – 6:05 **Panel Discussion**
End of Program E

PROGRAM F (SESSIONS 39-46)

MORE NEW DEVELOPMENTS IN THORACIC AORTIC DISEASE, TEVAR, AORTIC DISSECTIONS, TAAAs, JUXTA- AND PARARENAL AAAs, PARALLEL GRAFTS, FENESTRATED AND BRANCHED EVAR (F/B/EVAR), MULTILAYER BARE STENTS, INFRARENAL AAAs AND STANDARD EVAR, AND HOT NEW AORTIC TOPICS

Trianon Ballroom, 3rd Floor

SESSION 39 (Trianon Ballroom, 3rd Floor)

MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INFLAMMATORY ANEURYSMS AND THEIR TREATMENT

Moderators: *Ramon Berguer, MD, PhD*

Timothy A. Resch, MD, PhD

- 6:50 – 6:55** A Novel Low Profile Stent-Graft For The Treatment Of All Thoracic Aortic Segments: What Makes It Unique And Clinical Status
Francesco Setacci, MD
- 6:56 – 7:01** Options For Left Subclavian Revascularization During TEVAR: Laser Fenestration, Open Bypass, Single Branch Device (Gore), Etc.: Advantages And Limitations Of Each
Timothy A. Resch, MD, PhD
- 7:02 – 7:07** Challenges And Successes With Endografts In The Treatment Of Ascending Aortic Dissections (TAADs), Penetrating Ulcers And Pseudoaneurysms
Rodney A. White, MD
- 7:08 – 7:13** **DEBATE:** The STABILISE Technique To Eliminate The False Lumen And Relaminate The Aorta Will Change The Treatment Of Acute And Subacute TBADs And Will Replace Most False Lumen Occlusion Devices And F/B/EVAR Treatments: How To Do It And Precautions
Igor A. Laskowski, MD, PhD
Heepeel Chang, MD
- 7:14 – 7:19** **DEBATE:** Not So Fast! A Multimodular Approach To Treating Acute, Subacute And Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug Or Other Techniques
Tilo Kölbel, MD, PhD
Fiona Rohlfes, MD, PhD
- 7:20 – 7:25** Outer/Inner/Upward Branches Or Fenestrations: Strategies For Complex Aortic Repair For Patients With Chronic TBADs: Advantages And Limitations Of Each
Bijan Modarai, PhD
- 7:26 – 7:31** Current Advances In The Treatment For Inflammatory Aneurysms: How Effective Are EVAR And TEVAR
Furuzan Numan, MD
- 7:32 – 7:37** Update On The Experience With BeGrafts (From Bentley), A Balloon Expandable Covered Stent For Treating Aortic Coarctations, Aneurysms And Midaortic Syndrome: Advantages And Limitations
Elchanan Bruckheimer, MBBS
- 7:38 – 7:43** Relay Custom Made Endografts (Terumo) For TEVAR, Scalloped, Etc.: When And Why Are They Advantageous And Do They Still Have A Role In View Of Other New Endografts
Michael P. Jenkins, MBBS, BSc, MS
Mo S. Hamady, MD
- 7:44 – 7:51** **Panel Discussion**

SESSION 40 (Trianon Ballroom, 3rd Floor)

**MORE ADVANCES RELATED TO TREATING
PATHOLOGY INVOLVING THE ASCENDING AORTA
AND THE AORTIC ARCH; AORTIC DISSECTIONS,
INTRAMURAL HEMATOMAS (IMHs) AND THEIR
TREATMENT**

Moderators: *Rodney A. White, MD*
Tilo Kölbel, MD, PhD

- 7:52 – 7:57** Debranching Aortic Arch Branches: When And How To Do It; Technical Tips And How To Avoid Pitfalls
Bernardo C. Mendes, MD
- 7:58 – 8:03** With TAADs When And How Should The Distal Aorta Be Treated By TEVAR Before Repair Of The Ascending Aorta
Ourania Preventza, MD
Joseph S. Coselli, MD
- 8:04 – 8:09** With TAADs Why And When Should TEVAR Of The Descending Thoracic Aorta Be Performed Prior To Open Type A Repair: Should The Procedures Be Staged
Mazin Foteh, MD
- 8:10 – 8:15** The Present Status Of Endovascular Treatment For Lesions Of The Aortic Arch: What Can Be Done, What Can't Be Done: What Has Changed In The Last Decade
Gustavo S. Oderich, MD
- 8:16 – 8:21** With Chronic TBADs Laser Assisted Resection Of The Dissection Septum Or Membrane Creates A Single Lumen TEVAR Landing Zone: How Is This Technique Performed And Updated Results
Nuno V. Dias, MD, PhD
Björn Sonesson, MD, PhD
- 8:22 – 8:27** **Panel Discussion**
- 8:27 – 8:32** Multicenter Study Of Physician Modified Endografts (PMEGs) For TAAA And Complex AAA Repairs: What Does It Show About Their Advantages And Limitations
Nikolaos Tsilimparis, MD, PhD
- 8:33 – 8:38** Updated 5-Year Results From The European Experience With The Novel Nexus Single And Double (Duo) Branched (OTS) Endovascular Devices (From Endospa) For The Treatment Of Zone 0 And 1 Aortic Arch Aneurysms: What Makes This Device Unique
Mario L. Lachat, MD
- 8:39 – 8:44** Status And Results From The US TRIOMPHE Trial Of The Endospa Nexus Endograft (OTS) For Treating Complex Aortic Arch Lesions Including Chronic Dissections
Ross Milner, MD
- 8:45 – 8:50** In Situ Fenestration For Endovascular Repair Of Aortic Arch Lesions: Does It Reduce Perioperative Strokes And How To Avoid Cerebral Ischemia During The Procedure
Ralf R. Kolvenbach, MD
- 8:51 – 8:56** Origins Of Intramural Hematomas (IMHs): Why So Many Prove Benign And Do Well With Medical Treatment: When And How To Treat Them With TEVAR
Frank J. Criado, MD
- 8:57 – 9:03** **Panel Discussion**
- 9:03 – 9:16** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 41 (Trianon Ballroom, 3rd Floor)

OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; INTERESTING NEW DEVICES FOR THEIR TREATMENT

Moderators: *Christopher J. Kwolek, MD, MBA*
Gilbert R. Upchurch, MD

COMPLEX AAAs AND TAAAs

- 9:16 – 9:21** Does Open Repair Still Remain The Gold Standard For Complex AAA Repair: What The Updated And Good Studies That Bear On This Question Show: It's Not The Old RCTs (EVAR 1, DREAM And OVER)
George Geroulakos, MD, PhD
- 9:22 – 9:27** TAAA Repairs For Aneurysms From Dissections And Degenerative Disease Are Best Treated By Combining Open And Endo Techniques: Technical Tips
Yamume Tshomba, MD
- 9:28 – 9:33** Hybrid Repair Of A TAAA (Proximal Endograft + Distal Open Repair - The Upchurch Procedure): When Is It Indicated; What Are The Advantages And Updated Results
Gilbert R. Upchurch, MD
Sal Scali, MD
Dean Arnaoutakis, MD
- 9:34 – 9:39** Endovascular Solutions To Effectively Deal With Hostile Neck Anatomy Of AAAs Other Than F/B/ EVAR: Why They Should Be Favored
Stavros K. Kakkos, MD, PhD
- 9:40 – 9:45** French National (Real World) Comparison Of Results Of F/EVAR And Open Repair (ORFEVAR Trial) For The Treatment Of Complex AAA (Juxtarenal, Suprarenal And Type IV TAAAs): Do We Need An RCT
Frederic Cochenec, MD, PhD
- 9:46 – 9:52** **Panel Discussion**
- 9:52 – 9:57** Optimal Surveillance Methods And Timing After F/B/ EVAR And EVAR
Sara L. Zettervall, MD
- 9:58–10:03** Secondary Interventions Up To 30 Days Following F/B/ EVAR Of Complex AAAs: How Morbid Are They
Jonathan R. Boyle, MD

TOPICS RELATED TO INTERESTING NEW DEVICES

- 10:04–10:09** Shape Memory Polymer Embolization Devices To Treat Gutter Endoleaks After Parallel Grafts: Technique And Results
James F. McKinsey, MD
- 10:10–10:15** Update On The TAMBE Endograft Device (Gore) For Treating Complex AAAs And TAAAs: Current Configuration And Advantages, Technique For Insertion: Now Approved By The FDA
Carlos H. Timaran, MD
- 10:16–10:21** Update On The WeFlow Device For Juxtarenal AAA, TAAA And Arch Repairs: A New Inner Branch And Outer Branch Approach: How Does It Work And Promising Results
Wei Guo, MD (PowerPoint Presentation With Synched Audio)
- 10:22–10:27** How To Prevent Patch Aneurysms After Open TAAA Repair With Long Antegrade Grafts: How To Treat Them When They Occur – Endo, Open
Manju Kalra, MBBS
- 10:28–10:33** Use Of FORS Technology (Philips) In The Treatment Of TAAAs: Technical Tips In Its Use: What Are Its Advantages, Limitations And Disadvantages
Geert Willem H. Schurink, MD, PhD

10:34-10:40 Panel Discussion

SESSION 42 (Trianon Ballroom, 3rd Floor)

**PROGRESS IN TREATING ILIAC ANEURYSMS;
ILIAC BRANCHED DEVICES (IBDs); UPDATE ON
MULTILAYER FLOW MODULATING (MLFM) AND
OTHER BARE STENTS FOR TREATING ANEURYSMS
AND DISSECTIONS**

*Moderators: Thomas S. Maldonado, MD
Rodney A. White, MD*

**TREATMENT OF ILIAC ANEURYSMS WITH IBDs OR
PARALLEL GRAFTS**

10:40-10:45 15-Year Experience With Iliac Branched Endografts For Aortoiliac Aneurysms: Advantages, Limitations: Long-Term Results Of The Various IBD Devices

Giovanni Pratesi, MD

10:46-10:51 5-Year Outcomes Of The ICEBERG Study Of The Gore IBD (IBE Device) For Revascularizing The Hypogastric Artery With Aortoiliac Aneurysms: Advantages And Limitations

Michel Reijnen, MD, PhD

10:52-10:57 5-Year Outcomes Of The Cook PRESERVE II Study Of The Cook IBD (ZBIS): Why Is It Different From Other IBD Devices: When Is It Contraindicated

W. Anthony Lee, MD

10:58-11:03 Advantages And Current Status Of The Artivion IBD Device For Treating Common And Internal Iliac Artery Aneurysms: From The PLIANT II Multicenter Study: When Will This Device Be Available In The US

Lee Bouwman, MD, PhD

11:04-11:09 Parallel Endograft Techniques For Treating Common And Internal Iliac Artery Aneurysms: When And Why They Are Better Than IBDs And How To Make Them Work Effectively

Armando C. Lobato, MD, PhD

11:10-11:15 Panel Discussion

**UPDATE ON MULTILAYER FLOW MODULATING
(MLFM) AND OTHER BARE STENTS**

11:16-11:21 Why MLFM Bare Stents Should Be The Treatment Of Choice For Visceral, Peripheral And Iliac Aneurysms: Advantages And Has Rupture Been Universally Prevented: What About For TAAAs

Rodney A. White, MD

11:22-11:27 Treatment Of Aortic Dissections With Multilayer Bare Stents (MLFM) And 9 Years Of Follow Up: When Are They Effective And When Aren't They

Victor S. Costache, MD, PhD

Ivo Petrov, MD, PhD

11:28-11:33 Value Of Multilayer Bare Stents (MLFM – Allay From Intressa) In The Treatment Of TBAD Patients With Or At High Risk Of End Organ Malperfusion: Long-Term Results

Claude D. Vaislic, MD

11:34-11:39 Role Of Bare Metal AMDS Stents From Artivion (Formerly Cryolife/Jotec) For Repair Of Acute Type A Dissections: Indications, Results And Limitations

Wilson Y. Szeto, MD (PowerPoint Presentation With Synched Audio)

11:40-11:45 Thoraflex Hybrid Graft Rescue When Treatment Of Aortic Dissection In The Arch With Bare Stents (AMDS From Artivion And Allay From Intressa) Fails: What Is The Mechanism Of Failure And What Is The Bailout Procedure

Mazin Foteh, MD

11:46–11:51 Aortic Dissection In Pregnancy: Why Is The Mortality So High: Why Is Its Diagnosis Delayed: How Should Its Treatment Differ From Non-Pregnant Patients
Richard G.J. Gibbs, FRCS

11:52–12:00 **Panel Discussion**

12:00– 1:00 **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 43 (Trianon Ballroom, 3rd Floor)

MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE

Moderators: *Michael L. Marin, MD*
Stephan Haulon, MD

1:00 – 1:05 Endovascular Strategies For Repairing Giant Hypogastric Artery Aneurysms (>6 cm): What Special Techniques Are Needed
Jacques Busquet, MD

1:06 – 1:11 Debunking The Lingering Myths Of Asymmetrical Saccular Aneurysms: Are They All Ticking Time Bombs, How Should Their Diameter Be Measured – To Include The Normal Aorta Or Not: Do They Rupture At A Smaller Diameter
Frank J. Criado, MD

1:12 – 1:17 A Direct Comparison Of Major Contemporary EVAR Devices – Looking At Long-Term Efficacy And Patient Survival Using Big Data And Linkage Techniques
Ramon L. Varcoe, MBBS, MS, PhD

1:18 – 1:23 EVAR Patients On Anticoagulation Have Increased Mortality, Endoleaks, Sac Expansion And Reinterventions: From A Meta-Analysis Of >35,000 Patients
George A. Antoniou, MD, PhD, MSc

1:24 – 1:29 Rapid Gate Cannulation During EVAR: A Technical Tip To Make It Quick And Easy
Felice Pecoraro, MD

1:30 – 1:35 **Panel Discussion**

1:36 – 1:41 Update On Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access And Closure For Complex AAA EVAR In Obese Or Scarred Groins – Even With Calcified Arteries: It Is Almost Always Possible
Barend M.E. Mees, MD, PhD

1:42 – 1:47 Lessons Learned From The Nellix Experience: Why Sac Sealing Should Still Be Pursued For EVAR, But Not From The Nellix Platform: What Changes Would Make Sac Sealing Devices Work
Matt M. Thompson, MD

1:48 – 1:53 How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How Does A Standard Protocol Help; How To Treat Them When They Occur
David J. Minion, MD

1:54 – 1:59 **DEBATE:** Repairs Of Small AAAs (<5.5 cm) Are Justified By Many Evidence Based Reasons: What Are These Reasons And What Are The Downsides
Jessica P. Simons, MD, MPH

2:00 – 2:05 **DEBATE:** There Is High Level Evidence That Men With AAAs <5.5 cm Should NOT Undergo Elective Repair: AAAs <6 cm In Men Rarely Rupture: The Thresholds For Repair Of Aortic And Iliac Aneurysms Need To Be Raised
Anders Wanhainen, MD, PhD

2:06 – 2:11 **Panel Discussion**

SESSION 44 (Trianon Ballroom, 3rd Floor)

MORE NEW DEVELOPMENTS IN AAAs: WITH HERITABLE AORTIC DISEASE (CONNECTIVE TISSUE GENETIC DISORDERS): HOW DOES THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR; OTHER RELATED AAA TOPICS

Moderators: *Evan C. Lipsitz, MD, MBA*
James H. Black, III, MD

TREATMENT OF AORTIC ANEURYSMS WITH HERITABLE AORTIC DISEASE AND CONNECTIVE TISSUE DISORDERS

2:12 – 2:17 In Patients With AAAs From Genetic Aortopathy (Heritable Aortic Disease): Is Active Exercise Beneficial Or Harmful
James H. Black, III, MD

2:18 – 2:23 Results Of Endovascular Graft Aortic Repair In Mixed Connective Tissue Disease (Heritable Aortic Disease) Patients: Is It Time To Change The Guidelines: In What Circumstance Is Endovascular Repair Indicated
Sal Scali, MD

2:24 – 2:29 Reasons To Change From Open To Endovascular Aortic Aneurysm Repair In Patients With Heritable Aortic Disease (Connective Tissue Disorders): When Is Open Repair Mandatory In This Setting; Technical Tips
Michael J. Jacobs, MD

2:30 – 2:35 Value Of F/B/EVAR In The Management Of Failed Open Repairs Of Complex AAAs In Patients With Heritable Aortic Disease: Technical Tips
Barend M.E. Mees, MD, PhD
Geert Willem H. Schurink, MD, PhD
Michael J. Jacobs, MD

2:36 – 2:41 Why Selection Of Bridging Stent-Graft Type Is Vitally Important For F/B/EVAR Treatment Of Complex AAAs In Patients With Heritable Aortic Disease: Which Stent-Graft Is Best
Gustavo S. Oderich, MD
Carlos H. Timaran, MD
Andres Schanzer, MD

THE EFFECT OF AAA SAC THROMBUS LOAD

2:42 – 2:47 **DEBATE:** Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective
Hence J.M. Verhagen, MD, PhD

2:48 – 2:53 **DEBATE:** Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated
David H. Deaton, MD

2:54 – 2:59 An RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: The Next Generation Of EVAR Endografts Must Prevent Endoleaks: How Can It Be Done
Dominique Fabre, MD, PhD
Stephan Haulon, MD

3:00 – 3:05 Value Of Preemptive Embolization Of AAA Side Branches (IMA And Lumbar) Prior To EVAR: Objective Evidence That It Prevents Sac Enlargement
Daniela Branzan, MD
Andrej Schmidt, MD

3:06 – 3:12 **Panel Discussion**

3:12 – 3:24 **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 45 (Trianon Ballroom, 3rd Floor)

MORE HOT AORTIC TOPICS

Moderators: *Peter Gloviczki, MD*

Jade S. Hiramoto, MD

3:24 – 3:29 What's New And What's Wrong With The New SVS Guidelines For Aortic Surgery
Michael C. Stoner, MD

3:30 – 3:35 Aorto-Enteric Fistulas Associated With Infected EVARs Or Open Prosthetic Grafts: What Are The Differences Between Them And What Are The Implications For Treatment
Sal Scali, MD

3:36 – 3:41 Active AAA Sac Management With Polymer Plugs: How To Use Them To Improve Outcomes By Preventing Endoleaks After EVAR: Results From The SHAPE AAA Trial (From Shape Memory)
Andrew Holden, MBChB

3:42 – 3:47 Fenestrated And Branched Graft Treatment Of Failed Open TAAA Repairs
Mazin Foteh, MD

3:48 – 3:53 Aortic Dissection Tear Size And Morphology: Why Is It Important: How Do Bare Stents Prevent Stent-Graft Induced New Entry Tears (SINEs) After Treatment Of Aortic Dissections
Shang Loh, MD

3:54 – 3:59 **Panel Discussion**

4:00 – 4:05 Coil Embolization To Treat Aortic 'Blebs', Entry-Tears And Pseudoaneurysms: How Does It Work, When Is It Indicated, And Results
Jos C. van den Berg, MD, PhD

4:06 – 4:11 Endovascular Treatment In Patients With Connective Tissue Disorders: When Can This Be Considered First Choice Treatment: Technical Tips And Results
Piergiorgio Cao, MD

4:12 – 4:17 Endovascular Management For Isolated Abdominal Aortic Dissection: When To Treat Invasively And When Not; What To Do If It Involves The Juxtarenal Aorta: How Does Treatment Differ From That Of AAAs
Chang Shu, MD

4:18 – 4:23 What Modifications Of The Distal Components Of F/ EVAR Endografts Help To Avoid Branch Vessel Stent-Graft Compression: Indications And Results
Nuno V. Dias, MD, PhD

4:24 – 4:29 Lipophilic Statins Like Lipitor Increase Risk Of Paraplegia More Than Hydrophilic Statins Like Crestor After B/EVAR For TAAA Repairs: What Is The Mechanism
Jade S. Hiramoto, MD

4:30 – 4:35 **Panel Discussion**

SESSION 46 (Trianon Ballroom, 3rd Floor)

**MORE SHORT HOT NEW TOPICS RELATED TO
AORTIC DISEASE AND ITS TREATMENT**

Moderators: *Andres Schanzer, MD*
Peter F. Lawrence, MD

- 4:36 – 4:41** **DEBATE ROUND 3 (Updated From 2023):** The Vast Majority Of Failed EVARs Can Be Treated Endovascularly
Ross Milner, MD
- 4:42 – 4:47** **DEBATE ROUND 3 (Updated From 2023):** Not So: Many Failed EVARs Are Best Repaired By Open Conversion
Michel Makaroun, MD
- 4:48 – 4:53** Are Low Profile Devices For EVAR And TEVAR Improving Or Worsening Their Outcomes
Naoki Fujimura, MD, PhD
- 4:54 – 4:59** Why EVAR Should Be Preferred Over Open Repair In Young Patients With Suitable Anatomy: From A Meta-Analysis Of >50,000 Patients
George A. Antoniou, MD, PhD, MSc
- 5:00 – 5:05** How Does The ASA-Score And Sarcopenia Influence SCI Risk After Endovascular TAAA Repair
Tilo Kölbel, MD, PhD
- 5:06 – 5:11** What Are The Differences Between The ACC/AHA And The European Guidelines On Ascending Aorta And Arch Disease
Ourania Preventza, MD
- 5:12 – 5:17** **Panel Discussion**
- 5:18 – 5:23** 10 Years Of PMEGs For Complex AAAs: How Do The Results Vary With And Without An IDE, The Extent Of The AAA And With And Without A Prior EVAR
Marc L. Schermerhorn, MD
- 5:24 – 5:29** With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula: It Improves Palliation But Does It Improve Survival
I-Hui Wu, MD, PhD
- 5:30 – 5:35** How Can AI Markedly Reduce Radiation, Contrast Usage And Complications For Complex TAAA Repair With PMEGs
Mahmoud B. Malas, MD, MHS
- 5:36 – 5:41** Pediatric Abdominal Aortic Aneurysms: What Is Their Etiology And How Should They Be Managed
Sherene Shalhub, MD, MPH
- 5:42 – 5:47** B/EVAR In Patients With A Narrow Paravisceral Aorta (<2.5 cm) Is Best Performed With Inner Branched Endografts: Technical Tips To Achieve Optimal Results
Michele Antonello, MD, PhD
Franco Grego, MD
- 5:48 – 5:53** ZFEN Versus Treo Endografts As Platforms For PMEG F/EVARs: Which Is Best And When: Technical Considerations, Advantages And Disadvantages
Joshua D. Adams, MD
- 5:54 – 5:59** When Can Duplex Ultrasound Fully Replace CT Surveillance After EVAR: When Is CT Surveillance Necessary
Sal Scali, MD
- 6:00 – 6:10** **Panel Discussion**
End of Program F

THURSDAY, NOVEMBER 21, 2024

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
 6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor
 6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT THURSDAY PROGRAMS

PROGRAM G (SESSIONS 47-54)

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

6:56 A.M. - 6:00 P.M.

Location: Grand Ballroom East, 3rd Floor

PROGRAM H (SESSIONS 55-63)

New Or Improved Devices For: Standard EVAR And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

7:00 A.M. - 5:59 P.M.

Location: Grand Ballroom West, 3rd Floor

PROGRAM I (SESSIONS 64-73)

Superficial Venous Disease

7:00 A.M. - 7:00 P.M.

Location: Trianon Ballroom, 3rd Floor

Course Leaders: Jose I. Almeida, MD
 Lowell S. Kabnick, MD
 Peter Glociczki, MD
 Thomas W. Wakefield, MD
 Steve Elias, MD

PROGRAM J (SESSIONS 74-78)

Multidisciplinary Stroke Prevention And Treatment

7:30 A.M. - 12:15 P.M.

Location: Murray Hill Suites, 2nd Floor

Course Leader: Allan L. Brook, MD

PROGRAM G (SESSIONS 47-54)

EXCITING NEW OR REDISCOVERED TECHNIQUES, CONCEPTS OR DEVICES; PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs; TRIBUTE TO OUR MILITARY; PROGRESS IN THE TREATMENT OF RUPTURED AAAs; MORE ABOUT NEW DEVICES, TECHNIQUES OR CONCEPTS; PROGRESS IN RADIATION SAFETY

Grand Ballroom East, 3rd Floor

SESSION 47 (Grand Ballroom East, 3rd Floor)

EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES, CONCEPTS

Moderators: Frank J. Veith, MD
 Michael B. Silva, Jr., MD
 Richard F. Neville, MD

6:56 – 7:01 A Patient-Centric Smartphone App For Monitoring Vascular And Endovascular Procedures: What Does It Measure And How Is It Helpful
 Todd R. Vogel, MD, MPH

- 7:02 – 7:07** A New Robotic Device (From Sentante) To Assist With Endovascular Treatments: It Can Accommodate 3 Devices At Once And Be Operated From A Great Distance
Gary M. Ansel, MD
- 7:08 – 7:13** Pediatric Vascular And Endovascular Surgery Is A New Subspecialty Within Vascular Surgery: In Pediatric Patients How Important Are Endovascular Techniques, What Modifications Are Needed And Why Most Aortic Lesions Need To Be Treated By Open Surgery
Alex Fairman, MD
- 7:14 – 7:19** Management Of Pediatric Arterial And Aortic Aneurysms In 2024: Differing Etiologies Necessitating Different Therapeutic Interventions
James C. Stanley, MD
- 7:20 – 7:25** Update On Remote Monitoring Of Vascular Graft Function And Other Parameters Including Blood Pressure: Where Is It At And Where Is It Going
Richard F. Neville, MD
- 7:26 – 7:31** **Panel Discussion**
- 7:32 – 7:37** Provider Skill Is Not Appropriately Recognized And Rewarded In The Health Care Value Equation Of Value = Outcome/Cost: Even Within A Specialty All Doctors Are Not Equal: There Are Stars, Superstars And Journeymen: What To Do About It
Lars B. Lonn, MD, PhD
- 7:38 – 7:43** Can Advances In MRI Eliminate Radiation From AAA Diagnosis, Its Endovascular Treatment And Its Follow Up: The Zero Radiation Project And Where It Stands
Kak Khee Yeung, MD, PhD
- 7:44 – 7:49** How And Why Do Thoracic Endografts For TEVAR Negatively Affect The Blood Pressure And The Heart: Can A Compliant Endograft Prevent The Problem; How Should It Be Made
Juan C. Parodi, MD (PowerPoint Presentation With Synched Audio)
- 7:50 – 7:55** The Negative Impact On Cardiovascular Hemodynamics: Lessons Of TEVAR, F/EVAR, B/EVAR And EVAR: What Causes The Problem And What Can Be Done To Fix It
Sherif A.H. Sultan, MD, PhD
- 7:56 – 8:01** Current Status And Future Potential Of Pig To Human Organ Xenografting
Robert A. Montgomery, MD, DPhil
- 8:02 – 8:07** **Panel Discussion**

SESSION 48 (Grand Ballroom East, 3rd Floor)

PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS

Moderators: *Matthew J. Eagleton, MD*
James F. McKinsey, MD
Jade S. Hiramoto, MD

- 8:08 – 8:13** Outcomes Of Leaving The Celiac Trunk Without A Stent Or Stent-Graft During 4 Vessel F/EVAR: Why A Stent Is Unnecessary And Can There Be Problems With Wires Across The Celiac Or SMA Orifices
Timothy A. Resch, MD, PhD
- 8:14 – 8:19** Value Of Parallel Endografts In The Management Of TAAAs And Other Aortoiliac Pathology: Why Do They Fail And How To Make Them Work
David J. Minion, MD

- 8:20 – 8:25** Complete Aortic Endovascular Repairs For Zones 0-10 Using Parallel Endografts With A Docking Station: How And Why To Make Them Work Effectively Despite Doubts About Parallel Grafts: What Are The Limitations
Manish Mehta, MD, MPH
- 8:26 – 8:31** **DEBATE:** Long-Term Results Of F/EVAR For Juxta- And Pararenal AAAs: Data From ARC Show That It Should Be The Procedure Of Choice
Andres Schanzer, MD
- 8:32 – 8:37** **DEBATE:** Not So: Other Data Including A Meta-Analysis Indicates That We Still Need An RCT Versus Open Repair To Determine The Best Treatment For Juxta- And Pararenal AAAs
Ian Loftus, MD
- 8:38 – 8:44** **Panel Discussion**
- 8:45 – 8:50** Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective: Advantages Of The Gore VBX Stent-Graft
Mark A. Farber, MD
- 8:51 – 8:56** Which Bridging Covered Stents Or Stent-Grafts Work Best For F/B/EVAR: A European Perspective: Why Renal Artery Bridging Stent-Grafts Are The Achilles Heel In B/EVAR And What To Do About It
Martin J. Austermann, MD
- 8:57 – 9:02** The Role Of Open Surgery As Both An Adjunct And Bailout For Failed F/B/EVAR Procedures For Complex AAAs: How To Choose Between Endo And Open Repairs As The Primary Procedure
Bijan Modarai, PhD
- 9:03 – 9:08** Aneurysm Rupture During The Interval Of Staged Endovascular TAAA Repairs: How Frequent Is It And What Can Be Done To Prevent It: Optimal Delay For Stage 2
Randall R. De Martino, MD
Bernardo C. Mendes, MD
- 9:09 – 9:14** Evolving Roles Of In Situ Laser F/EVAR For TAAA Repairs: Technical Tips And Results
Sukgu Han, MD
- 9:15 – 9:23** **Panel Discussion**
- 9:23 – 9:38** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 49 (Grand Ballroom East, 3rd Floor)

MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS

Moderators: *Gustavo S. Oderich, MD*

Timothy A. Resch, MD, PhD

Weiguo Fu, MD

- 9:38 – 9:43** The Value Of Intraoperative Cone Beam CT During F/B/EVAR: What Defects Can Be Detected That Would Otherwise Be Missed: What Equipment Is Required
Nuno V. Dias, MD, PhD
- 9:44 – 9:49** Causes Leading To Branch Leaks And Occlusions After F/B/EVAR: What Forces Are Important And What Can Be Done To Prevent Them
Thomas L. Forbes, MD
- 9:50 – 9:55** Update On Optimal Bridging Stent-Grafts For F/B/EVAR: Advantages And Disadvantages Of The BeGraft, BeGraft Plus (Bentley) And Advanta (iCast – Getinge): Experience With >2,000 Target Vessels
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD

- 9:56–10:01** AAA Sac Behavior After F/B/EVAR: What Is Its Impact On Overall Survival And What Are Its Predictors: From The US Aortic Research Consortium (ARC)
Darren B. Schneider, MD
- 10:02–10:07** Prediction Of 1-Year Mortality After Endovascular TAAA Repair: When Should We NOT Offer The Procedure
Adam Beck, MD
- 10:08–10:13** **Panel Discussion**
- 10:14–10:19** Reasons For And Outcomes Of Open AAA Repair In A High Volume Endovascular Center
Athanasios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD
- 10:20–10:25** F/EVAR Versus Ch/EVAR For Juxtarenal AAAs: How Do The Results Compare After Up To 8 Years Follow-Up In A Real World Experience
Ignacio Escotto, MD
- 10:26–10:31** Parallel Endografts For Aortoiliac Lesions: The Good, The Bad And The Ugly: A Balanced View
Grace J. Wang, MD, MSCE
- 10:32–10:37** Why Is A Distal AUI The Preferred Approach For ZFEN F/EVAR Treatment Of Failed EVAR Devices: When And How To Do It And Outcomes
Martin R. Back, MD
- 10:38–10:43** With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully
Andres Schanzer, MD
- 10:44–10:49** Tips For Beginners To Avoid Traps When Starting A F/BEVAR Program: It Is Doable But Not Simple
Piotr Myrcha, MD
- 10:50–10:56** **Panel Discussion**

SESSION 50 (Grand Ballroom East, 3rd Floor)

A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; UPDATE ON REBOA

Moderators: *Todd E. Rasmussen, MD*
Wayne F. Yakes, MD

- 10:56–11:06** The Battle of Midway: How It Saved The United States And The World (10-Minute Presentation)
Wayne F. Yakes, MD
- 11:07–11:12** Update On A Vascular Surgeon's Impressions About The Devastating Ukraine War: What Is Happening With Major Vascular Injuries
Andriy O. Nykonenko, MD
Oleksandr Sokolov, MD, PhD
- 11:13–11:18** What Is Happening With Major Vascular Injuries To Civilians During The Ukraine War: Are The Resources And Medical Personnel Adequate: Are The US And Western Europe Doing Enough
Yuliia Nahaliuk, MD
- 11:19–11:24** New Developments In Clinical Results After 2 Years With Tissue Engineered Human Biological Arterial Grafts (Humacyte) In Military And Civilian Studies
Todd E. Rasmussen, MD
Charles J. Fox, MD
Randall R. De Martino, MD
- 11:25–11:30** Lessons Learned On Treating Major Military And Civilian Vascular Trauma From The October 7, 2023 Attack On Israel And Its Combat Aftermath
Samy S. Nitecki, MD

- 11:31–11:36** How The US Military Pursued A Policy Of Zero Preventable Combat Deaths From Wounds In Iraq And Afghanistan: Leave No One Behind: How It Applies To Civilian Casualties
Todd E. Rasmussen, MD
- 11:37–11:42** Update On Isolated Limb Perfusion To Enable Traumatically Amputated Limb Reimplantation
Patrick F. Walker, MD
Zachary M. Arthurs, MD
- 11:43–11:48** Progress In Resuscitation And Endovascular Trauma Management With Catheter Based Treatments Including REBOA And Other Devices: What Is Partial And Intermittent REBOA And What Is Their Value
Tal M. Hörer, MD, PhD
- 11:49–11:54** When Is REBOA A Valuable Procedure And When Is It Not: Limitations And Precautions: Does It Have Value In Conditions Other Than Trauma
Joseph J. DuBose, MD
- 11:55–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 51 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS

Moderators: *Thomas L. Forbes, MD*
Martin Björck, MD, PhD
Frank J. Veith, MD

- 1:00 – 1:05** How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased And Is It Worthwhile
Matthew W. Mell, MD, MS
- 1:06 – 1:11** Selection Of Patients With Ruptured AAAs For Noninvasive (Comfort) Care Based On Scoring System Or Advanced Age Is Inappropriate And Unfair To Some Patients
Isabelle Van Herzele, MD, PhD (PowerPoint Presentation With Synched Audio)
- 1:12 – 1:17** Only One-Third Of Ruptured AAA Patients In The 3 RCTs Comparing EVAR With Open Repair Were Randomized: Why Does This And Other Flaws Invalidate The RCT Conclusions: RCTs Can Be Misleading
Thomas L. Forbes, MD
- 1:18 – 1:23** Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: Despite Its Flaws, EVAR Wins In The End – Especially In Patients >80
Willem Wisselink, MD
- 1:24 – 1:29** Reasons Why The Use Of Open Repair Versus EVAR For Ruptured AAAs Still Varies Greatly Even Though EVAR Has Been Proven Superior: Bias Rules
Martin Malina, MD, PhD
- 1:30 – 1:35** Update On Treating All (100%) Ruptured AAAs, Complex AAAs And Thoracic Aneurysms Endovascularly: A 15-Year Experience Shows This Is The Best Treatment And Lowers The Turndown Rate: What Adjuncts May Be Necessary To Achieve This
Tal M. Hörer, MD, PhD
David T. McGreevy, MD, PhD
- 1:36 – 1:41** Aortic Endograft Diameter Sizing With Ruptured Aneurysms: Why Is It Different And How To Do It
Zoran Rancic, MD, PhD

- 1:42 – 1:47** Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen
Martin Björck, MD, PhD
- 1:48 – 1:53** AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures
Piotr Szopinski, MD, PhD
- 1:54 – 1:59** **Panel Discussion**

SESSION 52 (Grand Ballroom East, 3rd Floor)

MORE NEW DEVELOPMENTS IN TECHNIQUES OF ENDO TREATMENT OF RUPTURED AAAs, COMPLEX AAAs AND TAAAs; WHAT IS AND SHOULD BE HAPPENING WITH AAA SCREENING

Moderators: *Keith D. Calligaro, MD*
Mario L. Lachat, MD
Manish Mehta, MD, MPH

CURRENT TECHNIQUES FOR TREATING RUPTURED ANEURYSMS

- 2:00 – 2:05** With Ruptured Complex AAAs And TAAAs Parallel Grafts Are The Best Treatment: They Are Simpler, More Effective And Less Costly Than Other Treatments
Manish Mehta, MD, MPH
- 2:06 – 2:11** In Situ Laser Fenestration For Endovascular Treatment Of Complex Ruptured AAAs: What Equipment Is Needed: When Is It Feasible And Why Is It Better Than Other Treatments: Technical Tips
Anders Wanhainen, MD, PhD
- 2:12 – 2:17** Physician Modified Endografts (PMEGs) And Off-The-Shelf (OTS) Devices Are Both Options For Urgent/ Emergent Treatment Of Ruptured Complex AAAs: Technical Tips
Bernardo C. Mendes, MD
Gustavo S. Oderich, MD
- 2:18 – 2:23** Modifications Of The TREO-FIT Endograft (Terumo) For EVAR That Make It Suitable For Physician Modification (PMEGs) For Use In Emergent And Ruptured Juxtarenal AAAs
Benjamin W. Starnes, MD
- 2:24 – 2:29** Applicability And Results Of Cook t-Branch OTS Endograft In Complex Ruptured AAAs: Advantages And Limitations
Ciro Ferrer, MD, PhD
Rocco Giudice, MD
- 2:30 – 2:35** Outcomes Of A Novel Off-The-Shelf Inner Branch Stent-Graft (E-nside From Artivion) For Urgent TAAA Repair: Insights From An Italian Multicenter Registry
Rocco Giudice, MD
- 2:36 – 2:41** For Treatment Of Ruptured Complex AAAs A Short Custom Made Single Fenestrated Graft Can Be Used To Revascularize The SMA Followed By A Bifurcated Graft And Laser Fenestration For The Renal Arteries: Technique And Experience
Nuno V. Dias, MD, PhD
- 2:42 – 2:47** **Panel Discussion**
- 2:48 – 2:53** A Transvenous (Transcaval) Approach To Endovascular Repair Of Ruptured Thoracic Aneurysms And TAAAs In Patients With Poor Arterial Access: Technical Tips And Can One Deal With Aortic Bifurcation Lesions
Tilo Kölbel, MD, PhD

2:54 – 2:59 Open Retroperitoneal Aortic Approach For Ruptured AAAs: Technical Tips, Advantages And Limitations: When Is It Better Than EVAR And F/EVAR
R. Clement Darling III, MD

NEW DEVELOPMENTS IN AAA SCREENING

3:00 – 3:05 Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed And How Should Screening Groups Be Expanded

Marc L. Schermerhorn, MD

Thomas F.X. O'Donnell, MD

3:06 – 3:11 New Developments In AAA Screening: Should We Change Who Is Being Screened

Jes S. Lindholt, MD

3:12 – 3:17 The Future Of AAA Screening: The Changing Epidemiology Especially Persistent Declining Prevalence Mandates Changes In Screening Recommendations

Anders Wanhainen, MD, PhD

3:18 – 3:23 Technical Tips To Deploy F/EVAR Endografts Precisely With Tortuous Anatomy: How To Compensate For Endograft Rotation And Still Match Fenestrations To Branch Orifices Perfectly

Neal S. Cayne, MD

Björn Sonesson, MD, PhD

3:24 – 3:36 **Panel Discussion And Break**

Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 53 (Grand Ballroom East, 3rd Floor)

EXCITING NEW OR UPDATED CONCEPTS, TECHNIQUES AND TREATMENTS

Moderators: *Fred A. Weaver, MD, MMM*

Matt M. Thompson, MD

3:36 – 3:41 Update On External Sirolimus Patch Wrap-Arounds For PTFE Graft Anastomoses: Do They Decrease Intimal Hyperplasia And Improve Prosthetic Graft Patency

Sriram S. Iyer, MD

3:42 – 3:47 Implantable Carotid Stent-Like Device To Stimulate The Carotid Sinus Nerve (Of Hering) And Treat Intractable CHF And Hypertension (The Barostim System): Current Clinical Status

Fred A. Weaver, MD, MMM

John F. Eidt, MD

Miguel Manzur, MD

3:48 – 3:53 Reducing Fiber And Lint Contamination During Endovascular And Surgical Procedures: Why Is It Important And How To Prevent it

John R. Laird, MD

3:54 – 3:59 Value Of Prostate Artery Embolization For BPH: Indications, Technique And Results

Lars B. Lonn, MD, PhD

4:00 – 4:05 Peripheral Embolization With TEVAR And EVAR Procedures: How Widespread And Important Is It And An Update On Devices To Prevent It

Ralf R. Kolvenbach, MD

4:06 – 4:11 Cancer Incidence After Lower Extremity Bypass Surgery: How Does It Affect Long-Term Outcome In Patients With CLTI: Why The Relationship With Cancer Exists

Dittmar Böckler, MD

- 4:12 – 4:17** Special Technical Tips For The Management Of Pediatric Vascular Trauma And Emergencies: Evolving Endovascular Strategies, Expanded Device Availability, And How To Deal With Spasm
Dawn M. Coleman, MD
- 4:18 – 4:23** Visceral Arterial Compression Syndromes And Their Relationship To Genetic Disorders: Current Optimal Diagnosis And Treatment
Wilhelm Sandmann, MD
- 4:24 – 4:29** High Resolution Infrared Thermography To Detect Vascular Pathology: How Does It Work And How Does It Help
Ivo Petrov, MD, PhD
- 4:30 – 4:37** **Panel Discussion**

SESSION 54 (Grand Ballroom East, 3rd Floor)

PROGRESS IN RADIATION SAFETY AND MORE NEW CONCEPTS, DEVICES AND TECHNIQUES

Moderators: *Lindsay Machan, MD*
Jacob Cynamon, MD

- 4:38 – 4:43** Intravascular Lithotripsy (From Shockwave): A New Valuable Tool To Facilitate Access For Large Sheaths In F/B/EVAR
Athanasios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD

WHAT'S NEW IN RADIATION SAFETY

- 4:44 – 4:49** The Occupational Hazards Of The Pregnant Surgeon: What Modifications In Practice And Techniques Are Necessary To Avoid Or Minimize Them
Venita R. Chandra, MD
- 4:50 – 4:55** Myths And Facts Regarding Radiation Protection And Safety: Imperfections In Protection From Leaded Glasses, Caps, Gloves And Light Weight Leaded Gowns
Lindsay Machan, MD
- 4:56 – 5:01** Improved Radiation Protection With The Protego System: What Is It, How Does It Work; Experience And Results With Operators, Staff And Patients
Venkatesh G. Ramaiah, MD

NEW CONCEPTS, ETC.

- 5:02 – 5:07** Endovascular Options For The Control Of Submassive And Massive Hemoptysis: It Is Lifesaving: When And How To Do It: Coils Are Required
Jacob Cynamon, MD
- 5:08 – 5:13** What's New In Gene And Stem Cell Therapy For No Option CLTI In 2024: Are There Technologies And Trials That Hold Promise – Like BioGenCell
Richard J. Powell, MD
Yael Porat, PhD
- 5:14 – 5:19** **Panel Discussion**
- 5:20 – 5:25** The Aortyx Aortic Patch: A More Compliant Way Than TEVAR To Seal Aortic Defects With TBADs And Other Lesions: A New Endovascular Approach: How Does It Work: Improved Delivery System And Progress To Date
Vicente Riambau, MD, PhD
- 5:26 – 5:31** Disseminated Fungal Infections Of The Vascular System: Why Are They Important And How Should They Be Diagnosed And Treated
Sateesh C. Babu, MD
- 5:32 – 5:37** Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential
Michael B. Silva, Jr., MD

- 5:38 – 5:43** Gore Excluder Iliac Branch Endoprosthesis (IBE) Extension Into The Gluteal Artery To Treat Hypogastric Aneurysms: Technique And Mid-Term Results
Mark W. Mewissen, MD
- 5:44 – 5:49** Best Bridging Stent Selection For The Gore Excluder Iliac Branch Endoprosthesis (IBE): What Works And What Doesn't
Steven Maximus, MD
Gustavo S. Oderich, MD
- 5:50 – 6:00** **Panel Discussion**
End of Program G

PROGRAM H (SESSIONS 55-63)

NEW OR IMPROVED DEVICES FOR: STANDARD EVAR AND MORE COMPLEX AAAs; REPAIRS OF TAAAs, THE ASCENDING AORTA, THE AORTIC ARCH, AND THE DESCENDING AORTA (TEVAR); NEW DEVICES FOR TREATING LOWER EXTREMITY LESIONS BY ENDO OR OPEN TECHNIQUES; UPDATE ON ENDOANCHORS AND FIXATION DEVICES AND NEW OR IMPROVED DEVICES FOR ENDOVASCULARLY REMOVING CLOT AND OCCLUDING BLOOD VESSELS

Grand Ballroom West, 3rd Floor

SESSION 55 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR

Moderators: *Eric L.G. Verhoeven, MD, PhD*

Enrico Ascher, MD

Rossi M. Silva, MD

- 7:00 – 7:05** Updated Results From The AFX 2-LIVE European Registry: An Experience With The Outcomes Of >500 AFX EVAR Cases: Benefits, Complications, Conversions And Technical Considerations
Francesco Speziale, MD
- 7:06 – 7:11** Current Status Of The AFX 2 Endograft (From Endologix) For EVAR: Is Increased Surveillance Indicated
Robert W. Chang, MD
- 7:12 – 7:17** Are We Overtreating AAAs: The Current Diameter Thresholds For AAA Repair (5.5 cm For Men; 5.0 cm For Women) Are No Longer Relevant: Based On New Scrutiny Of Old Trials And A Meta-Analysis Of AAA Rupture Risk
Timothy A. Resch, MD, PhD
- 7:18 – 7:23** Mid-Term Results Of The Alto (Ovation) Low Profile Endograft (From Endologix): Advantages And Current Role In Treating AAAs
Gianmarco de Donato, MD
- 7:24 – 7:29** Comparison Of Excluder Versus Endurant Endografts For EVAR: Which Graft Is Best And In What Circumstances: From A Multicenter Propensity Score Matched Study
Naoki Fujimura, MD, PhD
- 7:30 – 7:35** **Panel Discussion**
- 7:36 – 7:41** Gore Conformable Excluder For EVAR: Advantages And Indications: From The European EXCeL Registry
Marc R.H.M. van Sambeek, MD, PhD
- 7:42 – 7:47** How To Optimize Infrarenal Aortic Neck Sealing With Short Or Angulated Necks (>60-90 Degrees) Without Placing Branches In The Renals: The Unique Features Of The Gore Excluder Conformable AAA Endograft: >1 Year Results
Robert Y. Rhee, MD

7:48 – 7:53 New Polymer Filled Low Profile Endograft Device With O-Ring Sealing: Advantages, How Does It Work And Why Is It Better In Patients With Complex Proximal Neck Anatomy
Piotr Szopinski, MD, PhD

7:54 – 7:59 10-Year Results With The Gore Excluder Endograft For EVAR Show Its Durability: From The GREAT Registry
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD

8:00 – 8:05 Mid-Term Results Of EVAR With Endoanchors In Patients With Hostile Neck Anatomy: Do They Work Better When Used Prophylactically Or Therapeutically: Do They Work Equally Well With All Endografts
Apostolos K. Tassiopoulos, MD

8:06 – 8:11 **Panel Discussion**

SESSION 56 (Grand Ballroom West, 3rd Floor)

NEW OR UPDATED DEVICES FOR STANDARD EVAR OR F/B/EVAR

Moderators: *Christopher J. Kwolek, MD, MBA*
Margaret Tracci, MD, JD

STANDARD EVAR DEVICES

8:12 – 8:17 Five-Year Results And Advantages Of The TREO (Terumo) Endograft For Standard EVARs: Status In The US
Matthew J. Eagleton, MD

8:18 – 8:23 Real World Outcomes With The TREO Endograft (Terumo Aortic): Results From The European TIGER Registry
Vicente Riambau, MD, PhD

8:24 – 8:29 Status Of The Low Profile Alto Endograft (From Endologix) With More Proximal Polymer Sealing Rings For Standard EVAR: Up To 5-Year Results Show Its Advantages: Status Of The JAGUAR RCT Comparing It With Standard EVAR Endografts
Sean P. Lyden, MD
Christopher J. Kwolek, MD, MBA
Andrew Holden, MBChB

8:30 – 8:35 AFX 2 Anatomically Fixed (On The Aortic Bifurcation) Endografts For AAA Repair: The LEOPARD RCT 5-Year Results Show It Has Similar Outcomes To Other Widely Used Proximally Fixed Endografts
Christopher J. Kwolek, MD, MBA

F/B/EVAR TOPICS FOR COMPLEX AAAs

8:36 – 8:41 Comparison Of Various Fenestrated Endografts From Cook, Terumo, Etc.: Advantages And Limitations Of Each
Sonia Ronchey, MD, PhD

8:42 – 8:47 Real World Evaluation Of The OTS Pre-Cannulated Inner Branched Endograft (E-nside From Artivion) For Pararenal Aortic Aneurysms: Advantages And Limitations
Lee Bouwman, MD, PhD
Theodosios Bisdas, MD

8:48 – 8:53 One-Year Outcomes Of The Fenestrated Anaconda (Terumo Aortic) Endograft For Treating Complex AAAs From The GLOBAL FACT Study: What Makes This Endograft Different: Advantages And Limitations
Clark J. Zeebregts, MD, PhD

8:54 – 8:59 Retrospective Analysis Of Laser In Situ Fenestration Of All Endografts: What Does The LIFE Registry Show
Jonathan Bath, MD

9:00 – 9:06 **Panel Discussion**

9:06 – 9:19 **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 57 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS AND THORACIC AORTIC LESION REPAIRS (TEVAR)

Moderators: *Ross Milner, MD*
Carlos H. Timaran, MD

IMPROVED DEVICES FOR TAAA REPAIRS

- 9:20 – 9:25** Progress With A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Clinical Experience And Advantages
Sebastian E. Debus, MD, PhD
Sabine H. Wipper, MD, PhD
Randy D. Moore, MD
- 9:26 – 9:31** Value Of Endo TAAA Repair In Patients With Connective Tissue Disorders: Which Device Or Devices Are Best And Why
Gustavo S. Oderich, MD
- 9:32 – 9:37** Comparison Of The Cook t-Branch OTS Endograft Device With The E-nside (Artivion) Multibranched Device For Juxta- And Pararenal AAAs And TAAAs: Advantages And Limitations Of Each
Matteo Orrico, MD
Nicola Mangialardi, MD
- 9:38 – 9:43** Optimizing Endovascular Treatment Of TAAAs With The Cook OTS t-Branch Endograft: Technical Tips And Contraindications
Marcelo Ferreira, MD
- 9:44 – 9:49** Current Status And Results With Manifold Branched Grafts For TAAA Repairs: What Are They: What Are Their Limitations And Why Haven't They Been Commercialized
Murray L. Shames, MD
Patrick W. Kelly, MD
- 9:50 – 9:55** Treatment Of Narrow True Lumen In Chronic Aortic Dissection Using i-BEVAR E-nside OTS Endograft With Inner Branches (From Artivion): How Does IVUS Help
Giovanni Tinelli, MD, PhD
Dittmar Böckler, MD
- 9:56–10:01** Twinbranch – A New Approach: Evolution Of The Colt Manifold Device For TAAA Repairs To An Inner Branched Technology
Piotr Szopinski, MD, PhD
- 10:02–10:07** **Panel Discussion**

IMPROVED DEVICES FOR TEVAR

- 10:08–10:13** Low Profile Devices For TEVAR And B/EVAR: Disadvantages And Advantages Based On A 10-Year Experience With Matched Patients
Giovanni B. Torsello, MD
- 10:14–10:19** Current US Status And Results With The RelayPro NBS Endograft For TEVAR: Advantages And Limitations
Frank R. Arko, MD
- 10:20–10:25** Details Of A Novel Low Profile Stent-Graft For The TEVAR Treatment Of All Thoracic Aortic Segments: What Makes It Unique And Clinical Status
Francesco Setacci, MD
- 10:26–10:31** Hybrid Repair Of Arch And Descending Aorta Lesions With The Thoraflex Device And RelayPro TEVAR Device: Technical Tips And Clinical Experience
Francis Caputo, MD

10:32–10:37 Real World, Long-Term Results With Cook Zenith Alpha Thoracic Low-Profile Endograft: What Have We Learned
Germano C.G. Melissano, MD
Roberto L.V. Chiesa, MD

10:38–10:43 The New Cook Custom Single Branch Endograft For TEVAR Of Lesions Close To Or Involving The LSA: Advantages And Results
Tilo Kölbel, MD, PhD

10:44–10:49 Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations
Sukgu Han, MD

10:50–11:00 **Panel Discussion**

SESSION 58 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH AND TAAAs (See Also Sessions 1, 2, 3 And 40 For Related Topics)

Moderators: *Rodney A. White, MD*
Weiguo Fu, MD

11:00–11:05 Current Status And Results With Terumo Ascending Aorta Endograft: What Makes It Different And What Lesions Can It Treat
Vicente Riambau, MD, PhD
Afshin Assadian, MD
Mo S. Hamady, MD

11:06–11:11 Current Status In The US Of The Relay Branch Investigational Device (Terumo Aortic) For Endo Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations
Luis A. Sanchez, MD
Eric E. Roselli, MD

11:12–11:17 Aortic Arch Endovascular Repairs: Which Device Is Best For Degenerative Aneurysms And For Dissection: Technical Tips
Javairiah Fatima, MD

11:18–11:23 Update On Fenestrated Endovascular Aortic Repair Plus Chimney Graft For TAAA Repairs: The FEVAR/Ch Technique: When And How Is It Beneficial
Ross Milner, MD

11:24–11:29 Changes In The Aortic Valve And Aortic Morphometrics After Ascending Aorta And Arch Endograft Placement: Why Are They Important And How Can They Be Avoided
Jean Bismuth, MD
Ross Milner, MD

11:30–11:35 How To Manage Dissected Supra Aortic Trunks During Arch Branch Endovascular Repair
Stephan Haulon, MD

11:36–11:41 Preloaded Fenestrated Endografts With A Modified Biport Handle (From Cook): A Way To Make F/EVAR Easier: Results From An International Multicenter Study
Nikolaos Tsilimparis, MD, PhD

11:42–11:47 What Devices Are Best For Enabling Laser Fenestration For The Endo Treatment Of Arch Lesions: Is The Laser Hole In The Main Graft Made From Below Or Above: How Is The Brain Perfused After The Aortic Graft Is Deployed And Before The Hole Is Made
Jean M. Panneton, MD

- 11:48–11:53** How To Accommodate For Main Endograft Length Discrepancy And Avoid Errant Coverage Of The Supra Aortic Trunks During Emergency Repair Of Ascending Aortic Lesions Coverage
Gustavo S. Oderich, MD
Steven Maximus, MD
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 59 (Grand Ballroom West, 3rd Floor)

NEW OR UPDATED INFORMATION ON RE-ENTRY DEVICES, LOWER EXTREMITY PROSTHETIC GRAFTS (See Also Session 28) AND MANAGEMENT OF PERIGRAFT SEROMAS

Moderators: *Samuel R. Money, MD, MBA*
Patrick J. Lamparello, MD

A NEW LOOK AT RE-ENTRY DEVICES

- 1:00 – 1:05** Pros And Cons Of Re-Entry Devices In Treating CTOs: Why, Where And When To Use Them: Are They Worth The Cost And Have Other Techniques Like Retrograde Access Largely Replaced Them
Maria A. Ruffino, MD
- 1:06 – 1:11** Re-Entry Devices Are Currently Almost Never Necessary: Techniques To Treat Lower Extremity Lesions Successfully Without Them: When Might They Be Needed
Ali Amin, MD, RVT

PROSTHETIC GRAFTS

- 1:12 – 1:17** Final 5-Year Results Of The ZILVERPASS RCT Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long FemPop Lesions: Clinical And Financial Results And Their Implications
Michel J. Bosiers, MD
Marc Bosiers, MD
- 1:18 – 1:23** PTFE Bypasses To Infrapopliteal Targets Can Be Worthwhile For Limb Salvage In Patients With End Stage CLTI: When Is This So And Technical Tips To Make Them Work
Matthew T. Menard, MD
- 1:24 – 1:29** Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: The Heparin Coated Grafts Are Better And Worth The Cost: Based On A Propensity Matched Analysis
David J. Dexter, MD
- 1:30 – 1:35** Which Patients With CLTI Should Be Treated Primarily With A Heparin Bonded PTFE Graft And Why: How Can An Amputation-Free Survival Score Be Helpful
Carlo Pratesi, MD
Giovanni Pratesi, MD
- 1:36 – 1:41** Update On Novel Supramolecular Polymer Technology To Create Endogenous Tissue With Host Collagen And Endothelium Compatible With Flowing Blood: 2-Year Clinical Results Of The aXess Graft (From Xeltis)
Frans L. Moll, MD, PhD
- 1:42 – 1:47** Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology, When Do They Need To Be Treated And How
Jae S. Cho, MD
- 1:48 – 1:54** **Panel Discussion**

SESSION 60 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, ACCESSORIES, ETC. (See Also Sessions 23-27)

Moderators: *Maciej L. Dryjski, MD, PhD*
Sateesh C. Babu, MD

ATHERECTOMY AND LITHOTRIPSY RELATED TOPICS

1:54 – 1:59 A Balanced View Of The Value Of Atherectomy For Treatment Of Lower Extremity Lesions: Has It Been Overutilized And Why: When Can It Be Helpful And Which Device Is Best
John R. Laird, MD

2:00 – 2:05 The Value Of Directional Atherectomy Followed By DCBs For Long Calcified FemPop Lesions As Demonstrated By The Results Of The REALITY Trial
Brian G. DeRubertis, MD

2:06 – 2:11 Update On Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above And Below Knee De Novo Lesions And ISR
Craig M. Walker, MD

2:12 – 2:17 A New More Complex Device For Treating Calcified Arterial Lesions With Lithotripsy (From BOLT Medical): How Does It Work And Advantages
Marianne Brodmann, MD

2:18 – 2:23 Aortobifemoral Bypass For Aortoiliac Disease Has Gone From A Favored Procedure To A Rarity Because Of Endovascular Techniques Including Intravascular Lithotripsy (Shockwave): Options And Indications
Christopher J. Smolock, MD

2:24 – 2:30 **Panel Discussion**

ANCILLARY TECHNIQUES AND RELATED TOPICS

2:30 – 2:35 An Update On The Soundbite Technology For Traversing And Treating Calcified Arterial Lesions: How Does It Work, Advantages, And Clinical Experience
Marianne Brodmann, MD

2:36 – 2:41 How Do The Results Of Invasive Treatment Of FemPop Disease Differ In Women And Minorities: The ELEGANCE Global Registry Of Such Treatment With Eluvia DESs And Ranger DCBs Shows How
Eric A. Secemsky, MD, MSc (PowerPoint Presentation With Synched Audio)
Lee Kirksey, MD

NEW INFORMATION ON STENTS AND COVERED STENTS

2:42 – 2:47 5-Year Results With The VBX Covered Stent For Aortoiliac Disease: Patency Rates, Advantages And Cost Effectiveness
Ramon L. Varcoe, MBBS, MS, PhD (PowerPoint Presentation With Synched Audio)

2:48 – 2:53 The Eiffel Tower Technique For Endovascular Treatment Of Common Femoral Artery Bifurcation Lesions: What Is It And What Are Its Results: Lessons From The TECCO RCT
Yann Gouëffic, MD, PhD

2:54 – 2:59 Advantages Of Supera VMI Stent For Complex FemPop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position
Erwin Blessing, MD

3:00 – 3:06 **Panel Discussion**

3:06 – 3:18 **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 61 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICE
COMBINATIONS FOR LOWER EXTREMITY
TREATMENTS: ANGIOPLASTY BALLOON
IMPROVEMENTS

Moderators: *John R. Laird, MD*
Steven Kum, MD

- 3:18 – 3:23** The Value Of High-Pressure PTA Balloons And Long-Term Results Of pDVA (Percutaneous Deep Vein Arterialization): Practice Changing Techniques For CLTI: pDVA Produces Sustained Increased TcPO₂
Steven Kum, MD
- 3:24 – 3:29** Update On The Temporary Stent Assisted DCB Angioplasty In BTK Lesions With The Spur Spiked Stent System (Reflow Medical): The DEEPER OUS Trial
Michael K. W. Lichtenberg, MD
Thomas Zeller, MD
- 3:30 – 3:35** Update On The TOBA Trials Of The Tack Device (From Philips): Indications, Advantages In Improving Outcomes And Limitations
Patrick J. Geraghty, MD
- 3:36 – 3:41** The Serranator® Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations, Prevents Dissections, Lessens Elastic Recoil With PTA: Current Status
Steven Kum, MD
Andrew Holden, MBChB
- 3:42 – 3:47** Intravascular Lithotripsy (From Shockwave) In BTK Arteries: Updated Data And New Technologies
Andrew Holden, MBChB
- 3:48 – 3:53** IVUS Studies Before And After PTAs With The Ultrascore Scoring Balloons (From BD) Show The Benefits Of Such Balloons And How They Work
Robert E. Beasley, MD
- 3:54 – 3:59** Progress In Developing A Curved Angioplasty Balloon: How It Works And Why It's Important: When Will It Be Available
Timothy A.M. Chuter, MD
- 4:00 – 4:05** Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: When Does Dissection Have To Be Treated And When Not
Jos C. van den Berg, MD, PhD
- 4:06 – 4:12** **Panel Discussion**

SESSION 62 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES AND TECHNIQUES
TO PREVENT OR TREAT ENDOLEAKS OR DEVICE
MIGRATION: ENDOANCHORS, ETC.

Moderators: *William D. Jordan Jr., MD*
David H. Deaton, MD

- 4:12 – 4:17** New Findings From The ANCHOR Study Support The Prophylactic Use Of Heli-FX Endoanchor (Medtronic) Fixation: Use Of Its Variable Curve Sheath As A Rescue Tool To Fix Poorly Deployed Endografts
William D. Jordan Jr., MD
- 4:18 – 4:23** 5-Year Results Of Endoanchors In The Global ANCHOR Registry To Treat Complications With Focus On Preventing And Treating Type IA Endoleaks: Can Virtual Techniques Predict The Need For Endoanchors
Jean-Paul de Vries, MD, PhD

- 4:24 – 4:29** Endoanchors Improve Seal Zones And Outcomes With Fenestrated Endografts: When And Where Should They Be Used And Technical Tips
Shadi J. Abu-Halimah, MD
- 4:30 – 4:35** Prophylactic Endoanchors In TEVAR For Complex Anatomy Decrease Endoleaks And Reintervention Rates: Indications And Technical Tips For Their Use
Jean M. Panneton, MD
- 4:36 – 4:41** Novelrad Percutaneous Endovascular Suturing Device: How Does It Work And Clinical Experience
Elchanan Bruckheimer, MBBS
- 4:42 – 4:47** Update On The VESTECK Catheter Based Endosuturing Technology For EVAR And TEVAR Fixation: How Does It Work; How Is It Different From Endoanchors And Successful Clinical Results
Dainis K. Krievins, MD
Sean P. Lyden, MD
David H. Deaton, MD
- 4:48 – 4:54** **Panel Discussion**

SESSION 63 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION

(See Also Session 30)

Moderators: *James F. Benenati, MD*
Frank R. Arko, MD

CLOT REMOVING DEVICES

- 4:54 – 4:59** Endovascular Arterial Thrombo-Embolectomy Devices: What's The Difference Between Them: Jeti, Penumbra, AngioJet, Pounce, Etc.: What's Coming Down The Road
Loay S. Kabbani, MD, MHSA
- 5:00 – 5:05** Newer Pharmacomechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use: When Is Open Surgery Needed
Guillermo A. Escobar, MD
- 5:06 – 5:11** Different Options For Thrombosuction Treatment In ALI: Which Device For Which Case And When To Go For Open Surgery
Athanasios Katsargyris, MD
- 5:12 – 5:17** Endovascular Hydrodynamic Thrombectomy Of Occluded Visceral Vessels/Stents: Device Description And Clinical Experience
Marco V. Usai, MD
- 5:18 – 5:23** Rotarex Device Is A Treatment For Subacute Or Chronic Lower Extremity Thrombosed Bypasses Or Stents: How And When Does It Work And When Does It Not
Animesh Rathore, MD
- 5:24 – 5:29** **Panel Discussion**

ENDOASCULAR OCCLUSIVE DEVICES

- 5:30 – 5:35** Embolization Device Selection: The Pros And Cons Of Liquid Agents Versus Coils, Or Plugs
Frank R. Arko, MD
- 5:36 – 5:41** How Can Shape Memory Polymer Plug Embolization Devices Be Used To Improve Results After TEVAR For Degenerative Aneurysms And TBADs By False Lumen Obliteration
Virendra I. Patel, MD, MPH
- 5:42 – 5:47** Fibered And Non-Fibered Coil Embolism Technology: Which Type Of Coils Are Best For Different Indications
James F. Benenati, MD

5:48 – 5:53 Indications And Outcomes Of The Impede Embolization Plug (From Shape Memory) For Treatment Of Peripheral And Visceral Artery Lesions: What Makes It Unique
Robert A. Morgan, MD (PowerPoint Presentation With Synched Audio)

5:54 – 5:59 **Panel Discussion**
End of Program H

PROGRAM I (SESSIONS 64-73)
SUPERFICIAL VENOUS DISEASE
Trianon Ballroom, 3rd Floor

SESSION 64 (Trianon Ballroom, 3rd Floor)
VENOUS CLINICAL EXAMINATION AND
HEMODYNAMICS

Moderators: *Jose I. Almeida, MD*
Thomas F. O'Donnell, Jr., MD

- 7:00 – 7:04** Introduction To Veins At VEITH
Jose I. Almeida, MD
- 7:05 – 7:10** Overview Of Lymphatic Anatomy, And Physiology
Thomas F. O'Donnell, Jr., MD
- 7:11 – 7:16** Inflammatory Pathways In Chronic Venous Disease
Joseph D. Raffetto, MD
- 7:17 – 7:22** Genetics And Venous Disease
Sarah Onida, MD, PhD
- 7:23 – 7:28** Different Types Of Venous Reflux Identified In 100 Consecutive Patients And Their C Classification And Percentage
Ayman Fakhry, MD
- 7:29 – 7:34** We Should Revise The Definition Of Venous Reflux: What Other Modality Should We Consider
Fedor Lurie, MD, PhD
- 7:35 – 7:40** Factors Impacting Venous Return
Jose I. Almeida, MD
- 7:41 – 7:46** Venous Thermography And Its Clinical Use
Dale Maharaj, MBBS
- 7:47 – 7:52** **Panel Discussion**

SESSION 65 (Trianon Ballroom, 3rd Floor)
VENOUS GUIDELINES, IMPORTANT PAPERS, AND
REIMBURSEMENT

Moderators: *Ruth L. Bush, MD, MPH*
Armando Mansilha, MD, PhD

- 7:53 – 7:58** Are Venous Maps Standard Of Care: What Should They Include
Jan M. Sloves, RVT
- 7:59 – 8:04** SVS, AVF, AVLS Varicose Vein Guidelines
Peter Gloviczki, MD
- 8:05 – 8:10** A Comparison Of The Revised SVS/AVF/ASVL/ESVS Clinical Practice Guidelines In The Management Of Varicose Veins: Contact And Agree II Analysis
Thomas F. O'Donnell, Jr., MD
- 8:11 – 8:16** Summary Of Important Venous And Lymphatic Articles – International Angiology
Armando Mansilha, MD, PhD
- 8:17 – 8:22** Summary Of Important Venous And Lymphatic Articles – Journal of Phlebology – Editor's Choice
Alun H. Davies, MA, DM, DSc
- 8:23 – 8:28** Summary Of Important Venous And Lymphatic Articles – Journal of Vascular Surgery Venous and Lymphatic Disorders – Editor's Choice
Ruth L. Bush, MD, MPH
- 8:29 – 8:34** Primary Venous Insufficiency Increases Risk Of Deep Vein Thrombosis
Maxim Shaydakov, MD, PhD

8:35 – 8:40 Compression: Does It Work: What Data Do You Have To Support

William A. Marston, MD

8:41 – 8:46 Latin American Consensus On Superficial And Perforating Venous Mapping

Oscar H. Bottini, MD

8:47 – 8:52 **Panel Discussion**

SESSION 66 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES I

Moderators: *Kursat A. Bozkurt, MD*

Sergio Giancesini, MD, PhD

8:53 – 8:58 The Length Of Treated Great Saphenous Vein As A Marker Of Post-Procedural Improvement In Clinical And Patient Reported Outcomes

Windsor Ting, MD

8:59 – 9:04 Update On Fovellass – French Society of Phlebology Study: RCT Comparing Foam And EVLA In SSV Incompetence

Claudine M. Hamel-Desnos, MD

9:05 – 9:10 What Do You Treat First In C2s With Reflux Of The GSV, SSV, And Vein Of Giacomini

Jean Luc Gerard, MD

9:11 – 9:16 Saphenous Sparing: Why And Instructions For Users

Sergio Giancesini, MD, PhD

9:17 – 9:22 Thermal Saphenous Vein Recanalization: Risk Factors

Ruth L. Bush, MD, MPH

9:23 – 9:28 Ultrasound Aspects Of The Vein Over Time After Foam Sclerotherapy, And Clinical Consequences

Claudine M. Hamel-Desnos, MD

9:29 – 9:34 Thrombus Extension After Cyanoacrylate Closure Versus Endovenous Glue Induced Thrombosis: What Is The Difference

Nuttawut Sermsathanasawadi, MD, PhD

9:35 – 9:40 Synchronous Trial 12 Months Follow-Up Data (Simultaneous AASV Treatment For Patients Undergoing GSV Ablation)

Tobias Hirsch, MD

9:41 – 9:46 Effects Of Truncal Ablation On Pregnancy

Kursat A. Bozkurt, MD

9:47 – 9:52 Saphenous Ablation On Direct Oral Anticoagulants: Safe, Effective And Durable

Glenn Jacobowitz, MD

9:53 – 9:57 **Panel Discussion**

SESSION 67 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES II

Moderators: *Lowell S. Kabnick, MD*

Kathleen J. Ozsvath, MD

9:58–10:03 Decision Making In Saphenous Ablation: What To Use And When

Steve Elias, MD

10:04–10:09 Diameters Of The Great Saphenous Vein In Phlebological Practice In France: Report Of The DIAGRAVES Study By The French Society of Phlebology

Matthieu M.J. Josnin, MD

10:10–10:15 Non-Compounded Polidocanol 1% Endovenous Microfoam (Varithena) Or Thermal Ablation: A Network Meta-Analysis

Lowell S. Kabnick, MD

10:16–10:21 The Persistent Sciatic Vein

Julianne Stoughton, MD

10:22–10:27 SVT Treatment During Pregnancy: Treatment Choices

Kathleen J. Ozsvath, MD

- 10:28–10:33** Would Treatment Of The Whole Length Of The GSV Reduce Recurrence And Reinterventions
Alun H. Davies, MA, DM, DSc
- 10:34–10:39** Thermal Versus Nonthermal: Is It Time To Stop The FIRE
Sergio Giancesini, MD, PhD
- 10:40–10:44** African American Patient Outcomes After Saphenous Ablation For Advanced Venous Disease
Faisal Aziz, MD
- 10:45–10:49** The Use Of Simultaneous Foam Sclerotherapy And Thermal Treatment In Varicose Vein Treatment: Why
Tobias Hirsch, MD
- 10:50–10:54** Complications Of Endovenous Thermal Ablation Of The GSV
Dale Maharaj, MBBS
- 10:55–11:00** **Panel Discussion**

SESSION 68 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES III

Moderators: *Manj S. Gohel, MD*

Houman Jalaie, MD, PhD

- 11:01–11:05** When Is It OK To Ablate The Truncal Leg Veins With Chronic Iliofemoral Outflow Obstruction
Houman Jalaie, MD, PhD
- 11:06–11:10** SVT Medical Management In 2024: Is There A Role For Surgical Intervention And When
Manj S. Gohel, MD
- 11:11–11:15** Management Of Labial And Vulvar Veins
Julianne Stoughton, MD
- 11:16–11:20** VEINS – An International Platform Trial Collaboration
Sarah Onida, MD, PhD
- 11:21–11:25** What You Should Know About Klippel-Trenaunay Syndrome
Byung-Boong Lee, MD
- 11:26–11:30** Treatment And Pitfalls: Lateral Marginal Vein
Peter Gloviczki, MD
- 11:31–11:35** Overview Of Multicenter Venclose Study And Early Results
Erin H. Murphy, MD
- 11:36–11:40** Great Saphenous Vein Crossectomy: Why
Ayman Fakhry, MD
- 11:41–11:45** What Is Maven: Is There Any Data
Jeffrey G. Carr, MD
- 11:46–11:50** Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux
Natalie A. Marks, MD, RPVI, RVT
- 11:51–11:55** Safety And Efficacy Of Endovenous Ablation In Patients With A History Of Deep Venous Thrombosis
Mikel Sadek, MD
- 11:56–12:00** Value And Limitations Of Postoperative Duplex Scans After Endovenous Thermal Ablation
Natalie A. Marks, MD, RPVI, RVT
- 12:01–12:05** VEINRESET: US Multicenter HIFU Trial: 6-Month Results
Steve Elias, MD
- 12:06–12:11** **Panel Discussion**
- 12:12–1:12** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 69 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES IV

Moderators: *Lowell S. Kabnick, MD*
Jose I. Almeida, MD

- 1:13 – 1:18** Cyanoacrylate And The Small Saphenous Vein: How To Treat The Various Anatomy
Janna Bentley, MD
- 1:19 – 1:24** Lack Of Symptom Improvement: Why
Jeffrey G. Carr, MD
- 1:25 – 1:30** Is There Any Evidence For Compression
William A. Marston, MD
- 1:31 – 1:36** New Superficial Venous Devices: Pre FDA Approval
Lowell S. Kabnick, MD
- 1:37 – 1:42** Forecast For Venous Reimbursement 2025
John Blebea, MD, MBA
- 1:43 – 1:48** Factors Associated With Recanalization And Reintervention Following Below Knee Polidocanol Endovenous Microfoam
Natalie A. Marks, MD, RPVI, RVT
- 1:49 – 1:54** Which Saphenous Vein Recanalization Should Be Treated And By What Method: Evidence Based
Jose I. Almeida, MD
- 1:55 – 2:00** Varithena Meta-Analysis “RELOADED”, The Living Approach
Lowell S. Kabnick, MD
- 2:01 – 2:06** Accessory Veins And Their Impact On Recurrence
Kerstin S. Schick, MD
- 2:07 – 2:12** Deviation Operation In Patients With Deep Venous Reflux And CVI: First Clinical Results
Sebastian E. Debus, MD, PhD
- 2:13 – 2:18** Do You Need To Treat Venous Tributaries: Pros And Cons
Kerstin S. Schick, MD
- 2:19 – 2:24** Venous VQI: Ten Years Of Improving Venous Outcomes And Quality
Marc A. Passman, MD
- 2:25 – 2:30** **Panel Discussion**

SESSION 70 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES V

Moderators: *Victor M. Canata, MD, PhD*
Kasuo Miyake, MD, PhD

- 2:31 – 2:36** Venous Lesions Of The Face
Kasuo Miyake, MD, PhD
- 2:37 – 2:42** Truncal Vein Treatment For Chronic Venous Disease: Is Varithena Endovenous Ablation Or Physician Compounded Foam The Answer
Edward G. Mackay, MD
- 2:43 – 2:48** Physician Compounded Foam For Truncal Vein Disease: When And Where
Matthieu M.J. Josnin, MD
- 2:49 – 2:54** Varithena®VLU Registry: Update On The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence
Raghu Kolluri, MD
- 2:55 – 3:00** Phlebectomy Versus Sclerotherapy: Which Is Superior When Considering Efficacy, Complications, And Aesthetics
Alun H. Davies, MA, DM, DSc
- 3:01 – 3:06** Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique
Alvaro Orrego, MD
- 3:07 – 3:12** Tips And Tricks Of Sclerotherapy: What Makes It Easier And Successful
Victor M. Canata, MD, PhD

- 3:13 – 3:18** How To Avoid Complications From Sclerotherapy
Jean Luc Gerard, MD
- 3:19 – 3:24** Comparison Of Laser And Chemical Sclerosant Versus Sclerosant
Kasuo Miyake, MD, PhD
- 3:25 – 3:30** Quick Case 1: Ask The Panel Or Audience What Would You Do (Cosmetic)
Edward G. Mackay, MD
- 3:31 – 3:36** Quick Case 2: Ask The Panel Or Audience What Would You Do (Cosmetic)
Janna Bentley, MD
- 3:37 – 3:42** **Panel Discussion**

SESSION 71 (Trianon Ballroom, 3rd Floor)

SUPERFICIAL VEIN TREATMENT STRATEGIES VI

Moderators: *Kathleen D. Gibson, MD*
Sarah Onida, MD, PhD

- 3:43 – 3:48** Global Epidemiology Of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis
Sarah Onida, MD, PhD
- 3:49 – 3:54** When Evaluating Superficial Disease, When Do You Look For Deep Venous Obstruction
Gloria Salazar, MD
- 3:55 – 4:00** Not All C2 Disease Should Be Treated: An Algorithm To Predict Severity
Mikel Sadek, MD
- 4:01 – 4:06** Ablative Risks Prior To And After Flying: What Do You Tell Your Patients
Sarah Onida, MD, PhD
- 4:07 – 4:12** Body Mass Index And CEAP Clinical Severity Score
Oscar H. Bottini, MD
- 4:13 – 4:18** How Do We Assess Quality Of Life After Venous Interventions: Patient-Reported Outcomes For Chronic Venous Insufficiency
Kathleen D. Gibson, MD
- 4:19 – 4:24** Optimal Thromboprophylaxis And Post-Op Duplex Imaging Following Superficial Venous Procedures: Evidence Based
Andrea T. Obi, MD
- 4:25 – 4:30** Mechanical Chemically Assisted Ablation Of Varicose Veins For Venous Insufficiency: American Vein And Lymphatic Society Position Statement
John Blebea, MD, MBA
- 4:31 – 4:36** Radiofrequency Ablation Versus Polidocanol Endovenous Microfoam Ablation Of Large Diameter Saphenous And Tributary Veins
Juan Carlos Jimenez, MD, MBA
- 4:37 – 4:42** Turkish Glue And Perforating Veins In VLU Patients
Kursat A. Bozkurt, MD, PhD
- 4:43 – 4:48** Randomized Clinical Trial Comparing Cyanoacrylate Glue Closure With Surgical Stripping: 30D And 6M Outcomes
Manj S. Gohel, MD
- 4:49 – 4:54** How To Avoid Complications Of The Small Saphenous Vein
Jean Luc Gerard, MD
- 4:55 – 5:00** Mechanical Occlusion Segmental Chemical Ablation (MOSCA): Animal Study With Wavella Device
Steve Elias, MD
- 5:01 – 5:06** **Panel Discussion**

SESSION 72 (Trianon Ballroom, 3rd Floor)

LIPDEMA, LYMPHEDEMA, PHLEBOLYMPHEDEMA

Moderators: *Raghu Kolluri, MD*
Ayman Fakhry, MD

- 5:07 – 5:12** Lower Extremity Edema Workup
Maxim Shaydakov, MD, PhD
- 5:13 – 5:18** What Is Lipedema And The Current Management
Steven M. Dean, DO
- 5:19 – 5:24** Risks And Contraindications Of Medical Compression Treatment – A Critical Reappraisal: An International Consensus Statement
Tomasz Urbanek, MD, PhD
- 5:25 – 5:30** Venolymphatic Edema And Its Treatment Options
Raghu Kolluri, MD
- 5:31 – 5:36** Are Lymphedema, Lipedema, And Edema Related
Steven M. Dean, DO
- 5:37 – 5:42** Role Of Hydrotherapy In Lymphedema Treatment
Ayman Fakhry, MD
- 5:43 – 5:48** Update On Pharmacological Treatment For Lymphedema
Monika L. Glociczki, MD, PhD
- 5:49 – 5:54** **Panel Discussion**

SESSION 73 (Trianon Ballroom, 3rd Floor)

VENOUS ULCERS

Moderators: *Anil P. Hingorani, MD*
Monika L. Glociczki, MD, PhD

- 5:55 – 6:00** Outcome Of Early CAC And Compression Therapy In Healing Of VLU
Nuttawut Sermsathanasawadi, MD, PhD
- 6:01 – 6:06** Factors That Influence Venous Leg Ulcer Healing And Recurrence Rate After Endovenous Ablation Of Truncal Veins
Nuttawut Sermsathanasawadi, MD, PhD
- 6:07 – 6:12** Review Of Current Evidence For Topical Treatment For Venous Leg Ulcers
Yuri A. Casseres, MD, MSc
- 6:13 – 6:18** Why Venous Leg Ulcers Have Difficulty Healing
Joseph D. Raffetto, MD
- 6:19 – 6:24** Role Of Superficial Venous Therapies In Improving Venous Ulcer Healing: Choice Of Techniques And Use Of Adjunctive Strategies
Sung Yup Kim, MD
- 6:25 – 6:30** Venous Ulcers: The Contributions Of Deep, Perforator, And Superficial Procedures On Wound Healing
Peter F. Lawrence, MD
- 6:31 – 6:36** Skin Substitutes To Promote Venous Leg Ulcer Healing: What Is The Evidence
Yuri A. Casseres, MD, MSc
- 6:37 – 6:42** Compression, Oxygen, And Humidification – Improves Venous Wound Healing And Reduces Venous Ulcer Recurrence
Joann M. Lohr, MD
- 6:43 – 6:48** Update On Pharmacological Treatment For Venous Ulcers
Monika L. Glociczki, MD, PhD
- 6:49 – 6:54** Non-Bandage Therapy For Venous Ulcers – Single Arm Study
Sundaram Ravikumar, MD
- 6:55 – 7:00** **Panel Discussion**
- End of Program I**

PROGRAM J (SESSIONS 74-78)
MULTIDISCIPLINARY STROKE PREVENTION AND TREATMENT

Murray Hill Suites, 2nd Floor

SESSION 74 (Murray Hill Suites, 2nd Floor)

ADVANCES IN STROKE AND THE NEXT FRONTIER

Moderators: *Allan L. Brook, MD*

Joshua A. Hirsch, MD

- 7:30 – 7:40** Introduction
Allan L. Brook, MD
- 7:41 – 7:48** Evidence Of Acute Stroke Care And What Gaps Are Left To Fill
Daniel Antonello, MD
- 7:49 – 7:56** Stroke Imaging Triage: Pearls And Nuances Of Daily Practice
Rajiv Gupta, MD
- 7:57 – 8:04** Should ELVO Patients Go Directly To The Angio Suite
Reade A. De Leacy, MBBS
- 8:05 – 8:12** Next Generation Thrombectomy Devices And How They Impact Clinical Outcomes
David Fiorella, MD, PhD
- 8:13 – 8:20** Tandem Occlusions: Should We Stent – Above, Below, Both, Or Neither
Adnan H. Siddiqui, MD, PhD (PowerPoint Presentation With Synched Audio)
- 8:21 – 8:28** Carotid Access: Is It Time For This Time Saving Approach
Guilherme Dabus, MD
- 8:29 – 8:36** Imaging Pearls That Save Time
Lawrence N. Tanenbaum, MD
- 8:37 – 8:44** Aspirations In Aspiration Thrombectomy
James Milburn, MD
- 8:45 – 8:52** Distal/Middle Intracranial Occlusion Can Lead To Significant Morbidity: Should They Be Treated
Johanna Seiden, MD, MPH

SESSION 75 (Murray Hill Suites, 2nd Floor)

INTRACRANIAL HEMORRHAGE, VESSEL WALL IMAGING AND NEW DEVELOPMENTS

Moderators: *Gregg H. Zoarski, MD*

David Gordon, MD

- 8:53 – 9:00** Radial And Ulnar Anatomy/Access; Complication Management
Sudhakar R. Satti, MD
- 9:01 – 9:08** Literature That Has Changed Over The Last Year And How It Has Changed Our Practice
Chirag D. Gandhi, MD
- 9:09 – 9:16** INTRASACCULAR DEVICES: For SAH, Or Only Elective Cases
Ansaar T. Raj, MD (PowerPoint Presentation With Synched Audio)
- 9:17 – 9:24** A Neiman Fellow Analyzes How The No Surprises Act Interests With MT 4 ELVO Stroke
Joshua A. Hirsch, MD
- 9:25 – 9:32** Is There Any Imaging To Distinguish Intracranial Athero Versus Embolic Thrombus
Richard L. Zampolin, MD

SESSION 76 (Murray Hill Suites, 2nd Floor)

CAROTID AND CEREBRAL ANEURYSMS LATER TRENDS AND POTPOURRI

Moderators: *Reade A. De Leacy, MBBS*

Amichai J. Erdfarb, MD

- 9:33 – 9:40** Robots Are A Bust In The Brain, Or Are We Waiting For Next Generation Devices And Insights
Aquilla S. Turk, DO

- 9:41 – 9:48** Intracranial Aneurysm Literature: What Has ARISEn
David S. Liebeskind, MD (PowerPoint Presentation With Synched Audio)
- 9:49 – 9:56** Basilar Artery Thrombectomy: Planning For Efficient Revascularization
Jared Cooper, MD
- 9:57–10:04** SDH And MMA Embolization: What Is The Standard Of Care
Deepak Khatri, MD
- 10:05–10:12** MMA Embolization: Does The Embolic Material Really Matter And Why
J Mocco, MD, MS

SESSION 77 (Murray Hill Suites, 2nd Floor)

PEDIATRIC STROKE AND LESSONS TO BE LEARNED IN UNIQUE CEREBROVASCULAR ARENAS

Moderators: *Allan L. Brook, MD*
Peter K. Nelson, MD

- 10:13–10:20** Great Pediatric Neurointerventional Cases
Amanda Baker, MD
- 10:21–10:36** 70 Years Of NI Practice: My Most Interesting Case Pearls For All To Enjoy
Peter K. Nelson, MD
- 10:37–10:44** Dural Sinus Stenosis: Is There A Standard Of Care
Athos Patsalides, MD, MPH
- 10:45–10:52** Carotid Blowout: Evidence And Treatment Options
Guilherme Dabus, MD
- 10:53–11:00** Artificial Intelligence: Relevance In Stroke And How It Will Impact Our Lives
Allan L. Brook, MD

SESSION 78 (Murray Hill Suites, 2nd Floor)

CAROTID ARTERY THERAPY STARS AND LATEST TRENDS

Moderators: *Thomas G. Brott, MD*
Don Heck, MD

- 11:01–11:08** Carotid Artery Disease: New Trials And Best Literature 2023
Thomas G. Brott, MD
- 11:09–11:16** TCAR Is Better Than True Percutaneous Carotid Stenting: Myth Or Reality
Peter A. Schneider, MD
- 11:17–11:24** CAS Versus TCAR Versus CEA: They Cannot Be Equal And Why
Don Heck, MD
- 11:25–11:32** CEA Done Through A Microincision Versus TCAR: Why Do So Few Perform This
Enrico Ascher, MD
- 11:33–11:40** Latest Stenting Technology For The Carotid Artery: Does It Match The Evidence
Michele Antonello, MD, PhD
- 11:41–11:56** Encore: Why Does Everybody Outside Of Australia Overtreat Carotids (15-Minute Presentation)
Anne L. Abbott, MD, PhD (PowerPoint Presentation With Synched Audio)
- 11:57–12:15** **Panel Discussion**
End of Program J

FRIDAY, NOVEMBER 22, 2024

6:00 A.M. General Registration - Rhinelander Gallery, 2nd Floor
 6:00 A.M. Faculty Registration - Gramercy Suite West, 2nd Floor
 6:15 A.M. Continental Breakfast - Rhinelander Gallery, 2nd Floor

CONCURRENT FRIDAY PROGRAMS

PROGRAM K (SESSIONS 79-86)

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

6:40 A.M. - 5:32 P.M.

Location: Grand Ballroom East, 3rd Floor

PROGRAM L (SESSIONS 87-94)

New Developments In The Treatment Of Popliteal Disease; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

6:52 A.M. - 4:56 P.M.

Location: Grand Ballroom West, 3rd Floor

PROGRAM M (SESSIONS 95-105)

Deep Venous Disease

7:30 A.M. - 6:45 P.M.

Location: Trianon Ballroom, 3rd Floor

PROGRAM K (SESSIONS 79-86)

PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) WITH TAAAs AND COMPLEX AORTIC ANEURYSM REPAIRS; NEW DEVELOPMENTS IN CAROTID ARTERY DISEASE AND ITS TREATMENT: MESH COVERED STENTS AND TCAR, COGNITIVE CHANGES, TIMING OF TREATMENT, MEDICAL TREATMENT, UPDATE ON CAROTID TRIALS, TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS), STRING SIGN, CAROTID CLOT, SIGNIFICANCE OF MRI LESIONS, CAROTID CONTROVERSIES AND MORE CAROTID TOPICS; OTHER NEW ENDOVASCULAR TREATMENT CONCEPTS, TECHNIQUES; UPDATE ON PERCUTANEOUS ACCESS CLOSURE DEVICES AND WOUND CARE

Grand Ballroom East, 3rd Floor

SESSION 79 (Grand Ballroom East, 3rd Floor)

PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS

Moderators: *Germano C.G. Melissano, MD*
Christian D. Etz, MD, PhD
Adam Beck, MD

- 6:40 – 6:45** New Experimental Work In Avoiding SCI After TAAA Repair: How Can A Sheep Model Of TEVAR Be Helpful
Hamdy Awad, MD
- 6:46 – 6:51** With Complex AAAs And Type IV TAAAs, The Incidence Of SCI Is 3 Times Greater With Endovascular Repairs Than Open Repairs: Why Is This A Controversial Finding And How Can It Be So
George Geroulakos, MD, PhD
- 6:52 – 6:57** Prediction Of Spinal Cord Ischemia With AI After Aortic Procedures: Combinations Of Anatomic Features Accurately Predict Risk
Kak Khee Yeung, MD, PhD
- 6:58 – 7:03** What Is The Münster Strategy To Avoid SCI After F/B/ EVAR For TAAA: What Is The Proof That It Works
Martin J. Austermann, MD
- 7:04 – 7:09** How To Use Motor Evoked Potentials (MEPs) To Decrease The Incidence Of SCI After Open And Endo TAAA Repairs: What Else Is Important
James H. Black, III, MD
- 7:10 – 7:15** Role Of Direct Segmental Artery Revascularization To Prevent SCI After Endovascular TAAA Repairs: When And How To Do It
Sukgu Han, MD
- 7:16 – 7:21** Current Strategies To Minimize SCI With TAAA Repairs (Endo And Open) By Improving The Intraspinal Collateral Arterial Network: Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Progress Of The PAPA-ARTIS RCT
Christian D. Etz, MD, PhD
- 7:22 – 7:27** Extensive Single Center Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair: How And When To Do It: Why We Still Need An RCT
Daniela Branzan, MD
Andrej Schmidt, MD
- 7:28 – 7:33** Why Cerebrospinal Fluid (CSF) Drainage To Decrease SCI With TAAA Repair Is Not A Benign Procedure: When To Use It And When Not
Gustavo S. Oderich, MD
- 7:34 – 7:39** Prevention Of SCI After Endovascular TAAA Repairs: Lessons Learned From The US Aortic Research Consortium (ARC)
Adam Beck, MD
Mark A. Farber, MD
Andres Schanzer, MD
- 7:40 – 7:45** Shifts In Prevention Protocols For SCI During Open And Endovascular TAAA Repairs: What Is Agreed On And What Remains Controversial
Germano C.G. Melissano, MD
Roberto L.V. Chiesa, MD
- 7:46 – 7:54** **Panel Discussion**

SESSION 80 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS: UPDATE ON MESH COVERED STENTS AND TCAR (TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION)

Moderators: *Klaus D. Mathias, MD*

Marc L. Schermerhorn, MD

Bruce A. Perler, MD, MBA

- 7:54 – 7:59** Carotid Webs: An Important Etiology Of Devastating Strokes Especially In Young Women: How Should They Be Diagnosed And Treated
Bruce A. Perler, MD, MBA

MESH COVERED STENTS

- 8:00 – 8:05** Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter

D. Christopher Metzger, MD

Max Amor, MD

- 8:06 – 8:11** When You Can Do All, How To Decide Between CEA, TCAR And TFCAS: Will Mesh Covered Stents Like CGuard Make A Difference

Adnan H. Siddiqui, MD, PhD (PowerPoint Presentation With Synched Audio)

L. Nelson Hopkins, MD

- 8:12 – 8:17** Outcome Of TCAR Combined With A Mesh-Covered Stent (CGuard From InspireMD): The Best Of All Worlds: What Is The Proof

Ralf R. Kolvenbach, MD

- 8:18 – 8:23** Update On All Trial Results With CGuard And CGuard Prime MicroMesh Covered Stents (InspireMD): Are They Making A Difference And Limitations With Transfemoral/Transradial CAS: Evidence Summary And Long-Term Outcomes

Piotr Musialek, MD, DPhil

D. Christopher Metzger, MD

Stefan Müller-Hülsbeck, MD

- 8:24 – 8:29** US Studies And Status Of The CGuard And CGuard Prime MicroMesh Stents: Can They Be Used In TCAR And Are They Making A Difference

Patrick J. Geraghty, MD

- 8:30 – 8:35** Latest Real-World Results Of >2,000 Patients Treated With The Roadsaver (Terumo) Dual-Layer Micromesh Carotid Stent

Stefan Müller-Hülsbeck, MD

- 8:36 – 8:42** **Panel Discussion**

TCAR RELATED TOPICS

- 8:42 – 8:47** Update On Comparative Performance And Risks Of TCAR, Transfemoral CAS (TFCAS) And CEA With >50K TCAR, 25K TFCAS, And 100K CEA: This Population Based Study Shows That CEA Is Better Than TCAR Which Is Better Than TFCAS

Marc L. Schermerhorn, MD

Mahmoud B. Malas, MD, MHS

- 8:48 – 8:53** Is TCAR Ready To Replace CEA: What About The Clinical Results To Date: What About The Impact Of Clever Marketing: How Will We Find Out

Bruce A. Perler, MD, MBA

- 8:54 – 8:59** **DEBATE:** CEA Versus TCAR In A Single Center Propensity Matched Study: The Outcomes Of The Two Treatments Are Comparable At 30 Days But TCAR Has A Higher Mortality At 2 Years

Ali F. AbuRahma, MD

Zach AbuRahma, DO

- 9:00 – 9:05** **DEBATE:** Not So: TCAR Like TFCAS Has Durable Effectiveness Without Increased Mortality At 2 Years And Beyond
Sumaira Macdonald, MD, PhD
- 9:06 – 9:11** Favorable 30-Day Results Of TCAR In Good Risk Symptomatic And Asymptomatic Patients: Late Breaking Trial Results From ROADSTER 3 Shows That The Stroke, Death And MI Rates Are Lower Than In High Risk Patients
Marc L. Schermerhorn, MD
- 9:12 – 9:17** TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why TCAR Should Be The Procedure Of Choice In These Conditions
Peter A. Schneider, MD
- 9:18 – 9:23** **Panel Discussion**
- 9:24 – 9:34** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 81 (Grand Ballroom East, 3rd Floor)

MORE CAROTID HOT TOPICS RELATED TO TCAR, CAS AND EFFECTS OF INTERVENTIONS ON COGNITIVE FUNCTION

Moderators: *Thomas G. Brott, MD*

Peter L. Faries, MD

Michael B. Silva, Jr., MD

- 9:35 – 9:40** Comparative Cost Effectiveness Of TCAR, CEA, TFCAS: CEA Is More Cost Effective Than TCAR And TCAR Is More Cost Effective Than TFCAS
Mohammad H. Eslami, MD, MPH
- 9:41 – 9:46** Intracranial Angiography During TCAR: Why It Can Be Valuable And How To Do It In View Of Flow Reversal
Peter L. Faries, MD
- 9:47 – 9:52** Best Device Selection For CAS: What Stent Type And Design, What Type Of Cerebral Protection, What Approach And Delivery System: A Review Of The Evidence
Francesco Setacci, MD
Carlo Setacci, MD
- 9:53 – 9:58** Comparison Of SVS Versus ESVS Carotid Guidelines For Treatment Of Asymptomatic Carotid Artery Stenosis: What Is Known For Sure And What Remains Controversial
Ali F. AbuRahma, MD
- 9:59 – 10:04** Management Of Anticoagulants And Antiplatelet Therapy In TCAR Patients
Michael C. Stoner, MD

CAROTID STENOSIS AND COGNITIVE FUNCTION

- 10:05–10:10** Preservation Of Cognition: The New Role For Carotid Artery Interventions For Asymptomatic Disease: Will CREST 2 Confirm Or Deny Its Importance: Findings To Date
Wesley S. Moore, MD
Brajesh K. Lal, MD
Thomas G. Brott, MD
- 10:11–10:16** **DEBATE:** Carotid Intervention Improves Cognitive Function Of Patients With Severe Asymptomatic Carotid Stenosis (ACS): What About In Octogenarians: Should More Or Fewer ACS Patients Undergo Invasive Treatment
Wei Zhou, MD

10:17-10:22 **DEBATE:** Not So Fast: There Is Still Great Doubt That Eliminating ACS Improves Cognitive Function: It Should Not Be A Reason For Treating More ACS Patients

Anne L. Abbott, MD, PhD (PowerPoint Presentation With Synched Audio)

10:23-10:30 **Panel Discussion**

SESSION 82 (Grand Ballroom East, 3rd Floor)

MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, CAS AND CEA, NEW DEVICES, MESH COVERED STENTS, MINI-INCISION CEA, SIGNIFICANCE OF DW MRI DEFECTS, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS

Moderators: *Richard J. Powell, MD*

Wei Zhou, MD

Frank J. Veith, MD

10:30-10:35 Transradial CAS Using Novel Low-Profile Double-Mesh Stents (Roadsaver, Terumo): Results And Technical Tips

Andrea Kahlberg, MD (PowerPoint Presentation With Synched Audio)

10:36-10:41 Selecting Patients For Carotid Intervention Is Getting Harder: Candidates Are Older (And Sicker), Anatomic Imaging Is Not Standardized, Medical Therapy Is Improving, More Options For Intervention Exist And Cries For Non-Operative Management Are Getting Louder: Is Consensus Even Possible

Reese A. Wain, MD

SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER CEA/CAS

10:42-10:47 **DEBATE:** Silent DWI MRI Brain Lesions (Small Infarcts) After CEA/CAS Don't Matter

Thomas G. Brott, MD

10:48-10:53 **DEBATE:** Not So: Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Really Matter And Affect Cognitive Changes: The Size And Number Of DW MRI Defects Are Critical

Wei Zhou, MD

10:54-10:59 Neuroguard 3-In-1 Carotid Stent System (Contego Medical) With Integrated Balloon, Stent And Distal Filter: Trial Results And Advantages Including Preventing Particulate Emboli Released During Presumed Flow Reversal Protected CAS From Reaching The Brain (Or Distal Filter)

Sean P. Lyden, MD

Aleandros Mallios, MD

11:00-11:05 Minimal Incision CEA (MICE) Versus TCAR: Technical Tips For MICE, Cost Effectiveness, Advantages And Limitations Of Both

Enrico Ascher, MD

11:06-11:11 For Symptomatic Carotid Stenosis Invasive Treatment (TFCAS, CEA, TCAR) On Weekends Is More Risky: This Is Especially True For TFCAS Which Probably Should Not Be Performed On Weekends

Heepeel Chang, MD

11:12-11:18 **Panel Discussion**

11:18-11:23 What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Symptomatic): Can High Risk Plaques Be Made Low Risk And Smaller: All Stroke Patients Should Be On Statins Because They Markedly Decrease Recurrent Stroke And Mortality Rates

J. David Spence, MD

11:24–11:29 Technical Tips And Maneuvers To Make Treatment Of High Carotid Lesions Safe And Relatively Simple
Richard J. Powell, MD

11:30–11:35 What Are The Real Risk Factors For CEA, TFCAS And TCAR: Why Has CMS Gotten Their Risk Factors Wrong And How Have They Messed Up Their Reimbursement Incentives
Mahmoud B. Malas, MD, MHS

TIMING OF CAROTID INTERVENTIONS AFTER SYMPTOM ONSET

11:36–11:41 When Is Urgent (Within 48 Hours) CEA Or CAS Fairly Indicated After A Stroke: How Does Use Of tPA Influence Indications And Neurologic Outcomes In This Setting
Hernan A. Bazan, MD

11:42–11:47 When Is It Reasonable To Perform CEA Within 48 Hours After Stroke Symptoms Starts: Under What Conditions And What Precautions Should Be Taken
R. Clement Darling III, MD

11:48–11:53 With Crescendo TIAs And Thrombus Overlying A Plaque What Is The Best Invasive Treatment And When Should It Be Performed
Domenico Valenti, DMChir, PhD

11:54–12:00 **Panel Discussion**

12:00– 1:00 **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 83 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID AND SUBCLAVIAN TOPICS: UPDATES ON KEY CAROTID RCTs

Moderators: *Brajesh K. Lal, MD*
Wesley S. Moore, MD
Glenn M. LaMuraglia, MD

1:00 – 1:05 Lipid Management For High Risk Carotid Lesions: Statins, Ezetimibe, PCSK9 And What Else: Should LDL-C Be Monitored
Christos D. Liapis, MD

UPDATE ON CAROTID RCTs

1:06 – 1:11 Update On CREST 2: CEA Versus Best Medical Treatment (BMT) And CAS Versus BMT For Asymptomatic Carotid Stenosis (ACS): Recruitment And Findings To Date: Why Not Present The 30-Day And 1-Year Results: If BMT Showed No Difference In Stroke And Death Rates With Those Of CAS Or CEA, Wouldn't This Remove Justification For Invasive Treatment Of ACS Until A Benefit Was Shown
Thomas G. Brott, MD
Brajesh K. Lal, MD

1:12 – 1:17 Why The Carotid RCTs Fail To Support The Recent CMS Expansion Of Reimbursement For CAS To Treat Asymptomatic Disease (ACS): Do The 5-Year SPACE-2 Results Suggest That Such Expanded Reimbursement Be Delayed Until CREST-2 Data Is In
Caitlin W. Hicks, MD, MS

1:18 – 1:23 Why CREST-2 May Not Provide Any Valid Answers: Because Of Bad Patient Selection In CREST-2, And Because BMT May Not Be Optimal Without GLP-1 Agonists Which Decrease Stroke Rates: What Is The Evidence
Sumaira Macdonald, MD, PhD

- 1:24 – 1:29** Update On ACST-2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates Up To 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT
Richard Bulbulia, MA, MD
Alison Halliday, MS
- 1:30 – 1:35** Not So Fast! ACST-2 – Like CREST – Has Flaws That Invalidate Their Conclusions: Invasive Therapies May NOT Be Better Than BMT: What Are These Flaws
J. David Spence, MD
- 1:36 – 1:41** What Is The Proof That CAS Is Ever Indicated For ACS: The Evidence Does Not Yet Support It
Franco Grego, MD
- 1:42 – 1:47** **Panel Discussion**
- 1:48 – 1:53** Consecutive Monocenter Results With CAS For Asymptomatic Carotid Stenosis (ACS): We Should Not Need An RCT: But Why We Still Do
Klaus D. Mathias, MD
Anna Zeller, MD
- 1:54 – 1:59** The 2nd European Carotid Surgery Trial (ECST-2): What Will It Tell Us About Best Medical Therapy Versus Invasive Therapy And Progress To Date
Gert J. de Borst, MD, PhD
- 2:00 – 2:05** When A Duplex Scan Detects Subclavian Steal, Symptomatic Or Asymptomatic, What Is The Natural History And How Should It Be Managed
Ali F. AbuRahma, MD
- 2:06 – 2:11** **DEBATE:** Completion Imaging After CEA Is Unnecessary And Potentially Harmful
Ali F. AbuRahma, MD
- 2:12 – 2:17** **DEBATE:** Not So: Completion Imaging (Angiography Or Duplex) After CEA Is Necessary And Helpful
Keith D. Calligaro, MD
- 2:18 – 2:23** **Panel Discussion**

SESSION 84 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID TOPICS: TREATMENT IN 2024 OF RECURRENT CAROTID STENOSIS; STROKES DURING CAROTID TREATMENT; CAROTID NEAR OCCLUSIONS; SILENT CORONARY ISCHEMIA IN CAROTID PATIENTS

Moderators: *Keith D. Calligaro, MD*
Klaus D. Mathias, MD
Ali F. AbuRahma, MD

- 2:24 – 2:29** Most Recurrent Carotid Stenosis Is Benign: When Is Intervention Justified And What Intervention Should Be Used
Ashraf Mansour, MD
- 2:30 – 2:35** Current Best Treatment For Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: Who Should Be Involved And What Skills Are Needed
Gert J. de Borst, MD, PhD
- 2:36 – 2:41** Can TCAR Be Helpful In The Management Of Carotid String Sign Lesions Or Near Occlusions Of The Internal Carotid Artery: When Is Its Use Justified, Advantage And Technical Tips
Animesh Rathore, MD
- 2:42 – 2:47** Advances In The Diagnosis And Treatment Of Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA) In Symptomatic And Asymptomatic Patients: How Are They Best Treated: What Do The Current Guidelines Say
Christos D. Liapis, MD

- 2:48 – 2:53** Optical Coherence Tomography (OCT) Proves CAS Is Rendered Safer Because Mesh Covered Stents Decrease Emboli: The Imaging Evidence And What It Shows About The Interaction Between Stent And Plaque
Francesco Setacci, MD
Carlo Setacci, MD
- 2:54 – 2:59** Silent Coronary Ischemia As Detected By FFR_{CT} Is Common In Carotid Stenosis Patients: Coronary Revascularization In Such Patients Decreases Mortality: When Should It Be Done – Before Or After Carotid Treatment
Christopher K. Zarins, MD
Dainis K. Krievins, MD
- 3:00 – 3:05** Technical Tips To Enable TCAR In Difficult Anatomic Circumstances Including Use Of A Prosthetic Conduit
Ashraf Mansour, MD
- 3:06 – 3:11** Compared To CEA, TCAR Improves Operating Room (OR) Throughput But Is More Costly: Tips To Improve OR Efficiency
Gregg S. Landis, MD
- 3:12 – 3:19** **Panel Discussion**
- 3:19 – 3:30** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 85 (Grand Ballroom East, 3rd Floor)

UPDATED ENDOVASCULAR CONCEPT AND MORE HOT AND CONTROVERSIAL CAROTID TOPICS

Moderators: *Mark Conrad, MD, MMSc*

Jacob Cynamon, MD

Michael H. Wholey, MD, MBA

- 3:30 – 3:35** Update On Transvenous Liver Biopsies: What Equipment Is Needed And How To Do Them
Jacob Cynamon, MD
- 3:36 – 3:41** Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting
Juan C. Parodi, MD (PowerPoint Presentation With Synched Audio)
- 3:42 – 3:47** In Stent Stenosis After CAS: How Can It Be Predicted: When Is It Threatening And How Is It Best Managed
Jacques Busquet, MD
- 3:48 – 3:53** Anatomic And Procedural Correlates Of Intra- And Postoperative Hypotension With CAS: What Should Be Done About It
Michael C. Stoner, MD
- 3:54 – 3:59** **DEBATE:** CAS Is The Best Treatment For Young Healthy Patients With High Grade Asymptomatic Carotid Stenosis (ACS)
D. Christopher Metzger, MD
- 4:00 – 4:05** **DEBATE:** Not So: Even Young Patients With A High Grade ACS Should Not Be Treated By CAS Or CEA: BMT Should Suffice: Are There Any Exceptions
Anne L. Abbott, MD, PhD (PowerPoint Presentation With Synched Audio)
- 4:06 – 4:11** Why We Need An RCT Comparing TCAR With TFCAS, Transradial CAS And Best Medical Treatment For ACS And Symptomatic Carotid Stenosis
Michael H. Wholey, MD, MBA
- 4:12 – 4:17** New Technical Tips To Make Minimal Incision CEA (MICE) Easier And Better: Can Same Day Discharge Be Safe
Robert M. Proczka, MD, PhD
- 4:18 – 4:23** Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA And CAS: How To Decrease Them
Mark Conrad, MD, MMSc
W. Darrin Clouse, MD
- 4:24 – 4:30** **Panel Discussion**

SESSION 86 (Grand Ballroom East, 3rd Floor)

NEW CONCEPTS AND NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE AND WOUND CARE

Moderators: *Zvonimir Krajcer, MD*
Michael H. Wholey, MD, MBA
Kenneth Ouriel, MD, MBA

PROGRESS IN PERCUTANEOUS ACCESS AND CLOSURE

- 4:30 – 4:35** Update On Large Bore Percutaneous Access Closure: Current Status, New Devices, How To Avoid Complications And Where Do We Go From Here
Zvonimir Krajcer, MD
- 4:36 – 4:41** Large Bore Percutaneous Arterial Closure: Which Device Is Best: Advantages And Disadvantages Of The Manta Device
Michael J. Singh, MD
- 4:42 – 4:47** Current Approaches For Large Bore Device Arterial Closure After Percutaneous EVAR And TEVAR: Technical Tips And Causes Of Failure
Gianmarco de Donato, MD
- 4:48 – 4:53** How To Use Fascial Suture Technique To Control Percutaneous Large Vessel Access: Technical Tips And When To Use
Tal M. Hörer, MD, PhD
Thomas Larzon, MD, PhD
- 4:54 – 4:59** Results And Benefits Of The CELT ACD Femoral Arteriotomy Closure Device In The Office-Based Laboratory And Hospital
Joseph J. Ricotta II, MD, MS

PROGRESS IN WOUND CARE

- 5:00 – 5:05** Update/Review Of Recently Published AHA Guidelines For Treatment Of Diabetic Wounds In The Setting Of PAD
Katherine A. Gallagher, MD
- 5:06 – 5:11** A Single Device (From AOTI) For Triple Therapy (Local Oxygen, Compression And Humidification) Enhances Healing Of Non-Healing Lower Extremity Wounds And Incisions
David J. Dexter, MD
- 5:12 – 5:17** New Developments With The TAVITA System To Predict Wound And Amputation Healing And To Monitor The Effectiveness Of Revascularization Procedures: Hyperspectral Imaging Can Non-Invasively Determine Oxygenation And Perfusion: How Does It Work And Results
Jan-Willem Elshof, MD
- 5:18 – 5:23** Optimal Treatment For Deep Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg
Hosam F. El Sayed, MD
- 5:24 – 5:32** **Panel Discussion**
End of Program K

PROGRAM L (SESSIONS 87-94)

NEW DEVELOPMENTS IN THE TREATMENT OF POPLITEAL DISEASE; ADVANCES IN TREATING ARTERIAL AND GRAFT INFECTIONS; ADVANCES IN VASCULAR IMAGING AND GUIDANCE; AUGMENTED REALITY AND ARTIFICIAL INTELLIGENCE; RECORDED LIVE COMPLEX ENDOVASCULAR CASES FROM MÜNSTER, GERMANY; NEW DEVELOPMENTS IN THORACIC OUTLET SYNDROME MANAGEMENT; ADVANCES IN MEDICAL, DRUG, ANTICOAGULANT AND RARE VASCULAR DISEASE TREATMENT; AND ADVANCES IN THE TREATMENT OF VASCULAR TRAUMA
Grand Ballroom West, 3rd Floor

SESSION 87 (Grand Ballroom West, 3rd Floor)

POPLITEAL DISEASE TOPICS RELATED TO ANEURYSM TREATMENT, ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE AND TRAUMA

Moderators: Jason T. Lee, MD

Martin Björck, MD, PhD

POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS

- 6:52 – 6:57** Endovascular Repair For Popliteal Artery Aneurysm: Pitfalls And Complications: When Is Open Surgery Best
Irwin V. Mohan, MBBS, MD
- 6:58 – 7:03** Treatment Of Popliteal Aneurysms: When Conservative, When Open, When Endovascular: What Are The Hard Data
Martin Björck, MD, PhD
- 7:04 – 7:09** Endovascular Versus Open Repair: Why After 20 Years Of Selective Endografting, I Now Favor Open Repair In Most Patients
Martin R. Back, MD
- 7:10 – 7:15** Outpatient Endovascular Repair Of Popliteal Artery Aneurysms With Bare Metal Stents: It Shouldn't Work, But Does: What Is The Evidence
Sam S. Ahn, MD, MBA
- 7:16 – 7:21** Popliteal Artery Aneurysms – Back To Basics: Indications For Open Surgery And Rescue Procedures For Failed Endovascular Repairs
Jose Fernandes e Fernandes, MD, PhD

ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE AND TRAUMA

- 7:22 – 7:27** Updates On The Diagnosis And Treatment Of Popliteal Entrapments: What Are Their Misleading (Doppelganger) Diagnoses
Katherine A. Gallagher, MD
- 7:28 – 7:33** Management Of Functional Popliteal Artery Entrapment Syndrome In Athletes: What Is The Pathological Anatomy And What Symptoms Does It Cause: Technique Of Surgical Repair
Jason T. Lee, MD
- 7:34 – 7:39** Adventitial Cystic Disease Of The Popliteal Artery: Pathogenesis, Symptoms And Optimal Treatment
Irwin V. Mohan, MBBS, MD
- 7:40 – 7:45** What Is The Surgical Approach And Best Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation: How Can Associated Vein Injury Be Detected And What Should Its Treatment Be
Charles J. Fox, MD
- 7:46 – 7:56** **Panel Discussion**

SESSION 88 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN TREATING ARTERIAL (INCLUDING AORTIC) GRAFT INFECTIONS

Moderators: *Keith D. Calligaro, MD*
Manju Kalra, MBBS

7:56 – 8:01 Update On The NAIS Procedure (Deep Vein Reconstruction) For Infected Aortic Grafts: How To Make The Operation Easier And Faster: When Is It Indicated
John F. Eidt, MD

TREATMENT OF MYCOTIC ANEURYSMS

8:02 – 8:07 What Is The Best Treatment For Mycotic Aneurysms: Open, Endo, Or Hybrid: When Is EVAR Helpful
Yamume Tshomba, MD

8:08 – 8:13 Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques
Guillermo A. Escobar, MD

TREATMENT OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS

8:14 – 8:19 For Many Infected Prosthetic Arterial/Aortic Grafts, Endografts And Mycotic Aneurysms Less Than The Current Standard Radical Graft Excisional Treatment Is Best: Details And Examples Of This Less Radical Treatment
Martin Malina, MD, PhD

8:20 – 8:25 Support For The Graft Preservation Concept For Treating Prosthetic Aortic Graft Infections From A European Multicenter Study (VASGRA): All Or Part Of The Infected Graft May Be Preserved: Under What Circumstances
Zoran Rancic, MD, PhD

8:26 – 8:31 Optimal Techniques In 2024 For Treating Infected Aortoiliac Prosthetic Grafts And Endografts (Including EVAR, TEVAR, F/B/EVAR): From A Large National Cohort And The GRANDPA Global Registry
Anders Wanhainen, MD, PhD

8:32 – 8:37 **Panel Discussion**

8:38 – 8:43 With Aortic Graft Infection, How Can Inline (In Situ) Flow Be Reestablished: Indications: What Grafts: Technical Tips: Results
Peter F. Lawrence, MD

8:44 – 8:49 Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment: Does The Endograft Always Have To Be Removed
Mohammad H. Eslami, MD, MPH

8:50 – 8:55 The Real Truth About Use Of Cryopreserved Conduits (CryoGraft-Artivion) To Treat Infected Aortic/ Arterial Reconstructions: From A Large Single Center Experience: There Are Advantages And Limitations
Randall R. De Martino, MD
Manju Kalra, MBBS

8:56 – 9:01 Update On Surgical Treatment For Infected Thoracic Aortic Grafts And Endografts, With Or Without Aorto-Esophageal Or Aorto-Bronchial Fistulas: Optimal Techniques And Results From A Committed Center
Germano C.G. Melissano, MD
Andrea Kahlberg, MD
Roberto L.V. Chiesa, MD

- 9:02 – 9:07** New Concepts In Prosthetic Graft Infection In The Abdomen And Extremities: When Does The Entire Graft Need To Be Excised And When Can All Or Part Of The Graft Be Preserved: How To Make That Judgment
Waclaw B. Kuczmik, MD, PhD
- 9:08 – 9:13** Treatment Of Infected Aortic Grafts (Endo And Open): Explantation Or Preservation: Technical Tips
Javairiah Fatima, MD
- 9:14 – 9:20** **Panel Discussion**
- 9:20 – 9:34** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 89 (Grand Ballroom West, 3rd Floor)

PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS WITH LESS RADIATION EXPOSURE OR CONTRAST TOXICITY

Moderators: *Matthew J. Eagleton, MD*
Jan M.M. Heyligers, MD, PhD

- 9:34 – 9:39** Advantages And Disadvantages Of The Three Main Hybrid OR Suites (GE, Siemens, Philips): How To Pick The Best One For Your Institution
Bjoern D. Suckow, MD

ADVANCED ENDOVASCULAR GUIDANCE WITH LESS RADIATION

- 9:40 – 9:45** 3-Dimensional Advanced Guidance Systems For Endovascular Procedures: How Do The IOPS (Centerline), FORS (Philips), And Cydar (Medtronic) Systems Work And Reduce The Need For Radiation
Mark A. Adelman, MD
- 9:46 – 9:51** With F/B/EVAR For Complex AAAs, FORS Lumiguide Fiberoptic Guidance (Philips) Reduces Radiation Exposure Compared To Standard Imaging
Marc L. Schermerhorn, MD
- 9:52 – 9:57** New Facts And Myths About Decreasing Radiation Exposure: Leaded Caps And Glasses Don't Help; The Egg Nest System Of Shields Does: What Is It
Melissa L. Kirkwood, MD
- 9:58-10:03** What Is Redo Fusion And How Does It Help After Failed Endovascular Complex Aortic Procedures
Giovanni Tinelli, MD, PhD
- 10:04-10:09** **Panel Discussion**

DUPLEX AND INTRAVASCULAR ULTRASOUND

- 10:10-10:15** Duplex Ultrasound Guidance: When Can It Replace Fluoroscopy For Endovascular Procedures: Requirements, Advantages, Limitations: Is Its Use Becoming Widespread
Enrico Ascher, MD
Natalie A. Marks, MD, RPVI, RVT
- 10:16-10:21** Intraprocedural Duplex Ultrasound Guidance May Be Better And Cheaper Than IVUS For Most Endovascular Cases: When Is It Not
Eric A. Secemsky, MD, MSc (PowerPoint Presentation With Synched Audio)

EKG-GATED CTA

- 10:22-10:27** EKG-Gated CTA And Its Added Value For Sizing EVAR And TEVAR Endografts: How It Decreases Failures
Frans L. Moll, MD, PhD

VASCULAR HOLOGRAPHY

- 10:28–10:33** Update On The ARCUS System Of Augmented Reality (Derived From A Contrast CT) And Its Value In Vascular And Endovascular Procedures: How Does It Work And Experience To Date
Jan M.M. Heyligers, MD, PhD
- 10:34–10:39** Update On Holographic Guidance Of Endovascular Procedures (With Augmented Reality Goggles And No Screen): How Does It Work And Clinical Experience: What Is Possible And What Is Not
Claude Mialhe, MD
- 10:40–10:48** **Panel Discussion**

SESSION 90 (Grand Ballroom West, 3rd Floor)

ARTIFICIAL INTELLIGENCE WORKFLOWS IN AORTIC CARE: HOW TO DO THE MOST COMPLEX AORTIC CASES BY EXPERTS IN THE FIELD

Moderators: *Gustavo S. Oderich, MD*

Alan B. Lumsden, MD

Kak Khee Yeung, MD, PhD

- 10:49–10:54** Generative AI For Aortic Imaging: The Promise And Perils
Elsie Ross, MD, MSc

- 10:55–11:00** Personalized Treatment Of AAAs With AI: The Development Of The First Prediction Models Of The Vascul-Aid Project

Kak Khee Yeung, MD, PhD

- 11:01–11:06** AI Based Facial Analysis Identifies Phenotypic Features Of Heritable Aortic Diseases

David R. Murdock, MD

Dianna M. Milewicz, MD, PhD

- 11:07–11:12** AI Prediction Of Type I Endoleaks

Jean-Noel Albertini, MD

Stephan Haulon, MD

- 11:13–11:21** **Panel Discussion**

HOW TO DO THE MOST COMPLEX AORTIC CASES BY EXPERTS IN THE FIELD (VIDEO PRESENTATIONS)

- 11:22–11:27** Best Approach To Total Transfemoral TAAA Repair Using TAMBE Device
Sukgu Han, MD

- 11:28–11:33** Hybrid Intercostal Artery Bypass For TAAA Repair
Shahab Toursavadkahi, MD

- 11:34–11:39** Bidirectional Branch For Complex AAA
Nuno V. Dias, MD, PhD

- 11:40–11:45** Transcatheter Electrosurgical Septotomy 1-0-1
Mirza S. Baig, MD

- 11:46–11:51** Retrograde 3-Vessel Arch Branch Repair
Giuseppe Panuccio, MD
Tilo Kölbel, MD, PhD

- 11:52–12:00** **Panel Discussion**

- 12:00– 1:00** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 91 (Grand Ballroom West, 3rd Floor)

PRESENTATIONS AND CHALLENGING RECORDED LIVE CASES FROM MÜNSTER, GERMANY

Moderators: *Martin J. Austermann, MD*

Giovanni B. Torsello, MD

Marco V. Usai, MD

- 1:00 – 1:10** Endovascular Aortic Arch Repair With Double In Situ Fenestration
Marco V. Usai, MD

- 1:10 – 1:20** Single Branched TEVAR In A Complex Thoraco-abdominal Dissection
Martin J. Austermann, MD
- 1:20 – 1:30** Emergency B/EVAR To Treat A Covered Aortic Rupture After EVAR With Type I Endoleak
Martin J. Austermann, MD
- 1:30 – 1:37** Endovascular Treatment Of TAAA 4 Via Branched CMD With Short Proximal Sealing – Münster Experiences (5-Minute Presentation With 2-Minute Discussion)
Marco V. Usai, MD

SESSION 92 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)

Moderators: *Mark A. Adelman, MD*

Michael J. Singh, MD

- 1:38 – 1:43** For Venous TOS An Anterior Infraclavicular Approach Permits Resection Of The Anterior Third Of The First Rib Which Is Sufficient: Technique, Limitations And Results
Keith D. Calligaro, MD
Matthew J. Dougherty, MD
- 1:44 – 1:49** Minimal Invasive Transaxillary First Rib Resection Under Local And Regional Anesthesia For TOSs: How To Do It, Limitations And Precautions
Francesco Spinelli, MD
- 1:50 – 1:55** To Treat Various Forms Of TOSs, Resection Of The Middle Third Of The First Rib Is Sufficient: A 30-Year Experience: How To Do It And When Not To
Claude D. Vaislic, MD
- 1:56 – 2:01** Robotic Approach To Thoracic Outlet Decompression: How To Do It: Limitations And Contraindications
Katherine A. Teter, MD
- 2:02 – 2:07** Supraclavicular Approach To Arterial And Neurogenic TOS: Technical Tips
Mark A. Adelman, MD
- 2:08 – 2:13** Botox Injections In The Treatment Of Neurogenic TOS: How Does It Work, When To Do It, How To Do It And Results
Jason T. Lee, MD
- 2:14 – 2:19** Adolescent Neurogenic And Vascular TOSs: They Are Different And Uniquely Challenging: How To Diagnose Them And How Best To Treat Them In Athletes And Non-Athletes
Michael J. Singh, MD
- 2:20 – 2:25** Subclavian Artery Aneurysms In Patients With Genetic Arteriopathy: How Should They Be Worked Up And Treated
Sherene Shalhub, MD, MPH
- 2:26 – 2:32** **Panel Discussion**
- 2:32 – 2:42** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 93 (Grand Ballroom West, 3rd Floor)

BEST ANTIPLATELET REGIMENS UPDATE ON RARE VASCULAR DISEASES; NEW DEVELOPMENTS IN ANTIPLATELET AND ANTICOAGULATION REGIMENS AND MEDICAL AND DRUG TREATMENTS

Moderators: *Caron B. Rockman, MD*

Kellie R. Brown, MD

UPDATE ON TREATMENT OF RARE VASCULAR
DISEASES

- 2:42 – 2:47** Optimal Current Management Of Takayasu's Disease Involving The Supra-Aortic Branches: Technical Details For Open Surgical Management And What Is The Role For Endo Treatment With Bare Or Covered Stents
Kellie R. Brown, MD
- 2:48 – 2:53** The Present Status Of Buerger's Disease: Does It Still Exist; How To Diagnose And Treat It
Kamphol Laohapensang, MD
- 2:54 – 2:59** How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well
James H. Black, III, MD
- 3:00 – 3:05** Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help
Martin Björck, MD, PhD (PowerPoint Presentation With Synched Audio)

ANTIPLATELET AND ANTICOAGULATION
TREATMENT

- 3:06 – 3:11** Current Optimal Antiplatelet And Anticoagulation Treatment For Various Vascular Procedures In Various Vascular Beds: What Newer Drugs And DOACs Are Useful And What Is The Optimal Timing Of Treatment
Peter Henke, MD
- 3:12 – 3:17** Understanding The Barriers To Antiplatelet And Statin Adherence Following Vascular Interventions: What Should Be Done About It
Wei Zhou, MD
- 3:18 – 3:23** **Panel Discussion**
- 3:24 – 3:29** Next Generation Antithrombotic Agents: What's On The Horizon For Anticoagulant And Antithrombotic Drugs: How Will They Work And How Helpful Will They Be
Elliot L. Chaikof, MD, PhD
- 3:30 – 3:35** Lowering LDL-C And Controlling Elevated Blood Pressure And Lipoprotein Little A [Lp(a)] Can Lower Cardiovascular Risk 80%: What To Do If Patients Can't Tolerate A Statin Dose: Ezetimibe (Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid (Nexletol), Etc.
Richard Bulbulia, MA, MD

NEW DEVELOPMENTS IN MEDICAL MANAGEMENT

- 3:36 – 3:41** What Are The Best Medical Treatments After Carotid, Aortic And Lower Extremity Endovascular And Open Procedures
Maciej L. Dryjski, MD, PhD
- 3:42 – 3:47** Value And Limitations Of Statins And Non-Statins Lipid Lowering Agents And Other Medical Treatments In Patients With Carotid Artery Stenosis: Should They Be The Same Or Different In Patients Undergoing Invasive Procedures
Kosmas I. Paraskevas, MD
- 3:48 – 3:52** **Panel Discussion**

SESSION 94 (Grand Ballroom West, 3rd Floor)

ADVANCES IN THE ENDO AND OPEN TREATMENT
OF VASCULAR TRAUMA

Moderators: *Todd E. Rasmussen, MD*
Gilbert R. Upchurch, MD

- 3:52 – 3:57** Vascular Injuries After Blunt Abdominal Trauma: Diagnosis And Management: When Endo, When Open Treatment
Dittmar Böckler, MD

- 3:58 – 4:03** New Developments In The Endovascular Management Of Vascular Injuries: How Can A Hybrid Suite Be Helpful
Ravi R. Rajani, MD
UPDATE ON BLUNT THORACIC AORTIC INJURY (BTAI)
- 4:04 – 4:09** How To Manage Heparin In TEVAR For BTAI When Head Or Other Injuries Are Also Present: Some, None Or Just Sheath Flushing
Charles J. Fox, MD
- 4:10 – 4:15** Outcomes Of BTAI In >1,000 Patients: When Is Observation The Best Treatment; When Is TEVAR Best: When Is It Not: Technical Tips: From The Aortic Trauma Foundation Registry
Ali Azizzadeh, MD
- 4:16 – 4:21** Acute Thoracic Aortic Pseudo-Coarctation After BTAI: What Is It: How Does It Produce Distal Organ Ischemia: How Should It Be Diagnosed And Treated Emergently By TEVAR: Technical Tips
Erica L. Mitchell, MD, MEd
- 4:22 – 4:27** Classification Of BTAIs In Adults And Pediatric Patients: The Evidence Shows That Grades I And II Lesions Can Be Treated Conservatively Whereas Grades III And IV Should Be Treated Endovascularly: Recommendations For Graft Sizing In Children
Elina Quiroga, MD, MPH
- 4:28 – 4:33** Update On The Retrievable Rescue Stent-Graft For Treating Aortic And Vena Cava Injuries: What Is It: How Does It Work And Current Status
Bryan W. Tillman, MD, PhD
- 4:34 – 4:39** Update On Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions
Gilbert R. Upchurch, MD
- 4:40 – 4:45** Evolving Techniques In Pediatric Vascular And Endovascular Trauma Surgery: What Special Precautions Are Needed: How To Deal With Arterial Spasm: When And How Can Endovascular Grafts Be Used
Michael C. Dalsing, MD
- 4:46 – 4:56** **Panel Discussion**
End of Program L

PROGRAM M (SESSIONS 95-105)

DEEP VEIN DISEASE

Trianon Ballroom, 3rd Floor

SESSION 95 (Trianon Ballroom, 3rd Floor)

DEEP VEIN PHYSIOLOGY AND VEIN STENT ISSUES

Moderators: *Jose I. Almeida, MD*

Lowell S. Kabnick, MD

7:30 – 7:34 Introduction: Deep System

Lowell S. Kabnick, MD

7:35 – 7:40 Why Do We Call It Venous Hypertension

Brajesh K. Lal, MD

7:41 – 7:46 Appropriate Patient Selection For Iliac Vein Stenting

Jose I. Almeida, MD

7:47 – 7:52 Is 50% Stenosis The Cutpoint For Stenting

Mark H. Meissner, MD

7:53 – 7:58 Iliac Vein Duplex Ultrasound With Image Optimization

Jan M. Sloves, RVT

7:59 – 8:04 Physiologic Assessment Of The Severity Of Iliac Vein Obstruction

Fedor Lurie, MD, PhD

- 8:05 – 8:10** Approaching The NIVL Patient: How To Ensure Success
Mahmood Razavi, MD
- 8:11 – 8:16** An Ultrasound Imaging And Computational Fluid Dynamic Protocol To Assess Hemodynamics In Iliac Vein Compression Syndrome
Carlos Alberto Figueroa, PhD

8:17 – 8:22 Panel Discussion

SESSION 96 (Trianon Ballroom, 3rd Floor)

VENOUS STENT TRIALS

Moderators: *Alun H. Davies, MA, DM, DSc*
Erin H. Murphy, MD

- 8:23 – 8:28** RCT: Venous Stenting Versus Conservative Treatment In Deep Venous Obstruction
Houman Jalaie, MD, PhD
- 8:29 – 8:34** Early Experience With The Gore Viafort Venous Stent
Andrew Holden, MBChB
- 8:35 – 8:40** The BEYOND Venous Stent Registry
Michael K. W. Lichtenberg, MD
- 8:41 – 8:46** Criteria To Predict Mid-Term Outcome After Stenting Of Chronic Iliac Vein Obstructions (PROMISE Trial)
Iris Baumgartner, MD
- 8:47 – 8:52** Will The BEST Trial Answer The Question On Iliac Stenting
Alun H. Davies, MA, DM, DSc
- 8:53 – 8:58** A Look At Long-Term Venous Stent Data: ABRE Study 36-Month Clinical Outcome
Erin H. Murphy, MD
- 8:59 – 9:04** Zilver Vena Stent Trial: 4-Year Outcomes
Anthony J. Comerota, MD
- 9:05 – 9:10** Venovo Venous Registry: 36-Month Data Report From A Real World Registry
Michael K. W. Lichtenberg, MD
- 9:11 – 9:16 Panel Discussion**

SESSION 97 (Trianon Ballroom, 3rd Floor)

FEMORO-ILIOCAVAL CHRONIC TOTAL OCCLUSIONS, RECANALIZATION TECHNIQUES AND OTHER CONSIDERATIONS

Moderators: *Jose I. Almeida, MD*
Lowell S. Kabnick, MD

- 9:17 – 9:22** Steps To Minimize Complications During Central Venous Recanalization
Marcelo Guimaraes, MD, MBA
- 9:23 – 9:28** Ruptured IVC And Iliac Vein: Now What
Jose I. Almeida, MD
- 9:29 – 9:34** Outcomes And Predictors Of Failure Of Iliac Vein Stenting
Rabih A. Chaer, MD
- 9:35 – 9:40** Preclinical Data On Sirolimus Coated Balloons In Deep Veins: Results From The vSTRIDE Trial
Andrea T. Obi, MD
- 9:41 – 9:46** Results Of Revcore For Use In Chronic Deep Vein Stent Occlusion
Steven D. Abramowitz, MD
- 9:47 – 9:52** Hybrid Open And Endovascular Techniques For Complex Iliofemoral Disease
Erin H. Murphy, MD
- 9:53 – 9:58** Endovascular Brachiocephalic And IVC Bypass Graft Creation: Changing What Is (Im)Possible
Marcelo Guimaraes, MD, MBA
- 9:59-10:04** Veins Aren't Round – Stented Veins Don't Need To Be Either
Lowell S. Kabnick, MD
- 10:05-10:10 Panel Discussion**

SESSION 98 (Trianon Ballroom, 3rd Floor)

VENOUS THROMBOSIS SCIENCE AND TREATMENT STRATEGIES

Moderators: *Thomas W. Wakefield, MD*
Peter Henke, MD

- 10:11–10:16** Have Venous Trials Changed The Management Of The Ilio-Femoral DVT In 2024
Ali Amin, MD, RVT
- 10:17–10:22** Update Of Post-Thrombotic Syndrome Prevention
Tomasz Urbanek, MD, PhD
- 10:23–10:28** Update On Experimental DVT Vein Wall Injury
Peter Henke, MD
- 10:29–10:34** Venous Thromboembolism In The Context Of Chronic Venous Disease
Thomas W. Wakefield, MD
- 10:35–10:40** Inflow Assessment In PTS Patients
Jose I. Almeida, MD
- 10:41–10:46** Why Do VTE Risk Scores Fail To Prevent VTE
Peter Henke, MD
- 10:47–10:52** Inflammation, Selectins And Venous Thrombosis
Thomas W. Wakefield, MD
- 10:53–10:58** Predictive Modeling For Post-Thrombotic Syndrome In DVT Patients
Steven D. Abramowitz, MD
- 10:59–11:04** Assessing Radiation Exposure To Patients During Recanalization Of Chronic Venous Obstruction
Houman Jalaie, MD, PhD
- 11:05–11:10** **Panel Discussion**

SESSION 99 (Trianon Ballroom, 3rd Floor)

THROMBUS REMOVAL THROMBECTOMY DEVICES AND OTHER ISSUES TO CONSIDER

Moderators: *Patrick E. Muck, MD*
Robert B. McLafferty, MD, MBA

- 11:11–11:16** P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With Aspirex – 24-Month Results
Michael K.W. Lichtenberg, MD
- 11:17–11:22** Tips And Tricks With Lightning FLASH For PE And DVT Patients
Patrick E. Muck, MD
- 11:23–11:28** New Percutaneous Thrombectomy Reperfusion System
Patrick E. Muck, MD
- 11:29–11:34** CLOUT Registry For The Inari CloTrierer
David J. Dexter, MD
- 11:35–11:40** Obstruction Or Reflux: What To Treat First In Venous Ulcers
Robert B. McLafferty, MD, MBA
- 11:41–11:46** Venous Stent Thrombosis: Insights From The ABRE Study
Erin H. Murphy, MD
- 11:47–11:52** Thrombolysis For Acute DVT: Guidance From Current Clinical Trials
Brian G. DeRubertis, MD
- 11:53–11:58** **Panel Discussion**
- 11:59– 1:03** **Lunch Break – Rhinelander Gallery, 2nd Floor**
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 100 (Trianon Ballroom, 3rd Floor)

PELVIC VEIN DISORDERS

Moderators: *Cynthia K. Shortell, MD*
Mark H. Meissner, MD

- 1:04 – 1:09** The Role Of Conservative Pelvic Vein Management
Mark H. Meissner, MD

- 1:10 – 1:15** Management Of Symptomatic Vulvar Varices With And Without Pelvic Symptoms
Steve Elias, MD
- 1:16 – 1:21** Pelvic Venous Disease: New Terminology, New Treatment Approach, Still No Level 1 Data
Lindsay Machan, MD
- 1:22 – 1:27** Ovarian Vein Embolization: Which Patients Benefit
Mark H. Meissner, MD
- 1:28 – 1:33** Treatment Algorithm For Left Renal Vein Compression
Cynthia K. Shortell, MD
- 1:34 – 1:39** Outcomes Of Left Renal Vein Stenting In Patients With Nutcracker Syndrome
Rabih A. Chaer, MD
- 1:40 – 1:45** Open Surgical And Endovascular Treatment Of Nutcracker Syndrome: Do We Have The Answer Now
Manju Kalra, MBBS
- 1:46 – 1:51** RCT Of Pelvic Venous Embolization Versus Sham Procedure For Venous Origin Chronic Pelvic Pain In Women
Neil M. Khilnani, MD
- 1:52 – 1:57** Management Of Combined Iliac Vein Obstruction And Ovarian Reflux
Kush R. Desai, MD
- 1:58 – 2:03** **Panel Discussion**

SESSION 101 (Trianon Ballroom, 3rd Floor)

MORE VENOUS THROMBOSIS

Moderators: *Steve Elias, MD*

Andrea T. Obi, MD

- 2:04 – 2:09** Surgical Removal Of IVC Filters: Perforation Or Infiltration
Timothy K. Liem, MD, MBA
- 2:10 – 2:15** Update On Reversal Agents For The DOACs
Timothy K. Liem, MD, MBA
- 2:16 – 2:21** Which DOAC For What Disease: Review Of Ongoing Trials
Andrea T. Obi, MD
- 2:22 – 2:27** Hypercoagulable Work Up, Thrombophilia Testing, And Duration Of Anticoagulation
Rachel Rosovsky, MD, MPH
- 2:28 – 2:33** SVT Treatment Options: DOAC, LMWH, Nothing
Steve Elias, MD
- 2:34 – 2:39** Management Of Venous Thoracic Outlet Syndrome
Robert J. Beaulieu, MD
- 2:40 – 2:45** Factor XI Inhibitors: What Are They
Alex C. Spyropoulos, MD
- 2:46 – 2:51** **Panel Discussion**

SESSION 102 (Trianon Ballroom, 3rd Floor)

IVC FILTERS AND MORE ISSUES WITH STENTS

Moderators: *William A. Marston, MD*

Peter Gloviczki, MD

- 2:52 – 2:57** IVC Filter Retrieval: Basic And Advanced
Ripal T. Gandhi, MD
- 2:58 – 3:03** Bertram D. Cohn's Contributions To The Development Of The Original IVC Filter
Enrico Ascher, MD
- 3:04 – 3:09** Getting Out Of A Pinch: A Technique To Remove Frozen Central Venous Catheters
Scott L. Stevens, MD
- 3:10 – 3:15** Laser-Assisted IVC Filter Retrieval: When And How
Kush R. Desai, MD
- 3:16 – 3:21** Denali Filter Experience
Eric Hager, MD
- 3:22 – 3:27** Anticoagulation In Childhood, The Role For DOACs
Dawn M. Coleman, MD

- 3:28 – 3:33** Rethinking Filters: The Latest Evidence From The Cook IVC Filter Study
Rabih A. Chaer, MD
- 3:34 – 3:39** Migration Of Iliac And Renal Vein Stents: T-Stent Might Be A Solution To The Problem
Peter Gloviczki, MD
- 3:40 – 3:45** Outcome Of Venous Stents In Adolescents, Teenagers, And Pregnancy
Mahmood Razavi, MD
- 3:46 – 3:51** Acute Iliofemoral DVT In Adolescents And Young Adults And Whether They Should Undergo Stenting For May Thurner At The Time Of DVT Intervention
William A. Marston, MD
- 3:52 – 3:57** **Panel Discussion**

SESSION 103 (Trianon Ballroom, 3rd Floor)

MORE DEEP VENOUS OBSTRUCTION, VENA CAVA, AND STENTS

Moderators: *Erin H. Murphy, MD*
Efthymios (Makis) Avgerinos, MD

- 3:58 – 4:03** IVC Reconstruction Options
Erin H. Murphy, MD
- 4:04 – 4:09** Tips And Tricks For Optimal Management Of Primary And Secondary IVC Tumors
Jill J. Colglazier, MD
- 4:10 – 4:15** Stenting Across The IVC Filter Is A Safe And Effective Alternative To Complex Removal
Efthymios (Makis) Avgerinos, MD
- 4:16 – 4:21** Techniques For Open Removal Of Occluded Open And Closed Cell IVC And Iliofemoral Venous Stents
Steven D. Abramowitz, MD
- 4:22 – 4:27** Popliteal Venous Aneurysm Repair: How And When To Treat
Heron E. Rodriguez, MD
- 4:28 – 4:33** Effect Of Venoactive Compounds In Post-Thrombotic Syndrome
Monika L. Gloviczki, MD, PhD
- 4:34 – 4:39** Does Reducing Venous Hypertension By Ablation Or Venous Stenting “Cure” Edema In Patients With Venous Ulcers
Thomas F. O'Donnell, Jr., MD
- 4:40 – 4:45** Hemodynamic Consequences After Venous Stenting: An In Vitro Assessment
Houman Jalaie, MD, PhD
- 4:46 – 4:51** Measurement Of Edema Using Volumetric Plethysmography
Seshadri Raju, MD
- 4:52 – 4:57** **Panel Discussion**

SESSION 104 (Trianon Ballroom, 3rd Floor)

MORE IMPORTANT DEEP VENOUS CONCEPTS

Moderators: *Arjun Jayaraj, MD*
Rabih A. Chaer, MD

- 4:58 – 5:03** Ambulatory Venous Pressure Measurement Via Column Interruption Duration
Seshadri Raju, MD
- 5:04 – 5:09** Outcomes Of Acute Superior Mesenteric Venous Thrombosis
Rabih A. Chaer, MD
- 5:10 – 5:15** Suprainguinal Lymphatic Disease In Patients Undergoing Stenting For Chronic Iliofemoral Venous Obstruction
Arjun Jayaraj, MD
- 5:16 – 5:21** Open Surgical And Endovascular Treatment Of Superior Vena Cava Syndrome
Manju Kalra, MBBS

- 5:22 – 5:27** Treatment Effectiveness Of A Non-Pneumatic Compression Device Versus An Advanced Pneumatic Compression Device For Lower Extremity Lymphedema Swelling (TEAYS Study)
Thomas S. Maldonado, MD
- 5:28 – 5:33** Indications, Technical Aspects, And Outcomes Of Stent Placement In Chronic Iliofemoral Venous Obstruction
Maxim Shaydakov, MD, PhD
- 5:34 – 5:39** NIVL Management: Highlights From VIVA, AVF, AVLS, SCAI Consensus Statement
Kush R. Desai, MD
- 5:40 – 5:45** **Panel Discussion**

SESSION 105 (Trianon Ballroom, 3rd Floor)

VENOUS REFLUX ISSUES AND DEEP VEIN VALVE TECHNOLOGIES

Moderators: *Jorge H. Ulloa, MD*
Paul J. Gagne, MD

- 5:46 – 5:51** Long-Term Results Of The SAVVE Trial: A Bioprosthetic Valve
David J. Dexter, MD
- 5:52 – 5:57** An Update On The Cook Venous Valve Project
Paul J. Gagne, MD
- 5:58 – 6:03** Endovenous Delivery Of New Valve Prosthesis In Humans: The New Trend
Jorge H. Ulloa, MD
- 6:04 – 6:09** When Deep Venous Reflux Repair Is Not Effective: What Next
Marzia Lugli, MD
- 6:10 – 6:15** Deep Venous Reflux In Patients Undergoing Venous Treatments
Mikel Sadek, MD
- 6:16 – 6:21** Deep Reflux: What Happens After Concomitant Obstruction Correction
Marzia Lugli, MD
- 6:22 – 6:27** Deep Vein Valve Devices: What Outcome Measures Should Be Used
Fedor Lurie, MD, PhD
- 6:28 – 6:33** Initial Experience With Ultrasound-Facilitated, Thrombolytic Enhanced Thrombectomy (Sono Thrombectomy), In Patients With Acute Proximal Deep Vein Thrombosis
William A. Marston, MD
- 6:34 – 6:39** Venous Stent For The Iliofemoral Vein Investigational Clinical Trial Using The Duo Venous Stent System: The VIVID Trial
Mahmood Razavi, MD
- 6:40 – 6:45** **Panel Discussion**
- End of Program M**

SATURDAY, NOVEMBER 23, 2024

6:15 A.M. General Registration – Gramercy Suite East, 2nd Floor

6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor

6:30 A.M. Continental Breakfast – 3rd Floor Promenade/Foyer

CONCURRENT SATURDAY PROGRAMS

PROGRAM N (SESSIONS 106-109)

Topics Too Important To Miss In General And In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

7:00 A.M. - 12:06 P.M.

Location: Grand Ballroom East, 3rd Floor

PROGRAM O (SESSIONS 110-115)

Improving Outcomes In Hemodialysis Access

8:00 A.M. - 4:00 P.M.

Location: Grand Ballroom West, 3rd Floor

Course Leaders: Larry A. Scher, MD

Anton N. Sidawy, MD

Haimanot (Monnie) Wasse, MD, MPH

PROGRAM P (SESSIONS 116-125)

Advances In Vascular Imaging And Diagnosis

6:50 A.M. - 5:35 P.M.

Location: Murray Hill Suites, 2nd Floor

Course Leaders: George L. Berdejo, BA, RVT

Natalie A. Marks, MD, RPVI, RVT

PROGRAM N (SESSIONS 106-109)

TOPICS TOO IMPORTANT TO MISS IN GENERAL AND IN THE TREATMENT OF LOWER EXTREMITY, AORTIC OR CAROTID DISEASE

Grand Ballroom East, 3rd Floor

SESSION 106 (Grand Ballroom East, 3rd Floor)

MISCELLANEOUS/GENERAL TOPICS AND LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS

Moderators: Peter A. Schneider, MD

Venita R. Chandra, MD

Vikram S. Kashyap, MD

7:00 – 7:05 Current Status Of An Endovascular First Approach To Lower Extremity Revascularization For CLTI In The Context Of The BEST-CLI Trial: What Are The Exceptions

Justin George, MD

7:06 – 7:11 Radial Access Should Be In The Armamentarium Of Every Vascular Surgeon: Why, When And How To Use It: Equipment Needed And Technical Tips

Heron E. Rodriguez, MD

7:12 – 7:17 Essential Angiographic Skills For Endovascular Surgeons: Must Include Gantry Angle Projections, Image Settings, Contrast Dilution, Injection Pressure And Flow Rates, Frame Rates, Cone Beam CTs, Fusion, Etc.

Martin Malina, MD, PhD

7:18 – 7:23 Severe Iatrogenic Injuries: Etiologies, Locations, Diagnosis And Safe Endo Treatment Techniques: Precautions And Prevention

Samy S. Nitecki, MD

7:24 – 7:29 Novel Wire Fixation Device: How It Works, Where It Can Help And Advantages

Patrick E. Muck, MD

- 7:30 – 7:35** Does Hyperbaric Oxygen Therapy Really Work For Ischemic And Nonischemic Wounds In Vascular Patients: Is There Proof And Is It Worth The Cost
Robert B. McLafferty, MD, MBA
- 7:36 – 7:41** **Panel Discussion**
- IMPORTANT LOWER EXTREMITY TOPICS**
- 7:42 – 7:47** With Prograde CFA Punctures, How To Easily Get The Guidewire Down The SFA Rather Than The Deep Femoral
Ali Amin, MD, RVT
- 7:48 – 7:53** Prograde SFA Access Can Be Safe And Effective For Lower Extremity Endo Procedures; When And How To Do It And Obtain Secure Closure
Karan Garg, MD
Todd Berland, MD
- 7:54 – 7:59** Endovascular Treatment Of CFA Lesions Is Proving Superior To Endarterectomy Because Of Improvements In Technology And Technique And The Complications Of Endarterectomy: How To Do It And When Is Endarterectomy Still Mandatory
Martin Malina, MD, PhD
- 8:00 – 8:05** Ambulation Physical Therapy For PAD Is Now Covered By Medicare: Why Is It So Poorly Prescribed And What Can Be Done To Enhance Its Use
Caron B. Rockman, MD
Jeffrey S. Berger, MD, MS
- 8:06 – 8:11** Paclitaxel Use In CLTI Patients: Is There Still Any Evidence Of An Increased Amputation Risk
Peter A. Schneider, MD
- 8:12 – 8:17** Open Treatment First For CLTI In The Era Of BEST-CLI: When Is It Best: It's Not Just For Patients With Good Ipsilateral Great Saphenous Veins
Yana Etkin, MD
- 8:18 – 8:26** **Panel Discussion**

SESSION 107 (Grand Ballroom East, 3rd Floor)

MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS

Moderators: *Vikram S. Kashyap, MD*
Keith D. Calligaro, MD
Miguel F. Montero-Baker, MD

- 8:26 – 8:31** CLTI Nomenclature And Data End-Points Need Refurbishing: A Call To Action For The Next Decade Of Care
Miguel F. Montero-Baker, MD
- 8:32 – 8:37** Outcomes Of Interventions For PAD In African American Female Patients And Asian Patients: Is It Different And Why: Can Anything Be Done About It
Caron B. Rockman, MD
- 8:38 – 8:43** The Effect Of Optimal Medical Therapy On Outcomes In Patients With CLTI In The BEST-CLI Trial
Vikram S. Kashyap, MD
- 8:44 – 8:49** When Is Primary Amputation Ever Appropriate For Patients With CLTI: It's Much Less Common Than You Think
Christopher J. Abularrage, MD (PowerPoint Presentation With Synched Audio)
- 8:50 – 8:55** Duplex Ultrasound For Diagnosis Of Failing Stents Placed For Arterial Occlusive Disease: Why Is It Important And How Often Should It Be Done After Treatment In Claudicants; In CLTI Patients
Keith D. Calligaro, MD
- 8:56 – 9:01** **Panel Discussion**

- 9:02 – 9:07** Perfusion Imaging With Near-Infrared Spectroscopy (NIRS): How Is It Done And What Is Its Value In Patients Requiring Interventions For Lower Extremity Ischemia
Richard F. Neville, MD (Power Point Presentation with Synched Audio)
- 9:08 – 9:13** Can The BEST-CLI Trial Tell Us Whether Saving A Limb Also Prolongs Survival
Peter A. Schneider, MD
- 9:14 – 9:19** Never Say Never: Endovascular Profundaplasty Is Possible And Effective: How To Do It And Results
Pasqualino Sirignano, MD, PhD
Francesco Speziale, MD
- 9:20 – 9:25** Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access
Natalie A. Marks, MD, RPVI, RVT
Enrico Ascher, MD
- 9:26 – 9:31** Aggressive Interventions Including Atherectomy In Claudicants Leads To More Harm Than Good
Dipankar Mukherjee, MD
- 9:32 – 9:38** **Panel Discussion**
- 9:38 – 9:48** **Break – Visit Exhibits And Pavilions (3rd Floor)**

SESSION 108 (Grand Ballroom East, 3rd Floor)

AORTIC TOPICS TOO IMPORTANT TO MISS AND SPINE EXPOSURE

Moderators: *David J. Minion, MD*
William P. Robinson, MD
Kenneth Ouriel, MD, MBA

- 9:48 – 9:53** Contemporary Management Of Kommerell's Diverticulum And Aberrant Subclavian Artery: From The International Vascular Low Frequency Disorders Consortium
Peter F. Lawrence, MD
Jonathan Bath, MD
- 9:54 – 9:59** Retroperitoneal Bleeding Is A Catastrophic And Poorly Detected Complication Of Groin Access Above The Inguinal Ligament: Early Bird Bioimpedance Monitoring (From Saranas) Can Detect Early Retroperitoneal Access Bleeding: How Does It Work And Results
David O'Connor, MD
- 10:00–10:05** Outcomes Of EVAR In Over 18,000 High-Risk Patients Ineligible For Open Repair: When Is EVAR Justified Over No Intervention In Such Patients: Why Is EVAR 2 No Longer Relevant
George A. Antoniou, MD, PhD, MSc
- 10:06–10:11** Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And Need For F/EVAR
David J. Minion, MD
- SPINE EXPOSURE SURGERY (6-Minute Presentations)**
- 10:12–10:18** Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (6-Minute Presentation)
Jeffrey Jim, MD, MPH
- 10:19–10:25** Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (6-Minute Presentation)
William P. Robinson, MD
- 10:26–10:32** **Panel Discussion**

SESSION 109 (Grand Ballroom East, 3rd Floor)

AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS

Moderators: *Frank J. Veith, MD*
Enrico Ascher, MD
Mark A. Adelman, MD

TOPICS RELATED TO THE AORTA AND ITS BRANCHES

- 10:32-10:37** Isolated Mesenteric Artery Dissections Should Be Managed Medically In Most Cases: When Is Open Or Endo Treatment Needed And How To Do It
Heron E. Rodriguez, MD
- 10:38-10:43** Retroperitoneal Exposure Of The Visceral Aorta And Its Branches: It's Not Simple; Technical Tips
R. Clement Darling III, MD
- 10:44-10:49** Performance Of Newer Generation Endografts (Endologix) Anatomically Fixed On The Aortic Bifurcation For AAA Repair: Long-Term Outcomes In The Medicare Population
Mark Conrad, MD, MMSc
- 10:50-10:55** Fenestrated EVAR Versus Chimney EVAR For Juxtarenal AAAs: When Is One Better Than The Other And What Are The Critical Considerations
Piergiorgio Cao, MD
- 10:56-11:01** Balloon Optimized Molding For Better Deployment And Sealing Of Alto (From Endologix) Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks And Migration
David J. Minion, MD
- 11:02-11:07** The Vascular Surgeon's Role In TAVR Procedures Via The Common Carotid Artery: Pitfalls And Technical Tips
Gregg S. Landis, MD
- 11:08-11:13** **Panel Discussion**

CAROTID TOPICS

- 11:13-11:18** Tips And Tricks For Successful TCAR And When Is CEA And Best Medical Treatment Better Than TCAR
Jeffrey Jim, MD, MPHS
- 11:19-11:24** Techniques For Dealing With Challenging Carotid Lesions: How Does TCAR Facilitate Treatment When Nothing Else Could Work
Joseph J. Ricotta II, MD, MS
- 11:25-11:30** Shaking Limb Syndrome: What Is Its Symptoms And Why Is It A Good But Uncommon And Overlooked Indication For CEA Or CAS
Bruce A. Perler, MD, MBA
- 11:31-11:36** Value Of Lithotripsy (Shockwave) For TCAR Or CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions
Jeffrey Jim, MD, MPHS
Peter A. Schneider, MD
Max Amor, MD
- 11:37-11:42** Carotid Intervention Improves Mood In Depressed Patients With Carotid Stenosis: What Is The Evidence And Should All Depressed Patients With Carotid Disease Undergo Carotid Intervention
Wei Zhou, MD
- 11:43-11:48** Management Of Carotid Infections Including Post CEA With Patches: Outcomes Of Ipsilateral Carotid Bypass In Hostile Necks: Technical Tips
Heron E. Rodriguez, MD

- 11:49–11:54** Eagle Syndrome: Internal Carotid Artery Compression By A Hypertrophic Styloid Process: What Symptoms Does It Cause, How To Diagnose It And How To Fix It
Peter F. Lawrence, MD
- 11:55–12:00** Cerebral Hyperfusion Syndrome After Carotid Interventions: Who Is At Risk; How To Avoid And How To Treat
Enrico Ascher, MD
- 12:01–12:06** **Panel Discussion**
End of Program N
VEITH Symposium continues with the A-V Access Program in the Grand Ballroom West, 3rd floor, and the Advances in Vascular Imaging and Diagnosis Program in the Murray Hill Suites on the 2nd floor.

PROGRAM O (SESSIONS 110-115)
IMPROVING OUTCOMES IN HEMODIALYSIS ACCESS

Grand Ballroom West, 3rd Floor

SESSION 110 (Grand Ballroom West, 3rd Floor)

IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

Moderators: *Larry A. Scher, MD*
Anton N. Sidawy, MD, MPH

- 8:00 – 8:05** Introduction
Larry A. Scher, MD
Anton N. Sidawy, MD, MPH
- 8:06 – 8:13** It's Really All About The Patient!
Dori R. Schatell, MS
- 8:14 – 8:21** How To Improve The Patient Experience And 'Ace' The CMS Patient Experience Surveys
Terry Litchfield, MPA
- 8:22 – 8:29** What Is The Optimal Time For Access Placement In Patients With Chronic Kidney Disease
Charmaine Lok, MD
- 8:30 – 8:37** "Optimal Start" In The Era Of "Value Based Care"
Theodore F. Saad, MD
- 8:38 – 8:45** Does Inflow Reduction Improve Outflow Patency
Haimanot (Monnie) Wasse, MD, MPH
- 8:46 – 8:53** The Importance Of Vascular Access Registries In Improving Clinical Outcomes
Robert Shahverdyan, MD
- 8:54 – 9:04** **Panel Discussion**
- 9:05 – 9:12** Update On Access Cannulation: Is There Anything New On The Horizon
Deborah Brouwer-Maier, RN, CNN
- 9:13 – 9:20** Ultrasound Guided Cannulation For Hemodialysis Access – A Paradigm Shift
Vandana D. Niyyar, MD
- 9:21 – 9:28** Novel Methods To Predict And Assess AV Fistula Maturation
Peter Kotanko, MD
- 9:29 – 9:36** Early Follow Up After AV Fistula Creation Improves Access Related Outcomes
Yana Etkin, MD
- 9:37 – 9:44** Vascular Access Monitoring: Can We Do It Better
Charmaine Lok, MD
- 9:45 – 9:52** Tips And Techniques For The Use Of Ultrasound In AV Access
Robert Shahverdyan, MD
- 9:53–10:03** **Panel Discussion**
- 10:04–10:25** **Break - Visit Exhibits And Pavilions (3rd Floor)**

SESSION 111 (Grand Ballroom West, 3rd Floor)

MORE IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

Moderators: *Haimanot (Monnie) Wasse, MD, MPH*
Evan C. Lipsitz, MD, MBA

- 10:26–10:33** Strategies For Development Of A Health Care Network Dialysis Access Program
John R. Ross, Sr., MD
- 10:34–10:41** AV Fistula Maturation: Going Beyond Creation To Successful Cannulation
Neghae Mawla, MD
- 10:42–10:49** Access Surgery In The Breast Cancer Patient
Vicki J. Teodorescu, MD
- 10:50–10:57** Dialysis History: William J. Kolff, MD And The 80-Year Anniversary Of The First Dialysis
Theodore F. Saad, MD
- 10:58–11:05** Lessons Learned From Three Decades Of Dialysis Access Care
Sanford D. Altman, MD
- 11:06–11:16** **Panel Discussion**

SESSION 112 (Grand Ballroom West, 3rd Floor)

MINISYMPOSIUM: HEMODIALYSIS ACCESS INDUCED DISTAL ISCHEMIA (7-MINUTE TALKS)

Moderators: *Larry A. Scher, MD*
Yana Etkin, MD

- 11:17–11:24** Steal Syndrome: More Than A Blood Flow Problem
Sal Scali, MD
- 11:25–11:32** Can We Predict (And Prevent) Steal Syndrome
Matthew J. Dougherty, MD
- 11:33–11:40** Proximalization Should Replace DRIL For Treatment Of HAIDI
Homayoun Hashemi, MD, RVT
- 11:41–11:48** Contemporary Outcomes Of Distal Radial Artery Ligation For HAIDI
Mohamad A. Hussain, MD, PhD
- 11:49–11:59** **Panel Discussion**
- 12:00– 1:00** **Lunch Break - Mercury Rotunda & Ballroom (3rd Floor)**

SESSION 113 (Grand Ballroom West, 3rd Floor)

POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

Moderators: *Larry A. Scher, MD*
Anton N. Sidawy, MD, MPH

- 1:00 – 1:07** Reimbursement And Regulatory Update In Dialysis Access
Terry Litchfield, MPA
- 1:08 – 1:15** **DEBATE:** What Is Optimal For FDA Approval Of Novel Vascular Access Devices: Single Arm Clinical Trials Are Adequate To Support Approval Of Novel Vascular Access Devices
Ellen D. Dillavou, MD
- 1:16 – 1:23** **DEBATE:** Regulatory Approval Of Novel Vascular Access Devices: When A Randomized Clinical Study Could Help
Robert E. Lee, MD
- 1:24 – 1:31** Is Value Based Access Care Finally Ready For Prime Time
Evan C. Lipsitz, MD, MBA
- 1:32 – 1:39** Expanding Dialysis Innovations And Care Choices: Patients Say ‘If Not Us, Who’; ‘If Not Now, When’
Paul T. Conway, BA (PowerPoint Presentation With Synched Audio)
- 1:40 – 1:50** **Panel Discussion**

SESSION 114 (Grand Ballroom West, 3rd Floor)

NOVEL TECHNOLOGIES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

Moderators: *Haimanot (Monnie) Wasse, MD, MPH*
Clifford M. Sales, MD, MBA

- 1:51 – 1:58** Update On The Velocity Percutaneous AV Fistula (Venova Medical)
Robert Shahverdyan, MD
- 1:59 – 2:06** Use Of Bioengineered Vascular Wrap (SelfWrap) To Improve AV Fistula Outcomes (VenoStent)
Ellen D. Dillavou, MD
- 2:07 – 2:14** Safety And Efficacy Of HemoWrap Device For Post Cannulation Hemostasis
Sundaram Ravikumar, MD
- 2:15 – 2:22** Results Of A Phase 3 Study Comparing Efficacy And Safety Of Humacyte Tissue-Engineered Vessel With Autologous AV Fistulas In Patients With End Stage Renal Disease
C. Keith Ozaki, MD
- 2:23 – 2:30** Results Of Wrapsody Arteriovenous Access Efficacy (WAVE) PIVOTAL Trial
Mahmood Razavi, MD
- 2:31 – 2:38** Xeltis Vascular aXess Graft: Preliminary Results Of The US IDE Trial
John F. Lucas III, MD
- 2:39 – 2:49** **Panel Discussion**

SESSION 115 (Grand Ballroom West, 3rd Floor)

UPDATE ON CLINICAL CHALLENGES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)

Moderators: *Larry A. Scher, MD*
Surendra Shenoy, MD, PhD

- 2:50 – 2:57** Dear Surgeons: Design Me A Better Access – Observations Of An Interventional Nephrologist
Neghae Mawla, MD
- 2:58 – 3:05** Creating Autogenous Hemodialysis Access In Children And Adolescents
William Jennings, MD (PowerPoint Presentation With Synched Audio)
- 3:06 – 3:13** Should We Be Performing More Lower Extremity Access Procedures
Jeremy S. Crane, MBChB, MD
- 3:14 – 3:21** Safe And Effective HeRO Graft Placement: Technique And Results
Karl A. Illig, MD
- 3:22 – 3:29** Treatment Options For Venous Thoracic Outlet Syndrome In Dialysis Patients
Mark G. Davies, MD
- 3:30 – 3:37** Current Strategies For Selection Of Biologic Versus Prosthetic Grafts For Hemodialysis Access
Jesse Garcia, MD
- 3:38 – 3:45** Can We Make A Fistula Last Forever
Surendra Shenoy, MD, PhD
- 3:46 – 4:00** **Panel Discussion**
End of Program O

PROGRAM P (SESSIONS 116-125)

ADVANCES IN VASCULAR IMAGING AND DIAGNOSIS

Murray Hill Suites, 2nd Floor

SESSION 116 (Murray Hill Suites, 2nd Floor)

MANAGING THE PATIENT WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (PAD): STRENGTHS AND WEAKNESSES OF THE DIAGNOSTIC TECHNIQUES, WHO NEEDS WHICH TESTS AND WHEN

(PAD is a very complex disease with many available diagnostic modalities. Armed with the right information, a thorough history and physical exam, and the appropriate diagnostic/imaging modality, the patient will be on the right track to getting the help and care he or she needs. How Much is Enough? What Do We Need for Diagnosis, Management and Treatment of PAD?)

Moderator: *Ann Marie Kupinski, PhD, RVT*

- 6:50 – 7:00** Welcome And Opening Remarks: Navigating The Meeting And Optimizing Your Experience
George L. Berdejo, BA, RVT
- 7:00 – 7:08** The History And Physical Examination Matters And Guides The Workup
Anahita Dua, MD, MS, MBA
- 7:08 – 7:16** Still Important Role Of Physiologic Testing
Ann Marie Kupinski, PhD, RVT
- 7:16 – 7:24** Role Of Duplex Ultrasound In The PAD Workup
Natalie A. Marks, MD, RPVI, RVT
- 7:24 – 7:32** Evolving And Expanding Role Of Pedal Artery Imaging
Jill S. Sommerset, BS, RVT
- 7:32 – 7:40** What About CTA And MRA
David L. Dawson, MD
- 7:40 – 7:48** Strategic Use Of Contrast Arteriography
John Carson, MD
- 7:48 – 8:05** **Panel Discussion: Putting It All Together**

SESSION 117 (Murray Hill Suites, 2nd Floor)

ABDOMINAL IMAGING TIPS AND TRICKS: LESSONS LEARNED FROM CASE STUDY PRESENTATIONS

Moderator: *Laurence Needleman, MD*

- 8:05 – 8:15** Renal Artery Scanning
Patrick A. Washko, BS, BSRT, RDMS, RVT
- 8:15 – 8:25** 5 Tips For A Liver Duplex Exam
Robert De Jong, RDMS, RVT
- 8:25 – 8:35** Mesenteric With Focus On Median Arcuate Ligament Syndrome
Phillip J. Bendick, PhD, RVT
- 8:35 – 8:45** Duplex Sureillance After Complex Aortic Endovascular Repair
R. Eugene Zierler, MD, RPVI
- 8:45 – 8:55** Bonus Lecture: Who Is The Right Patient For The Renal Artry Duplex Examination
Laurence Needleman, MD
- 8:55 – 9:10** **Panel Discussion**
- 9:10 – 9:30** **Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 118 (Murray Hill Suites, 2nd Floor)

CEREBROVASCULAR

Moderator: *R. Eugene Zierler, MD, RPVI*

- 9:30 – 9:40** Evolution And Review Of Carotid Duplex Criteria: From Strandness To IAC Consensus
R. Eugene Zierler, MD, RPVI
- 9:40 – 9:50** Review Of IAC Consensus Criteria: How To Transition And Incorporate It Into Your Practice
Heather L. Gornik, MD

9:50 – 10:00 The Role Of Alternative Imaging For Carotid Disease; What's Best And When Is It Necessary
Leslie M. Scoutt, MD

10:00–10:10 **Panel Discussion**

SESSION 119 (Murray Hill Suites, 2nd Floor)

PRACTICE ENHANCEMENTS AND PHILOSOPHICAL ISSUES I

Moderator: *George L. Berdejo, BA, RVT*

10:10–10:20 Variability Of Practice Patterns From A Survey Of International Vascular Specialists: Lessons Learned And How We Can Be More Value Added
Jill S. Sommerset, BS, RVT

10:20–10:30 How To Recruit, Train, And Retain Vascular Sonographers
George L. Berdejo, BA, RVT

10:30–10:40 State Of Vascular Ultrasound Education And Training
Traci B. Fox, EdD, RDMS, RVT

10:40–10:50 Is There A Role For Advanced Practice Vascular Sonography
Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS

10:50–11:00 Sonographer Burnout: How Real Is This And How Can It Be Addressed
Aubrey J. Rybyinski, BS, RDMS, RVT

11:00–11:10 What's Happening With The Workforce: Is The Projected Sonographer Shortage Real, How Can It Be Addressed
Traci B. Fox, EdD, RDMS, RVT

11:10–11:25 **Panel Discussion**

11:25–11:40 **Lunch Break - South Corridor, 2nd Floor**

SESSION 120 (Nassau Suites, 2nd Floor)

TECHNICAL SKILLS LAB

(This session will allow you to visit with recognized experts in the field in an informal setting with opportunity for "hands-on" time and conversation to glean technical tips in various areas of vascular ultrasound and physiologic testing.)

Moderators: *Fernando Amador, RVT*
Richard Dubin, AAS-DMS, RVT, RDMS

11:40–12:40 Station 1: Pedal Artery Imaging
Jill S. Sommerset, BS, RVT

11:40–12:40 Station 2: Carotid Artery Imaging
William N. Del Valle, RVT

11:40–12:40 Station 3: Transcranial Duplex
Joseph P. Hughes, MBA, RVT, RVS, RPhS

11:40–12:40 Station 4: Pelvic Vein Imaging
Jan M. Sloves, RVT

11:40–12:40 Station 5: Renal Artery Imaging
Patrick A. Washko, BS, BSRT, RDMS, RVT

11:40–12:40 Station 6: Physiologic Test
Traci B. Fox, EdD, RDMS, RVT

11:40–12:40 Station 7: Hemodialysis Access
Ann Marie Kupinski, PhD, RVT

11:40–12:40 Station 8: Hepato-Portal Imaging
Robert De Jong, RDMS, RVT

12:40–12:45 **Transition To Plenary Sessions (Murray Hill Suites, 2nd Floor)**

SESSION 121 (Murray Hill Suites, 2nd Floor)

INTERPRETING WITH THE MASTERS

Moderator: *Laurence Needleman, MD*

12:45 – 1:50 Panel Discussion: *Interpreting With The Masters*

Panelists: Phillip J. Bendick, PhD, RVT
David L. Dawson, MD
Anahita Dua, MD, MS, MBA
Heather L. Gornik, MD
Ann Marie Kupinski, PhD, RVT
Leslie M. Scoutt, MD
R. Eugene Zierler, MD, RPVI

SESSION 122 (Murray Hill Suites, 2nd Floor)

WHAT THE VASCULAR SPECIALIST SHOULD EXPECT FROM A WELL-DONE VASCULAR ULTRASOUND EVALUATION

Moderator: *David L. Dawson, MD*

1:50 – 2:00 The Lower Extremity Arterial Mapping
Jill S. Sommerset, BS, RVT

2:00 – 2:10 The Lower Extremity Vein Evaluation For Reflux
Nicos Labropoulos, BSc (Med), PhD, RVT

2:10 – 2:20 The Ilio-Caval Evaluation In Chronic Venous Insufficiency
Jan M. Sloves, RVT

SESSION 123 (Murray Hill Suites, 2nd Floor)

VENOUS IMAGING: TESTING FOR CHRONIC VENOUS INSUFFICIENCY, LEG REFLUX AND PELVIC VEIN DISORDERS

Moderators: *David L. Dawson, MD*

Nicos Labropoulos, BSc (Med), PhD, RVT

2:20 – 2:30 The Anterior Saphenous Vein: Anatomic And Clinical Considerations For The Vascular Sonographer
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

2:30 – 2:40 The Role Of Duplex Ultrasound In The Evaluation Of The Post-Thrombotic Syndrome
Jan M. Sloves, RVT

2:40 – 2:50 Evaluation For Pelvic Vein Reflux
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

2:50 – 3:00 Duplex Ultrasound Follow-up After Interventions: When, How Often, What To Look For
Neil M. Khilnani, MD

3:00 – 3:15 Panel Discussion (Combined Sessions 122 And 123)

3:15 – 3:30 Break

SESSION 124 (Murray Hill Suites, 2nd Floor)

THE EVOLVING HEALTHCARE ENVIRONMENT: IMPACT ON PAYMENT, POLICY, LAB MANAGEMENT AND SVU UPDATES

Moderator: *Anne M. Jones, BSN, RVT, RDMS*

3:30 – 3:40 Current Critical Issues For The Vascular Professional
Anne M. Jones, BSN, RVT, RDMS

3:40 – 3:50 SVU Updates, Where Are We With The Strategic Plan, And Highlights Of The 2024 SVU Annual Conference
Josh D. Lee, MBA

3:50 – 4:00 Update On The Status Of *The Journal of Vascular Ultrasound* (JVU)
David L. Dawson, MD

4:00 – 4:10 Reimbursement Updates: Is There Any Good News
Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS

4:10 – 4:30 Panel Discussion

SESSION 125 (Murray Hill Suites, 2nd Floor)

HEMODIALYSIS ACCESS, CURVEBALLS AND CONTROVERSIES

Moderator: *Joseph P. Hughes, MBA, RVT, RVS, RPhS*

4:30 – 4:40 What Do I Do When I Find Non-Vascular Pathology
On My Vascular Ultrasound Study

Patrick A. Washko, BS, BSRT, RDMS, RVT

4:40 – 4:50 Utility Of The Toe-Brachial Index

William N. Del Valle, RVT

4:50 – 5:00 Current Applications For Contrast Enhanced
Ultrasound In The Vascular Laboratory

Leslie M. Scoutt, MD

5:00 – 5:10 'Volume Flow: Is This A Wild Goose Chase'

Ann Marie Kupinski, PhD, RVT

5:10 – 5:20 Noninvasive Evaluation Of Arterial Steal After Dialysis
Access

Phillip J. Bendick, PhD, RVT

5:20 – 5:30 **Panel Discussion**

5:30 – 5:35 **Raffle (You Must Be Present To Win)**

End of Program P

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

A

Anne L. Abbott, MD, PhD, FRACP
Melbourne, Australia

Dorothy B. Abel, BSBME
Columbia, Maryland

Cherrie Z. Abraham, MD
Portland, Oregon

Steven D. Abramowitz, MD
Washington, District of Columbia

Shadi J. Abu-Halimah, MD
Charleston, West Virginia

Christopher J. Abularrage, MD
Baltimore, Maryland

Ali F. AbuRahma, MD
Charleston, West Virginia

Joshua D. Adams, MD
Roanoke, Virginia

Mark A. Adelman, MD
New York, New York

Sam S. Ahn, MD, MBA
Fort Worth, Texas

Olamide Alabi, MD
Atlanta, Georgia

Jean-Noel Albertini, MD
Saint-Etienne, France

Jose I. Almeida, MD, RPVI, RVT
Miami, Florida

Jean-Marc Alsac, MD, PhD
Paris, France

Sanford D. Altman, MD
Miami, Florida

Fernando Amador, RVT
New York, New York

Ali Amin, MD, RVT
Reading, Pennsylvania

Gary M. Ansel, MD
Columbus, Ohio

Michele Antonello, MD, PhD
Padua, Italy

Daniel Antoniello, MD
Bronx, New York

George A. Antoniou, MD, PhD, MSc
Manchester, United Kingdom

Frank R. Arko, MD
Charlotte, North Carolina

Zachary M. Arthurs, MD
Charleston, South Carolina

Enrico Ascher, MD
New York, New York

Martin J. Austermann, MD
Münster, Germany

Efthymios (Makis) Avgerinos, MD
Athens, Greece

Hamdy Awad, MD
Upper Arlington, Ohio

Faisal Aziz, MD
Hershey, Pennsylvania

Ali Azizzadeh, MD
Los Angeles, California

Nobuyoshi Azuma, MD
Asahikawa, Hokkaido, Japan

Sateesh C. Babu, MD
Valhalla, New York

Martin R. Back, MD
Gainesville, Florida

Mirza S. Baig, MD
Dallas, Texas

Charles J. Bailey, MD
Tampa, Florida

Amanda Baker, MD
Bronx, New York

Jonathan Bath, MD
Columbia, Missouri

Iris Baumgartner, MD
Bern, Switzerland

Hernan A. Bazan, MD, DFSVS
New Orleans, Louisiana

Robert E. Beasley, MD, FSCAI
Miami Beach, Florida

Robert J. Beaulieu, MD, MSE
Ann Arbor, Michigan

Adam Beck, MD
Birmingham, Alabama

Jean Pierre Becquemin, MD
Paris, France

Christian A. Behrendt, MD
Hamburg, Germany

Phillip J. Bendick, PhD, RVT
Royal Oak, Michigan

James F. Benenati, MD
Miami, Florida

Janna Bentley, MD
British Columbia, Canada

George L. Berdejo, BA, RVT
White Plains, New York

Ramon Berguer, MD, PhD
Ann Arbor, Michigan

Colin D. Bicknell, MD
London, United Kingdom

Jean Bismuth, MD
Tampa, Florida

Martin Björck, MD, PhD
Uppsala, Sweden

James H. Black, III, MD
Baltimore, Maryland

Jan D. Blankensteijn, MD
Amsterdam, The Netherlands

John Blebea, MD, MBA
Saginaw, Michigan

Erwin Blessing, MD
Hamburg, Germany

Dittmar Böckler, MD
Heidelberg, Germany

Michel J. Bosiers, MD
Bern, Switzerland

Oscar H. Bottini, MD
Buenos Aires, Argentina

Lee Bouwman, MD, PhD
Spaubeek, The Netherlands

Jonathan R. Boyle, MD, MA (Cantab)
Cambridge, United Kingdom

Kursat A. Bozkurt, MD
Istanbul, Turkey

Andrew W. Bradbury, MD
Birmingham, United Kingdom

Daniela Branzan, MD
Munich, Germany

B

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Clayton J. Brinster, MD
Chicago, Illinois

Marianne Brodmann, MD
Graz, Austria

Allan L. Brook, MD
Bronx, New York

Thomas G. Brott, MD
Jacksonville, Florida

Deborah Brouwer-Maier, RN, CNN
Lansdale, Pennsylvania

Kellie R. Brown, MD
Milwaukee, Wisconsin

O. William Brown, MD, JD
Royal Oak, Michigan

Elchanan Bruckheimer, MBBS
Petah-Tikva, Israel

Jacob Budtz-Lilly, MD, PhD
Aarhus, Denmark

Richard Bulbulia, MA, MD
Oxford, United Kingdom

Ruth L. Bush, MD, MPH
Galveston, Texas

Jacques Busquet, MD
Paris, France

C

Keith D. Calligaro, MD
Philadelphia, Pennsylvania

Victor M. Canata, MD, PhD
Asuncion, Paraguay

Ludovic Canaud, MD, PhD
Montpellier, France

Piergiorgio Cao, MD
Rome, Italy

Laura Capoccia, MD, PhD
Caserta, Italy

Francis Caputo, MD
Cleveland, Ohio

Jeffrey G. Carr, MD
Tyler, Texas

John Carson, MD
Falmouth, Maine

Yuri A. Casseres, MD, MSc
Oranjestad, Aruba

Neal S. Cayne, MD
New York, New York

Rabih A. Chaer, MD
Pittsburgh, Pennsylvania

Elliot L. Chaikof, MD, PhD
Boston, Massachusetts

Venita R. Chandra, MD
Stanford, California

Heepeel Chang, MD
Hackensack, New Jersey

Robert W. Chang, MD
San Francisco, California

Zhong Chen, MD
Beijing, China

Jae S. Cho, MD
Cleveland, Ohio

Timothy A.M. Chuter, MD
San Francisco, California

Daniel G. Clair, MD
Nashville, Tennessee

Timothy W.I. Clark, MD
Philadelphia, Pennsylvania

Rachel E. Clough, PhD, FRCS
London, United Kingdom

W. Darrin Clouse, MD
Charlottesville, Virginia

Frederic Cochenne, MD, PhD
Paris, France

Dawn M. Coleman, MD
Durham, North Carolina

Jill J. Colglazier, MD
Rochester, Minnesota

Anthony J. Comerota, MD
Alexandria, Virginia

Mark Conrad, MD, MMSc
Brighton, Massachusetts

Michael S. Conte, MD
San Francisco, California

Paul T. Conway, BA
Washington, District of Columbia

Jared Cooper, MD
White Plains, New York

Joseph S. Coselli, MD
Houston, Texas

Victor S. Costache, MD, PhD
Bucuresti, Romania

Jeremy S. Crane, MBChB, MD
London, United Kingdom

Frank J. Criado, MD
Baltimore, Maryland

Jack L. Cronenwett, MD
Lebanon, New Hampshire

Jacob Cynamon, MD
New York, New York

D

Guilherme Dabus, MD
Miami, Florida

Michael D. Dake, MD
Tucson, Arizona

Ronald L. Dalman, MD
Stanford, California

Michael C. Dalsing, MD
Roswell, Georgia

R. Clement Darling III, MD
Albany, New York

Alun H. Davies, MA, DM, DSc
London, United Kingdom

Mark G. Davies, MD
Houston, Texas

David L. Dawson, MD
Temple, Texas

Gert J. de Borst, MD, PhD
Utrecht, The Netherlands

Gianmarco de Donato, MD
Siena, Italy

Robert De Jong, RDMS, RVT
Baltimore, Maryland

Reade A. De Leacy, MBBS
New York, New York

Randall R. De Martino, MD
Rochester, Minnesota

Jean-Paul de Vries, MD, PhD
Groningen, The Netherlands

Steven M. Dean, DO
Columbus, Ohio

David H. Deaton, MD
Crownsville, Maryland

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Sebastian E. Debus, MD, PhD

Hamburg, Germany

William N. Del Valle, RVT

Bronx, New York

Colin P. Derdeyn, MD

Charlottesville, Virginia

Brian G. DeRubertis, MD

New York, New York

Kush R. Desai, MD

Chicago, Illinois

Nimesh Desai, MD, PhD

Philadelphia, Pennsylvania

David J. Dexter, MD

Norfolk, Virginia

Nuno V. Dias, MD, PhD

Malmö, Sweden

Alan M. Dietzek, MD, RPVI

Danbury, Connecticut

Ellen D. Dillavou, MD

Raleigh, North Carolina

Hasan H. Dosluoglu, MD

Buffalo, New York

Matthew J. Dougherty, MD

Philadelphia, Pennsylvania

Maciej L. Dryjski, MD, PhD

Buffalo, New York

Anahita Dua, MD, MS, MBA

Boston, Massachusetts

Richard Dubin, AAS-DMS, RVT,

Bronx, New York **RDMS**

Joseph J. DuBose, MD

Austin, Texas

David M. Dudzinski, MD

Boston, Massachusetts

E

Matthew J. Eagleton, MD

Boston, Massachusetts

John F. Eidt, MD

Dallas, Texas

Hosam F. El Sayed, MD

Norfolk, Virginia

Jens Eldrup-Jorgensen, MD

Portland, Maine

Steve Elias, MD

Englewood, New Jersey

Jan-Willem Elshof, MD

Venlo, The Netherlands

Amichai J. Erdfarb, MD

New York, New York

Guillermo A. Escobar, MD

Atlanta, Georgia

Ignacio Escotto, MD

Mexico City, Mexico

Mohammad H. Eslami, MD, MPH

Charleston, West Virginia

Anthony L. Estrera, MD

Houston, Texas

Yana Etkin, MD

New York, New York

Christian D. Etz, MD, PhD

Rostock, Germany

F

Dominique Fabre, MD, PhD

Garches, France

Gianluca Faggioli, MD

Bologna, Italy

Alex Fairman, MD

Philadelphia, Pennsylvania

Ayman Fakhry, MD

Alexandria, Egypt

Fabrizio Fanelli, MD

Florence, Italy

Alik Farber, MD, MBA

Boston, Massachusetts

Mark A. Farber, MD

Chapel Hill, North Carolina

Peter L. Faries, MD

New York, New York

Javairiah Fatima, MD

Washington, District of Columbia

Jose Fernandes e Fernandes, MD,

Lisbon, Portugal **PhD**

Roberto Ferraresi, MD

Milan, Italy

Marcelo Ferreira, MD

Rio de Janeiro, Brazil

Ciro Ferrer, MD, PhD

Rome, Italy

Carlos Alberto Figueroa, PhD

Ann Arbor, Michigan

David Fiorella, MD, PhD

Stony Brook, New York

Thomas L. Forbes, MD

Toronto, Ontario, Canada

Mazin Foteh, MD

Dallas, Texas

Charles J. Fox, MD

Baltimore, Maryland

Traci B. Fox, EdD, RDMS, RVT

Philadelphia, Pennsylvania

Weiguo Fu, MD

Shanghai, China

Naoki Fujimura, MD, PhD

Tokyo, Japan

G

Paul J. Gagne, MD

Darien, Connecticut

Katherine A. Gallagher, MD

Ann Arbor, Michigan

Chirag D. Gandhi, MD

Valhalla, New York

Ripal T. Gandhi, MD

Miami, Florida

Jesse Garcia, MD

Washington, District of Columbia

Lawrence A. Garcia, MD

Roslyn, New York

Karan Garg, MD

New York, New York

Justin George, MD

New York, New York

Patrick J. Geraghty, MD

Saint Louis, Missouri

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Jean Luc Gerard, MD

Creteil, France

George Geroulakos, MD, PhD

Athens, Greece

Brian B. Ghoshhajra, MD, MBA

Boston, Massachusetts

Sergio Giancesini, MD, PhD

Ferrara, Italy

Richard G.J. Gibbs

London, United Kingdom

Kathleen D. Gibson, MD

Bellevue, Washington

Rocco Giudice, MD

Rome, Italy

Lauren Glassmoyer, MD

Philadelphia, Pennsylvania

Monika L. Gloviczki, MD, PhD

Rochester, Minnesota

Peter Gloviczki, MD

Scottsdale, Arizona

Manj S. Gohel, MD

Cambridge, United Kingdom

Jerry Goldstone, MD

Stanford, California

Philip P. Goodney, MD, MS

Lebanon, New Hampshire

David Gordon, MD

Mount Kisco, New York

Heather L. Gornik, MD

Cleveland, Ohio

Yann Gouëffic, MD, PhD

Paris, France

Assaf Graif, MD

Newark, Delaware

William A. Gray, MD

Philadelphia, Pennsylvania

Franco Grego, MD

Padua, Italy

Marcelo Guimaraes, MD, MBA

Charleston, South Carolina

Wei Guo, MD

Beijing, China

Rajiv Gupta, MD

Boston, Massachusetts

H

Eric Hager, MD

Pittsburgh, Pennsylvania

Claudine M. Hamel-Desnos, MD

Paris, France

Daniel K. Han, MD

New York, New York

Sukgu Han, MD

Los Angeles, California

Linda M. Harris, MD

Buffalo, New York

Homayoun Hashemi, MD, RVT

McLean, Virginia

Stephan Haulon, MD

Paris, France

Don Heck, MD

Winston-Salem, North Carolina

Peter Henke, MD

Ann Arbor, Michigan

Jan M.M. Heyligers, MD, PhD

Tilburg, The Netherlands

Caitlin W. Hicks, MD, MS

Baltimore, Maryland

Anil P. Hingorani, MD

Brooklyn, New York

Jade S. Hiramoto, MD

San Francisco, California

Joshua A. Hirsch, MD

Boston, Massachusetts

Tobias Hirsch, MD

Halle, Germany

Kim J. Hodgson, MD

Springfield, Illinois

Tal M. Hörer, MD, PhD

Örebro, Sweden

Andrew Holden, MBChB

Auckland, New Zealand

Joseph P. Hughes, MBA, RVT, RVS,

Taunton, Massachusetts **RPhS**

Misty D. Humphries, MD, MAS

Sacramento, California

Mohamad A. Hussain, MD, PhD

Boston, Massachusetts

Osamu Iida, MD, PhD

Osaka, Japan

Karl A. Illig, MD

Houston, Texas

Sriram S. Iyer, MD

New York, New York

Glenn Jacobowitz, MD

New York, New York

Michael J. Jacobs, MD

Maastricht, The Netherlands

Michael R. Jaff, DO

Boston, Massachusetts

Krishna Jain, MD

Chicago, Illinois

Houman Jalaie, MD, PhD

Aachen, Germany

Arjun Jayaraj, MD

Jackson, Mississippi

Michael P. Jenkins, MBBS, BSc, MS

London, United Kingdom

William Jennings, MD

Tulsa, Oklahoma

Jeffrey Jim, MD, MPH

Minneapolis, Minnesota

Juan Carlos Jimenez, MD, MBA

Los Angeles, California

Anne M. Jones, BSN, RVT, RDMS

Winston Salem, North Carolina and

Augusta, Georgia

William D. Jordan Jr., MD

Augusta, Georgia

Matthieu M.J. Josnin, MD

La Roche sur Yon, France

K

Loay S. Kabbani, MD, MHSA

Detroit, Michigan

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

- Lowell S. Kabnick, MD**
Lake Worth Beach, Florida
- Andrea Kahlberg, MD**
Milan, Italy
- Stavros K. Kakkos, MD, PhD**
Patras, Greece
- Manju Kalra, MBBS**
Rochester, Minnesota
- Vikram S. Kashyap, MD**
Grand Rapids, Michigan
- Piotr M. Kasprzak, MD**
Regensburg, Germany
- Konstantinos Katsanos, MSc, MD, PhD**
Patras, Greece
- Athanasios Katsargyris, MD**
Nuremberg, Germany and Athens, Greece
- Barry T. Katzen, MD**
Miami, Florida
- Deepak Khatri, MD**
Bronx, New York
- Neil M. Khilnani, MD**
New York, New York
- Ali B. Khoynzhad, MD, PhD**
Manhattan Beach, California
- Sung Yup Kim, MD**
New York, New York
- Nicholas Kipshidze, MD, PhD, DSc**
New York, New York
- Melissa L. Kirkwood, MD**
Dallas, Texas
- Tilo Kölbel, MD, PhD**
Hamburg, Germany
- Raghu Kolluri, MD**
Columbus, Ohio
- Ralf R. Kolvenbach, MD**
Duesseldorf, Germany
- Kimihiko Komori, MD, PhD**
Nagoya, Japan
- Peter Kotanko, MD**
New York, New York
- Panos Kougias, MD, MSc**
Brooklyn, New York
- Zvonimir Krajcer, MD**
Houston, Texas
- Dainis K. Krievins, MD**
Riga, Latvia
- Boonprasit Kritpracha, MD**
Hat Yai, Songkhla, Thailand
- Waclaw B. Kuczmik, MD, PhD**
Katowice, Poland
- Steven Kum, MD**
Singapore
- Ann Marie Kupinski, PhD, RVT**
Albany, New York
- Toru Kuratani, MD, PhD**
Osaka, Japan
- Christopher J. Kwolek, MD, MBA**
Boston, Massachusetts
- John R. Laird, MD**
St. Helena, California
- Brajesh K. Lal, MD**
Baltimore, Maryland
- Patrick J. Lamparello, MD**
New York, New York
- Glenn M. LaMuraglia, MD**
Boston, Massachusetts
- Gregg S. Landis, MD**
New Hyde Park, New York
- Werner Lang, MD**
Erlangen, Germany
- Kamphol Laohapensang, MD**
Chiang Mai, Thailand
- Igor A. Laskowski, MD, PhD**
Valhalla, New York
- Peter F. Lawrence, MD**
Los Angeles, California
- Jeffrey H. Lawson, MD, PhD**
Durham, North Carolina
- Byung-Boong Lee, MD**
Washington, District of Columbia
- Jason T. Lee, MD**
Stanford, California
- Josh D. Lee, MBA**
Knoxville, Tennessee
- Robert E. Lee, MD**
Grosse Pointe Shores, Michigan
- W. Anthony Lee, MD**
Boca Raton, Florida
- Christos D. Liapis, MD**
Athens, Greece
- Michael K.W. Lichtenberg, MD**
Arnsberg, Germany
- David S. Liebeskind, MD**
Los Angeles, California
- Timothy K. Liem, MD, MBA**
Portland, Oregon
- Francesco Liistro, MD**
Arezzo, Italy
- Jes S. Lindholt, MD**
Odense, Denmark
- Thomas F. Lindsay, MDCM**
Toronto, Ontario, Canada
- Evan C. Lipsitz, MD, MBA**
New York, New York
- Terry Litchfield, MPA**
Blanchardville, Wisconsin
- Armando C. Lobato, MD, PhD**
São Paulo, Brazil
- Ian Loftus, MD**
London, United Kingdom
- Shang Loh, MD**
Philadelphia, Pennsylvania
- Joann M. Lohr, MD**
Columbia, South Carolina
- Charmaine Lok, MD**
Toronto, Ontario, Canada
- Joseph V. Lombardi, MD, MBA**
Camden, New Jersey
- Lars B. Lonn, MD, PhD**
Copenhagen, Denmark
- Robert A. Lookstein, MD, MHCDL**
New York, New York
- Qingsheng Lu, MD**
Shanghai, China
- L**
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT
Stony Brook, New York
- Mario L. Lachat, MD**
Zurich, Switzerland

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

John F. Lucas III, MD
Greenwood, Mississippi

Marzia Lugli, MD
Modena, Italy

Alan B. Lumsden, MD
Houston, Texas

Fedor Lurie, MD, PhD
Toledo, Ohio

Sean P. Lyden, MD
Cleveland, Ohio

M

Sumaira Macdonald, MD, PhD
Sunnyvale, California

Thanila A. Macedo, MD
Houston, Texas

Lindsay Machan, MD
Vancouver, British Columbia, Canada

Edward G. Mackay, MD
St. Petersburg, Florida

Dale Maharaj, MBBS
Trinidad and Tobago, West Indies

Michel Makaroun, MD
Pittsburgh, Pennsylvania

Mahmoud B. Malas, MD, MHS
San Diego, California

Thomas S. Maldonado, MD
New York, New York

Martin Malina, MD, PhD
London, United Kingdom

Nicola Mangialardi, MD
Rome, Italy

Armando Mansilha, MD, PhD
Porto, Portugal

Ashraf Mansour, MD
Grand Rapids, Michigan

Marco G. Manzi, MD
Abano Terme, Italy

Michael L. Marin, MD
New York, New York

Natalie A. Marks, MD, RPVI, RVT
Brooklyn, New York

William A. Marston, MD
Chapel Hill, North Carolina

Klaus D. Mathias, MD
Hamburg, Germany

Jon S. Matsumura, MD
Aurora, Colorado

Mark A. Mattos, MD
Flint, Michigan

Neghae Mawla, MD
Dallas, Texas

Steven Maximus, MD
Houston, Texas

David T. McGreevy, MD, PhD
Orebro, Sweden

James F. McKinsey, MD
New York, New York

Robert B. McLafferty, MD, MBA
Portland, Oregon

Barend M.E. Mees, MD, PhD
Maastricht, The Netherlands

Roxana Mehran, MD
New York, New York

Manish Mehta, MD, MPH
Latham, New York

Mark H. Meissner, MD
Seattle, Washington

Germano C.G. Melissano, MD
Milan, Italy

Matthew W. Mell, MD, MS
Sacramento, California

Matthew T. Menard, MD
Boston, Massachusetts

Bernardo C. Mendes, MD
Rochester, Minnesota

Valerie M. Merkle, PhD
Silver Spring, Maryland

Geno J. Merli, MD
Philadelphia, Pennsylvania

D. Christopher Metzger, MD
Columbus, Ohio

Mark W. Mewissen, MD, RVT
Milwaukee, Wisconsin

Claude Mialhe, MD
Le Tholonet, France

James Milburn, MD
New Orleans, Louisiana

Charles C. Miller, PhD
Houston, Texas

Joseph L. Mills, MD
Houston, Texas

Ross Milner, MD
Chicago, Illinois

David J. Minion, MD
Lexington, Kentucky

Erica L. Mitchell, MD, MED
Memphis, Tennessee

Kasuo Miyake, MD, PhD
São Paulo, Brazil

J Mocco, MD, MS
New York, New York

Bijan Modarai, PhD
London, United Kingdom

Irwin V. Mohan, MBBS, MD
Sydney, Australia

Frans L. Moll, MD, PhD
Utrecht, The Netherlands

Samuel R. Money, MD, MBA
New Orleans, Louisiana

Miguel F. Montero-Baker, MD
Houston, Texas

Robert A. Montgomery, MD, DPhil
New York, New York

Randy D. Moore, MD
Chestermere, Alberta, Canada

Wesley S. Moore, MD
Los Angeles, California

Robert A. Morgan, MD
London, United Kingdom

Patrick E. Muck, MD
Cincinnati, Ohio

Stefan Müller-Hülsbeck, MD
Flensburg, Germany

Dipankar Mukherjee, MD
Falls Church, Virginia

David R. Murdock, MD
Houston, Texas

Erin H. Murphy, MD
Charlotte, North Carolina

Piotr Musialek, MD, DPhil
Krakow, Poland

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Firas F. Mussa, MD

Houston, Texas

Pramook Mutirangura, FRCS

(EDINBURGH)

Bangkok, Thailand

Piotr Myrcha, MD

Warsaw, Poland

N

Yuliia Nahaliuk, MD

Kyiv, Ukraine

Laurence Needleman, MD

Philadelphia, Pennsylvania

Peter K. Nelson, MD

New York, New York

Richard F. Neville, MD

Fairfax, Virginia

Christoph A. Nienaber, MD, PhD

London, United Kingdom

Sigrid Nikol, MD

Hamburg, Germany

Samy S. Nitecki, MD

Haifa, Israel

Vandana D. Niyyar, MD

Atlanta, Georgia

Katariina M. Noronen, MD

Helsinki, Finland

Furuzan Numan, MD

Istanbul, Turkey

Andriy O. Nykonenko, MD

Zaporizhzhia, Ukraine

O

David O'Connor, MD

Hackensack, New Jersey

Thomas F. O'Donnell, Jr., MD

Boston, Massachusetts

Andrea T. Obi, MD

Ann Arbor, Michigan

Paulo E. Ocke Reis, MD, PhD

Rio de Janeiro, Brazil

Gustavo S. Oderich, MD

Houston, Texas

Sarah Onida, MD, PhD

London, United Kingdom

Alvaro Orrego, MD

Vina del Mar, Chile

Matteo Orrico, MD

Rome, Italy

Kenneth Ouriel, MD, MBA

New York, New York

C. Keith Ozaki, MD

Boston, Massachusetts

Kathleen J. Ozsvath, MD

Troy, New York

P

Jean M. Panneton, MD

Norfolk, Virginia

Giuseppe Panuccio, MD, PhD

Hamburg, Germany

Rajiv Parakh, MBBS, MS

Gurgaon, India

Kosmas I. Paraskevas, MD

Athens, Greece

Sahil A. Parikh, MD

New York, New York

Juan C. Parodi, MD

Buenos Aires, Argentina

Marc A. Passman, MD

Birmingham, Alabama

Virendra I. Patel, MD, MPH

New York, New York

Lorenzo Patrone, MD

Florence, Italy

Athos Patsalides, MD, MPH

New York, New York

Felice Pecoraro, MD

Palermo, Italy

Bruce A. Perler, MD, MBA

Baltimore, Maryland

Jennifer L. Perri, MD, MBA

Durham, North Carolina

Ivo Petrov, MD, PhD

Sofia, Bulgaria

Janet T. Powell, MD, PhD

London, United Kingdom

Richard J. Powell, MD

Lebanon, New Hampshire

Carlo Pratesi, MD

Florence, Italy

Giovanni Pratesi, MD

Genoa, Italy

Ourania Preventza, MD

Charlottesville, Virginia

Robert M. Proczka, MD, PhD

Warsaw, Poland

Q

Elina Quiroga, MD, MPH

Seattle, Washington

R

Joseph D. Raffetto, MD

West Roxbury, Massachusetts

Ansaar T. Rai, MD

Morgantown, West Virginia

Ravi R. Rajani, MD

Atlanta, Georgia

Seshadri Raju, MD

Jackson, Mississippi

Venkatesh G. Ramaiah, MD

Scottsdale, Arizona

Zoran Rancic, MD, PhD

Lachen, Switzerland

Hisham Rashid, FRCS

London, United Kingdom

Todd E. Rasmussen, MD

Rochester, Minnesota

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

- Animesh Rathore, MD**
Norfolk, Virginia
- Sundaram Ravikumar, MD**
Dobbs Ferry, New York
- Mahmood Razavi, MD**
Orange, California
- Michel Reijnen, MD, PhD**
Arnhem, The Netherlands
- Timothy A. Resch, MD, PhD**
Copenhagen, Denmark
- Robert Y. Rhee, MD**
Brooklyn, New York
- Vicente Rimbau, MD, PhD**
Barcelona, Spain
- Jean-Baptiste Ricco, MD, PhD**
Poitiers, France
- Götz M. Richter, MD, PhD**
Stuttgart, Germany
- Joseph J. Ricotta II, MD, MS**
Boca Raton, Florida
- Celia Riga, MD**
London, United Kingdom
- William P. Robinson, MD**
Springfield, Illinois
- Caron B. Rockman, MD**
Hackensack, New Jersey
- Sean P. Roddy, MD**
Albany, New York
- Heron E. Rodriguez, MD**
Chicago, Illinois
- Sonia Ronchey, MD, PhD**
Rome, Italy
- Eric E. Roselli, MD**
Cleveland, Ohio
- Kenneth Rosenfield, MD**
Boston, Massachusetts
- Rachel Rosovsky, MD, MPH**
Boston, Massachusetts
- Elsie Ross, MD, MSc**
San Diego, California
- John R. Ross, Sr., MD**
Orangeburg, South Carolina
- Vincent L. Rowe, MD**
Los Angeles, California
- Maria A. Ruffino, MD**
Lugano, Switzerland
- Aubrey J. Rybynski, BS, RDMS, RVT**
Turnersville, New Jersey
- Wilhelm Sandmann, MD**
Duesseldorf, Germany
- Timur P. Sarac, MD**
Dublin, Ohio
- Pierre G. Sarradon, MD**
Toulon, France
- Sudhakar R. Satti, MD**
Newark, Delaware
- Sal Scali, MD**
Gainesville, Florida
- Andres Schanzer, MD**
Worcester, Massachusetts
- Dori R. Schatell, MS**
Catonsville, Maryland
- Dierk Scheinert, MD**
Leipzig, Germany
- Larry A. Scher, MD**
Bronx, New York
- Marc L. Schermerhorn, MD**
Boston, Massachusetts
- Kerstin S. Schick, MD**
Munich, Germany
- Andrej Schmidt, MD**
Leipzig, Germany
- Darren B. Schneider, MD**
Philadelphia, Pennsylvania
- Peter A. Schneider, MD**
San Francisco, California
- Geert Willem H. Schurink, MD, PhD**
Maastricht, The Netherlands
- Leslie M. Scoutt, MD**
New Haven, Connecticut
- Eric A. Secemsky, MD, MSc**
Boston, Massachusetts
- Johanna Seiden, MD, MPH**
Bronx, New York
- Nuttawut Sermsathanasawadi, MD, PhD**
Bangkok, Thailand
- Francesco Setacci, MD**
Catania, Italy
- Robert Shahverdyan, MD**
Hamburg, Germany
- Sherene Shalhub, MD, MPH**
Portland, Oregon
- Murray L. Shames, MD**
Tampa, Florida
- Aditya Sharma, MD**
Charlottesville, Virginia
- Palma M. Shaw, MD, MBA, RPVI**
Syracuse, New York
- Maxim Shaydakov, MD, PhD**
Pittsburgh, Pennsylvania
- Malachi Sheahan, MD**
New Orleans, Louisiana
- Surendra Shenoy, MD, PhD**
St. Louis, Missouri
- Chun Che Shih, MD, PhD**
Taipei, Taiwan
- Cynthia K. Shortell, MD**
Durham, North Carolina
- Chang Shu, MD**
Beijing & Chang Sha, Hunan Province, China
- Anton N. Sidawy, MD, MPH**
Washington, District of Columbia



Theodore F. Saad, MD
Newark, Delaware

Mikel Sadek, MD
New York, New York

Hazim J. Safi, MD
Houston, Texas

Natzi Sakalihan, MD, PhD
Liege, Belgium

Gloria Salazar, MD
Chapel Hill, North Carolina

Clifford M. Sales, MD, MBA
Livingston, New Jersey

Russell H. Samson, MD, RVT
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Adnan H. Siddiqui, MD, PhD
Buffalo, New York

Michael B. Silva, Jr., MD
Galveston, Texas

Rossi M. Silva, MD
Rio de Janeiro, Brazil

Jessica P. Simons, MD, MPH
Worcester, Massachusetts

Michael J. Singh, MD
Pittsburgh, Pennsylvania

Niten Singh, MD
Seattle, Washington

Jeffrey J. Siracuse, MD, MBA
Boston, Massachusetts

Pasqualino Sirignano, MD, PhD
Rome, Italy

Jan M. Sloves, RVT
New York, New York

Christopher J. Smolock, MD
New York, New York

Jill S. Sommerset, BS, RVT
Houston, Texas

J. David Spence, MD
London, Ontario, Canada

Francesco Speziale, MD
Rome, Italy

Francesco Spinelli, MD
Rome, Italy

Alex C. Spyropoulos, MD
New York, New York

James C. Stanley, MD
Ann Arbor, Michigan

Benjamin W. Starnes, MD
Seattle, Washington

Scott L. Stevens, MD
Knoxville, Tennessee

David H. Stone, MD
Hanover, New Hampshire

Patrick A. Stone, MD
Nashville, Tennessee

Michael C. Stoner, MD
Rochester, New York

Julianne Stoughton, MD
Boston, Massachusetts

Bjoern D. Suckow, MD
Lebanon, New Hampshire

Timothy M. Sullivan, MD
Livingston, Montana

Sherif A.H. Sultan, MD, PhD
Galway, Ireland

Wilson Y. Szeto, MD
Philadelphia, Pennsylvania

Piotr Szopinski, MD, PhD
Warsaw, Poland

T

Rami Tadros, MD
New York, New York

Lawrence N. Tanenbaum, MD
Riverside, Connecticut

Apostolos K. Tassiopoulos, MD
Stony Brook, New York

Vicki J. Teodorescu, MD
Atlanta, Georgia

Gunnar Tepe, MD
Rosenheim, Germany

Katherine A. Teter, MD
New York, New York

Matt M. Thompson, MD
Irvine, California

Bryan W. Tillman, MD, PhD
Columbus, Ohio

Carlos H. Timaran, MD
Dallas, Texas

Giovanni Tinelli, MD, PhD
Rome, Italy

Windsor Ting, MD
New York, New York

Giovanni B. Torsello, MD
Münster, Germany

Shahab Toursavadkahi, MD
Baltimore, Maryland

Margaret Tracci, MD, JD
Charlottesville, Virginia

Santi Trimarchi, MD, PhD
Milan, Italy

Patrick Troy, MD
Hartford, Connecticut

Yamume Tshomba, MD
Rome, Italy

Nikolaos Tsilimparis, MD, PhD
Munich, Germany

Aquilla S. Turk, DO
Greenville, South Carolina

U

Jorge H. Ulloa, MD
Bogota, Colombia

Gilbert R. Upchurch, MD
Gainesville, Florida

Tomasz Urbanek, MD, PhD
Katowice, Poland

Marco V. Usai, MD
North Rhine-Westphalia, Germany

V

Claude D. Vaislic, MD
Le Chesnay, France

Domenico Valenti, PhD
London, United Kingdom

S. Rao Vallabhaneni, MD
Liverpool, United Kingdom

Jos C. van den Berg, MD, PhD
Lugano, Switzerland

Joost van Herwaarden, MD, PhD
Utrecht, The Netherlands

Isabelle Van Herzeele, MD, PhD
Ghent, Belgium

Marc R.H.M. van Sambeek, MD, PhD
Eindhoven, The Netherlands

Ramon L. Varcoe, MBBS, MS
Sydney, Australia

Ravi K. Veeraswamy, MD
Charleston, South Carolina

Frank J. Veith, MD
*Cleveland, Ohio &
New York, New York*

Maarit Venermo, MD, PhD
Helsinki, Finland

Hence J.M. Verhagen, MD, PhD
Rotterdam, The Netherlands

FACULTY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Eric L.G. Verhoeven, MD, PhD

Nuremberg, Germany

Fabio Verzini, MD, PhD

Turin, Italy

Todd R. Vogel, MD, MPH

Columbia, Missouri

W

Reese A. Wain, MD

New York, New York

Thomas W. Wakefield, MD

Ann Arbor, Michigan

Ron Waksman, MD

Washington, District of Columbia

Craig M. Walker, MD

Houma, Louisiana

Patrick F. Walker, MD

Bethesda, Maryland

Grace J. Wang, MD, MSCE

Philadelphia, Pennsylvania

Anders Wanhainen, MD, PhD

Uppsala, Sweden

Patrick A. Washko, BS, RVT

Raleigh, North Carolina

Haimanot (Monnie) Wasse, MD,

Chicago, Illinois

MPH

Fred A. Weaver, MD, MMM

Los Angeles, California

Mitchell D. Weinberg, MD

Staten Island, New York

Rodney A. White, MD

Long Beach, California

Michael H. Wholey, MD, MBA

San Antonio, Texas

David M. Williams, MD

Ann Arbor, Michigan

Willem Wisselink, MD

Chicago, Illinois

I-Hui Wu, MD, PhD

Taipei, Taiwan

Y

Wayne F. Yakes, MD

Englewood, Colorado

Kak Khee Yeung, MD, PhD

Amsterdam, The Netherlands

Z

Richard L. Zampolin, MD

New York, New York

Christopher K. Zarins, MD

Stanford, California

Hany M. Zayed, MD

London, United Kingdom

Clark J. Zeebregts, MD, PhD

Groningen, The Netherlands

Sara L. Zettervall, MD

Seattle, Washington

Wayne W. Zhang, MD

Seattle, Washington

Wei Zhou, MD

Tucson, Arizona

R. Eugene Zierler, MD, RPVI

Seattle, Washington

Gregg H. Zoarski, MD

Newark, Delaware

REGISTRATION

Tuesday, November 19 - Saturday, November 23, 2024
New York Hilton-Midtown

FULL REGISTRATION (TUESDAY - SATURDAY)

Tuition

Tuition includes access to any Thursday and Saturday Only Component.

Registration fee includes breakfast, lunch and breaks

Physicians (excluding Fellows/Trainees and Residents)

\$1399

US 2nd Year Fellows in an RRC-approved 2-Year Vascular Fellowship **OR** 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2024, **AND** Canadian Vascular Surgery Fellows in Training (**Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.**) Letter of verification on official hospital stationery must be obtained prior to registration and emailed to registrar@veithsymposium.org. The letter must include the start and end date of vascular fellowship. Please note that if you are participating in any program as faculty (i.e., Associate Faculty Global Podium Presentations Program), a registration fee is required, and you will not be eligible to register complimentary under any educational grant.

Complimentary

PGY-6 Fellows & PGY-4 Residents

Complimentary

Complimentary tuition is available but limited. Contact admin@veithsymposium.org for more details.

Non-US Fellows and Residents (Trainees)

\$699

Letter of verification from Chief of Service must be obtained prior to registration and emailed to registrar@veithsymposium.org.

Non-Finishing U.S. Fellows/Residents, Nurses, Technologists

\$650

Medical Students

\$500

(Letter of verification from Dean must be obtained prior to registration and emailed to registrar@veithsymposium.org.)

Allied Health Care Professionals, Venture Capitalists, and All Others

\$950

VV@Vs® - Venous Venous and More Venous® Workshop

\$25

Wednesday, November 20, 2024 from 1:00 P.M. - 6:00 P.M.,
Registration is limited to 200 fully paid VEITHsymposium registrants including Industry Personnel. (This is a non-CME Activity.)

THURSDAY ONLY - NOVEMBER 21, 2024

Multidisciplinary Stroke Prevention and Treatment

\$349

7:30 A.M. to 12:15 P.M.

Tuition includes access to any VEITHsymposium Thursday Sessions.

FRIDAY ONLY - NOVEMBER 22, 2024

VEITHsymposium Fellows & Residents Career Development Program

8:00 A.M. to 5:00 P.M.

(This is a non-CME Activity.)

Potential Employer/Recruiter

\$500

(For Employers/Recruiters not registered at VEITHsymposium)

Tuition includes access to VEITHsymposium Friday Sessions.

SATURDAY ONLY COMPONENTS - NOVEMBER 23, 2024

VEITHsymposium (Miscellaneous Topics)

\$349

7:00 A.M. - 12:30 P.M.

Tuition includes access to any Saturday Only Component.

Hemodialysis Access (Physicians only)

\$349

8:00 A.M. - 4:00 P.M.

Tuition includes access to any Saturday Only Component.

Hemodialysis Access (Non-Physicians)

\$150

8:00 A.M. - 4:00 P.M.

(This rate is not available to industry personnel.)

Tuition includes access to Hemodialysis Access Only.

Cancellation Policy: There is a \$95 cancellation fee if canceled in writing by October 19, 2024. No refunds will be made thereafter.

Online: www.veithsymposium.org/registration

Phone: 800-987-9314, (select option 1) with payment information

Mail: Please make checks payable to the Cleveland Clinic Educational Foundation and print and mail your receipt to:

The Cleveland Clinic Educational Foundation

Attn: EJCC070

P.O. Box 931653

Cleveland, OH 44193-1082

Please notify registrar@veithsymposium.org if sending by overnight mail or courier service.

Email: registrar@veithsymposium.org

Checks must be received by October 31, 2024

REGISTER ONLINE AT

WWW.VEITHSYMPOSIUM.ORG/REGISTRATION

VEITHSYMPOSIUM ON DEMAND

www.veithondemand.com



**VIEW THE
ENTIRE 2024
VEITHSYMPOSIUM
ONLINE**

Purchase all the Talks, Slides, and Videos
- fully synchronized - and all the Panels.
This Library or Components thereof can be used
as an Educational Resource or Teaching Tool.

**For more information on how to obtain the
VEITHsymposium Online Library, please call
800-987-9314 (select option 3).**

www.veithsymposium.org

VEITH SYMPOSIUM[®]
Connecting The **Vascular** Community

SAVE THE DATE

Tuesday - Saturday, November 18-22, 2025

VEITH
VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman

Frank J. Veith, MD

Executive Co-Chairman

Enrico Ascher, MD

Symposium Co-Chairmen

Kenneth Ouriel, MD, MBA

Sean P. Lyden, MD

Sponsored by

 **Cleveland Clinic**


Hilton

www.VEITHsymposium.org



Cleveland Clinic

THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION

PO BOX 931653

CLEVELAND, OH 44193-1082

- **VVs @ Vs®** - Venous Venous and More Venous® Workshop at VEITHsymposium - Wednesday, November 20, 2024
- **Controversies in Venous Disease Management** - Wednesday, November 20, 2024
- **International Society for Women Vascular Surgeons** - Wednesday, November 20, 2024
- **Multidisciplinary Stroke Prevention and Treatment** - Thursday, November 21, 2024
- **Advances in Vascular Imaging and Diagnosis** - Friday - Saturday, November 22-23, 2024
- **Open Vascular Techniques** - Friday, November 22, 2024
- **Outpatient Facilities for Vascular Procedures and Clinical Research** - Friday, November 22, 2024

AGAIN THIS YEAR

- **Associate Faculty Global Podium Presentations Program** - Wednesday - Friday, November 20-22, 2024
- **The Frank J. Veith International Society Associate Faculty Global Podium Presentations Program** at VEITHsymposium - Wednesday - Friday, November 20-22, 2024
- **The SVS/ESVS/NICE/ACC/AHA Debates on Guidelines for the Management of Abdominal Aortic Aneurysms** - Friday, November 22, 2024
- **World Federation of Vascular Surgery at VEITHsymposium** - Thursday, November 21, 2024
- **BEST-CLI: New Data and Evolving Perspectives** - Thursday, November 21, 2024
- **J. Leonel Villavicencio Latin-American Program at VEITHsymposium** - Friday, November 22, 2024
- **Vascular Fellows & Residents Career Development Program** - Friday, November 22, 2024

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.

Download The VEITHsymposium
App To Stay Up To Date



Tuesday - Saturday
November 19-23, 2024



iOS and Android